Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTO1 | P78417 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16285077 | 0.81 | MGAM (0.41) | GSTO1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL3968188 | 0.81 | GSTO1 (0.40) | GSTO1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL20125982 | 0.80 | CA12 (0.56) | GSTO1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL20125929 | 0.80 | LMNA (0.36) | LMNATSHRPSMB5CA12CA1 | |
| SCHEMBL20125956 | 0.80 | KMT2A (0.53) | GSTO1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL7480284 | 0.79 | GSTO1 (0.39) | GSTO1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL23298170 | 0.79 | GSTO1 (0.42) | GSTO1CA12CA1CA2CA9 | |
| SCHEMBL28274977 | 0.78 | KMT2A (0.36) | KMT2AMEN1ALDH1A1LMNATSHR | |
| SCHEMBL15482781 | 0.78 | MGAM (0.38) | KMT2AMEN1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL20125897 | 0.77 | CA12 (0.41) | GSTO1ALDH1A1TSHRHSD17B10CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2364 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343802-B1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | AVECIA BIOTECHNOLOGY INC (US) | 2012-05-30 | — | — | EP | claimed |
| EP-2332954-A2 | Process for the preparation of phosphorothionate oligonucleotides | Avecia Biotechnology, Inc. (US) | 2011-06-15 | — | — | EP | claimed |
| US-20090286435-A1 | Method for Producing, and a Substrate with, a Surface with Specific Characteristics | SURFACE INNOVATIONS LIMITED (GB) | 2009-11-19 | — | — | US | claimed |
| EP-2076549-A2 | A METHOD FOR PRODUCING SURFACES AND SUBSTRATES HAVING SAID SURFACES SO FORMED | UNIVERSITY OF DURHAM (GB) | 2009-07-08 | — | — | EP | claimed |
| WO-2008050122-A2 | A METHOD FOR PRODUCING SURFACES AND SUBSTRATES HAVING SAID SURFACES SO FORMED | UNIVERSITY OF DURHAM (GB) | 2008-05-02 | — | — | WO | claimed |
| EP-1868739-A2 | METHOD FOR PRODUCING, AND A SUBSTRATE WITH, A SURFACE WITH SPECIFIC CHARACTERISTICS | UNIVERSITY OF DURHAM (GB) | 2007-12-26 | — | — | EP | claimed |
| WO-2006109055-A2 | METHOD FOR COATING A SUBSTRATE TO GIVE PROTEIN RESISTANCE AND COATED SUBSTRATE | UNIVERSITY OF DURHAM (GB) | 2006-10-19 | — | — | WO | claimed |
| US-6768005-B2 | GENERATION OF PREFERENTIAL OLIGONUCLEOTIDES; GENERATE SOLID SUPPORT, INCUBATE WITH OLIGONUCLEOTIDES, ATTACH OLIGONUCLELOTIDE TO SOLID SUPPORT, EXPOSE TO ACETONITRILE, RECOVER ADJUSTED OLIGONUCLEOTIDE | AVECIA LIMITED (GB) | 2004-07-27 | — | — | US | claimed |
| US-20030229221-A1 | Process for the preparation of phosphorothioate oligonucleotides | AVECIA LIMITED (GB) | 2003-12-11 | — | — | US | claimed |
| US-20030203390-A1 | Comprises coded particle immobilized on microarrays for use in synthesizing, screening and monitoring biological, pharmacological or chemical compounds | KAYE PAUL H (GB) | 2003-10-30 | — | — | US | claimed |
| EP-1343802-A2 | PROCESS FOR THE PREPARATION OF PHOSPHOROTHIONATE OLIGONUCLEOTIDES | Avecia Limited (GB) | 2003-09-17 | — | — | EP | claimed |
| US-20020111479-A1 | Generation of preferential oligonucleotides; generate solid support, incubate with oligonucleotides, attach oligonuclelotide to solid support, expose to acetonitrile, recover adjusted oligonucleotide | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2002-08-15 | — | — | US | claimed |
| EP-1224193-A1 | PROCESS FOR THE PREPARATION OF PHOSPHOROTHIOATE TRIESTERS AND OLIGONUCLEOTIDES | Avecia Limited (GB) | 2002-07-24 | — | — | EP | claimed |
| WO-2002046205-A2 | PROCESS FOR THE PREPARATION OF PHOSPHOROTHIONATE OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 2002-06-13 | — | — | WO | claimed |
| EP-0863797-B1 | CODED PARTICLES FOR PROCESS SEQUENCE TRACKING IN COMBINATORIAL COMPOUND LIBRARY PREPARATION | UNIV HERTFORDSHIRE (GB) | 2001-12-12 | — | — | EP | claimed |
| WO-2001027126-A1 | PROCESS FOR THE PREPARATION OF PHOSPHOROTHIOATE TRIESTERS AND OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 2001-04-19 | — | — | WO | claimed |
| EP-1018365-A2 | Coded particles for process sequence tracking in combinatorial compound library preparation | UNIVERSITY OF HERTFORDSHIRE (GB) | 2000-07-12 | — | — | EP | claimed |
| EP-0863797-A1 | CODED PARTICLES FOR PROCESS SEQUENCE TRACKING IN COMBINATORIAL COMPOUND LIBRARY PREPARATION | UNIVERSITY OF HERTFORDSHIRE (GB) | 1998-09-16 | — | — | EP | claimed |
| WO-1997015390-A1 | CODED PARTICLES FOR PROCESS SEQUENCE TRACKING IN COMBINATORIAL COMPOUND LIBRARY PREPARATION | UNIVERSITY OF HERTFORDSHIRE (GB) | 1997-05-01 | — | — | WO | claimed |
| US-20260116918-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2026-04-30 | — | — | US | disclosed |
| US-20260116950-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2026-04-30 | — | — | US | disclosed |
| EP-3909942-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID AMIDE COMPOUND | RICOH CO LTD (JP) | 2026-04-08 | — | — | EP | disclosed |
| US-20260028387-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2026-01-29 | — | — | US | disclosed |
| US-20250235519-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-07-24 | — | — | US | disclosed |
| US-20250223335-A1 | PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-07-10 | — | — | US | disclosed |
| US-12351616-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-07-08 | — | — | US | disclosed |
| WO-2025136809-A2 | FOXP3 PEPTIDES AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12318407-B2 | Peptides displayed by HLA for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-06-03 | — | — | US | disclosed |
| US-20250154459-A1 | PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-05-15 | — | — | US | disclosed |
| US-12295996-B2 | Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-05-13 | — | — | US | disclosed |
| US-12295994-B2 | Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-05-13 | — | — | US | disclosed |
| US-12297254-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-05-13 | — | — | US | disclosed |
| US-12295995-B2 | Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-05-13 | — | — | US | disclosed |
| US-12297245-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-05-13 | — | — | US | disclosed |
| US-20250144192-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| WO-2025096203-A1 | TARGETING A CHIMERIC RNA FOR TREATING CANCER | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250145686-A1 | UTERINE CANCER TREATMENTS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250145684-A1 | IMMUNOTHERAPY WITH B*08 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-12290530-B2 | Peptides displayed by HLA for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-05-06 | — | — | US | disclosed |
| US-12285443-B2 | Peptides displayed by HLA for use immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-04-29 | — | — | US | disclosed |
| US-12286491-B2 | Image forming device and image forming method | RICOH COMPANY, LTD. (JP) | 2025-04-29 | — | — | US | disclosed |
| US-12281146-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-04-22 | — | — | US | disclosed |
| EP-4536681-A1 | VIRAL PEPTIDES AND USES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-12275775-B2 | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-04-15 | — | — | US | disclosed |
| US-12275768-B2 | In immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-04-15 | — | — | US | disclosed |
| US-12275776-B2 | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-04-15 | — | — | US | disclosed |
| US-12274716-B2 | Peptides displayed by HLA for use immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-04-15 | — | — | US | disclosed |
| EP-3647319-B1 | PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME | XDCEXPLORER SHANGHAI CO LTD (CN) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025064470-A1 | VIRAL PEPTIDES AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025064738-A1 | DNTT 250-258 OFF-TARGET PEPTIDES AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025064761-A1 | KRAS10-18 G12D OFF-TARGET PEPTIDES AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-12258382-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-03-25 | — | — | US | disclosed |
| US-12257269-B2 | Peptides displayed by HLA for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-03-25 | — | — | US | disclosed |
| US-20250092104-A1 | IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-03-20 | — | — | US | disclosed |
| CN-119604519-A | Viral peptides and uses thereof | 瑞泽恩制药公司 | 2025-03-11 | — | — | CN | disclosed |
| US-12247057-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-03-11 | — | — | US | disclosed |
| US-12246039-B2 | Peptides displayed by HLA for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-03-11 | — | — | US | disclosed |
| US-20250074961-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST SMALL CELL LUNG CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-03-06 | — | — | US | disclosed |
| US-12240878-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-03-04 | — | — | US | disclosed |
| US-12240877-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-03-04 | — | — | US | disclosed |
| US-20250066422-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-02-27 | — | — | US | disclosed |
| WO-2025040598-A2 | PEPTIDES DISPLAYED BY MHC FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-02-27 | — | — | WO | disclosed |
| US-12234276-B2 | Uterine cancer treatments | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-02-25 | — | — | US | disclosed |
| US-12234298-B2 | Immunotherapy against several tumors including neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-02-25 | — | — | US | disclosed |
| US-12227556-B2 | Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-02-18 | — | — | US | disclosed |
| US-12226466-B2 | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-02-18 | — | — | US | disclosed |
| US-12226467-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-02-18 | — | — | US | disclosed |
| US-20250049886-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-02-13 | — | — | US | disclosed |
| US-20250051857-A1 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-02-13 | — | — | US | disclosed |
| US-12221493-B2 | Immunotherapy against several tumors including neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-02-11 | — | — | US | disclosed |
| US-12221468-B2 | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-02-11 | — | — | US | disclosed |
| US-12221467-B2 | Uterine cancer treatments | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-02-11 | — | — | US | disclosed |
| US-12221626-B2 | Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-02-11 | — | — | US | disclosed |
| US-12214025-B2 | Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-02-04 | — | — | US | disclosed |
| US-12202878-B2 | Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-01-21 | — | — | US | disclosed |
| EP-3616711-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-01-15 | — | — | EP | disclosed |
| EP-4491191-A2 | UTERINE CANCER TREATMENTS | immatics biotechnologies GmbH (DE) | 2025-01-15 | — | — | EP | disclosed |
| EP-3616710-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-01-15 | — | — | EP | disclosed |
| EP-3613427-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-01-15 | — | — | EP | disclosed |
| EP-3616709-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-01-15 | — | — | EP | disclosed |
| US-12193998-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
| US-12193999-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
| US-12195509-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
| US-12195508-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
| US-12195516-B2 | Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
| US-12193997-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
| US-12195507-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
| US-12195506-B2 | Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
| US-20250014675-A1 | OFF-TARGET PREDICTION METHOD FOR ANTIGEN-RECOGNITION MOLECULES BINDING TO MHC-PEPTIDE TARGETS | REGENERON PHARMACEUTICALS, INC. (US) | 2025-01-09 | — | — | US | disclosed |
| EP-3616708-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-01-08 | — | — | EP | disclosed |
| US-12186276-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-01-07 | — | — | US | disclosed |
| US-12186277-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-01-07 | — | — | US | disclosed |
| US-12180259-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-12-31 | — | — | US | disclosed |
| US-12180256-B2 | Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-12-31 | — | — | US | disclosed |
| US-20240425558-A1 | PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-12-26 | — | — | US | disclosed |
| US-12173043-B2 | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-12-24 | — | — | US | disclosed |
| US-12171819-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-12-24 | — | — | US | disclosed |
| US-12168043-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-12-17 | — | — | US | disclosed |
| US-20240408166-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-12-12 | — | — | US | disclosed |
| US-12162917-B2 | B*44 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-12-10 | — | — | US | disclosed |
| US-12156905-B2 | CCR8 peptide and T cells for use in immunotherapeutic treatment of various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-12-03 | — | — | US | disclosed |
| US-12150979-B2 | Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-11-26 | — | — | US | disclosed |
| EP-3426281-B1 | UTERINE CANCER TREATMENTS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-11-20 | — | — | EP | disclosed |
| US-12144852-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-11-19 | — | — | US | disclosed |
| US-20240374640-A1 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-11-14 | — | — | US | disclosed |
| US-20240374642-A1 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-11-14 | — | — | US | disclosed |
| EP-4461371-A2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | immatics biotechnologies GmbH (DE) | 2024-11-13 | — | — | EP | disclosed |
| US-20240366669-A1 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-11-07 | — | — | US | disclosed |
| EP-3715357-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-11-06 | — | — | EP | disclosed |
| US-20240358757-A1 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-10-31 | — | — | US | disclosed |
| US-20240358755-A1 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-10-31 | — | — | US | disclosed |
| US-20240358756-A1 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-10-31 | — | — | US | disclosed |
| EP-4453942-A2 | OFF-TARGET PREDICTION METHOD FOR ANTIGEN-RECOGNITION MOLECULES BINDING TO MHC-PEPTIDE TARGETS | Regeneron Pharmaceuticals, Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-3738606-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-10-30 | — | — | EP | disclosed |
| US-12129312-B2 | Peptide compound, application thereof and composition containing same | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| US-20240350602-A1 | NOVEL PEPTIDES & COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML & OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-10-24 | — | — | US | disclosed |
| US-12121572-B2 | Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-10-22 | — | — | US | disclosed |
| EP-3753570-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-10-02 | — | — | EP | disclosed |
| US-12103984-B2 | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-10-01 | — | — | US | disclosed |
| US-12102670-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-10-01 | — | — | US | disclosed |
| US-12098183-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-09-24 | — | — | US | disclosed |
| US-12097249-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-09-24 | — | — | US | disclosed |
| US-12097248-B2 | Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-09-24 | — | — | US | disclosed |
| CN-118679522-A | Off-target prediction method of antigen recognition molecules combined with MHC-peptide targets | 瑞泽恩制药公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20240307447-A1 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-09-19 | — | — | US | disclosed |
| US-20240299455-A1 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-09-12 | — | — | US | disclosed |
| US-12084486-B2 | Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-09-10 | — | — | US | disclosed |
| US-12084522-B2 | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-09-10 | — | — | US | disclosed |
| US-20240294633-A1 | ANTIBODY SPECIFIC FOR ANTI-BCL-6 ANTIBODY AND METHODS OF USE | NONAGEN THERAPEUTICS CORPORATION | 2024-09-05 | — | — | US | disclosed |
| US-20240294602-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-09-05 | — | — | US | disclosed |
| US-12076380-B2 | Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-09-03 | — | — | US | disclosed |
| US-12076379-B2 | A*03 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-09-03 | — | — | US | disclosed |
| US-12076381-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-09-03 | — | — | US | disclosed |
| US-20240285738-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-08-29 | — | — | US | disclosed |
| US-12071458-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-08-27 | — | — | US | disclosed |
| US-12070491-B2 | Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-08-27 | — | — | US | disclosed |
| US-20240279306-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-08-22 | — | — | US | disclosed |
| US-12065477-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-08-20 | — | — | US | disclosed |
| US-12065471-B2 | B*44 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-08-20 | — | — | US | disclosed |
| US-12064465-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-08-20 | — | — | US | disclosed |
| US-20240269183-A1 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-08-15 | — | — | US | disclosed |
| US-20240269184-A1 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-08-15 | — | — | US | disclosed |
| US-12060399-B2 | Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-08-13 | — | — | US | disclosed |
| US-12060406-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-08-13 | — | — | US | disclosed |
| US-12059458-B2 | Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-08-13 | — | — | US | disclosed |
| US-12060400-B2 | Peptides for use in immunotherapy against cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-08-13 | — | — | US | disclosed |
| US-20240254161-A1 | Neoantigens Expressed In Ovarian Cancer And Their Uses | JANSSEN BIOTECH INC (US) | 2024-08-01 | — | — | US | disclosed |
| US-20240254191-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-08-01 | — | — | US | disclosed |
| US-20240247044-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-07-25 | — | — | US | disclosed |
| US-20240245723-A1 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-07-25 | — | — | US | disclosed |
| US-20240247045-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-07-25 | — | — | US | disclosed |
| US-20240239867-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-07-18 | — | — | US | disclosed |
| US-20240239866-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-07-18 | — | — | US | disclosed |
| US-20240239865-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-07-18 | — | — | US | disclosed |
| US-12036271-B2 | Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-07-16 | — | — | US | disclosed |
| EP-4397676-A2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | Immatics Biotechnologies GmbH (DE) | 2024-07-10 | — | — | EP | disclosed |
| US-12029785-B2 | GINS2 peptide and T cells for use in immunotherapeutic treatment of various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-07-09 | — | — | US | disclosed |
| CN-112469306-B | Composition, artificial nail composition, nail decorating material, artificial nail, storage container, image forming apparatus, and image forming method | 株式会社理光 | 2024-07-05 | — | — | CN | disclosed |
| US-20240218044-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-07-04 | — | — | US | disclosed |
| EP-3456347-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-07-03 | — | — | EP | disclosed |
| EP-3388080-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (SEQ ID 243 - SPC25-001) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-07-03 | — | — | EP | disclosed |
| US-12023372-B2 | Peptides and T cells for use in immunotherapeutic treatment of various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-07-02 | — | — | US | disclosed |
| US-12023398-B2 | Composition, artificial nail composition, nail decoration material, artificial nail, stored container, image forming apparatus, and image forming method | RICOH COMPANY, LTD. (JP) | 2024-07-02 | — | — | US | disclosed |
| US-12023398-B2 | Composition, artificial nail composition, nail decoration material, artificial nail, stored container, image forming apparatus, and image forming method | RICOH COMPANY, LTD. (JP) | 2024-07-02 | — | — | US | disclosed |
| US-12023398-B2 | Composition, artificial nail composition, nail decoration material, artificial nail, stored container, image forming apparatus, and image forming method | RICOH COMPANY, LTD. (JP) | 2024-07-02 | — | — | US | disclosed |
| US-20240209023-A1 | PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-12018064-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-06-25 | — | — | US | disclosed |
| CN-118221800-A | Novel immunotherapy against a variety of tumors, such as lung cancer including NSCLC | 伊玛提克斯生物技术有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-12005105-B2 | Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-06-11 | — | — | US | disclosed |
| US-12006349-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-06-11 | — | — | US | disclosed |
| US-20240182522-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-06-06 | — | — | US | disclosed |
| US-11999774-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-06-04 | — | — | US | disclosed |
| EP-3388076-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (SEQ ID 274 - IGF-004) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-05-29 | — | — | EP | disclosed |
| EP-3388079-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (SEQ ID 253 - RAD54B) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-05-29 | — | — | EP | disclosed |
| EP-3388078-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (SEQ ID 23 - MMP-002) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-20240166716-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-05-23 | — | — | US | disclosed |
| US-20240166714-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-05-23 | — | — | US | disclosed |
| US-20240166713-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-05-23 | — | — | US | disclosed |
| US-20240166715-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-05-23 | — | — | US | disclosed |
| US-20240166712-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-05-23 | — | — | US | disclosed |
| US-20240166717-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-05-23 | — | — | US | disclosed |
| US-11986497-B2 | Immunotherapy against neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-05-21 | — | — | US | disclosed |
| US-20240158461-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-05-16 | — | — | US | disclosed |
| US-20240158460-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-05-16 | — | — | US | disclosed |
| US-20240150429-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-05-09 | — | — | US | disclosed |
| US-20240150430-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-05-09 | — | — | US | disclosed |
| US-11975058-B2 | Peptides and T cells for use in immunotherapeutic treatment of various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-05-07 | — | — | US | disclosed |
| US-11975042-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-05-07 | — | — | US | disclosed |
| US-11976020-B2 | Method for producing (meth)acrylic acid amide compound, composition, and active energy ray-curable composition | RICOH COMPANY, LTD. (JP) | 2024-05-07 | — | — | US | disclosed |
| US-20240139265-A1 | PROSTATE NEOANTIGENS AND THEIR USES | JANSEN BIOTECH INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240141013-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-05-02 | — | — | US | disclosed |
| US-11969464-B2 | Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-04-30 | — | — | US | disclosed |
| US-11969455-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-04-30 | — | — | US | disclosed |
| US-20240131131-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-04-25 | — | — | US | disclosed |
| US-20240132570-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-04-25 | — | — | US | disclosed |
| US-11965013-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-04-23 | — | — | US | disclosed |
| US-11957742-B2 | Method for treating non-small lung cancer with a population of activated T cells | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-04-16 | — | — | US | disclosed |
| US-11957729-B2 | Powerful MHC-class II peptides derived from survivin | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-04-16 | — | — | US | disclosed |
| US-11957716-B2 | Peptides displayed by HLA for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-04-16 | — | — | US | disclosed |
| US-11957730-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-04-16 | — | — | US | disclosed |
| CN-110041402-B | Novel immunotherapy against a variety of tumors, such as lung cancer including NSCLC | 伊玛提克斯生物技术有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20240117003-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-04-11 | — | — | US | disclosed |
| US-20240117004-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-04-11 | — | — | US | disclosed |
| US-11952409-B2 | Amidated peptides and their deamidated counterparts displayed by non-HLA-A*02 for use in immunotherapy against different types of cancers preliminary class | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-04-09 | — | — | US | disclosed |
| US-11951160-B2 | Peptides and T cells for use in immunotherapeutic treatment of various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-04-09 | — | — | US | disclosed |
| US-11951132-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-04-09 | — | — | US | disclosed |
| US-20240109949-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-04-04 | — | — | US | disclosed |
| US-11945881-B2 | Neoantigens expressed in ovarian cancer and their uses | JANSSEN BIOTECH, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-11945850-B2 | B*44 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-04-02 | — | — | US | disclosed |
| US-11939366-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11939400-B2 | Immunotherapy against several tumors including lung cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11939401-B2 | Immunotherapy against several tumors including lung cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11938176-B2 | Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11932678-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-03-19 | — | — | US | disclosed |
| US-20240083947-A1 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-03-14 | — | — | US | disclosed |
| US-20240083969-A1 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-03-14 | — | — | US | disclosed |
| US-20240076349-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-03-07 | — | — | US | disclosed |
| US-20240075118-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-03-07 | — | — | US | disclosed |
| US-20240075119-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-03-07 | — | — | US | disclosed |
| US-11918607-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-03-05 | — | — | US | disclosed |
| US-11919940-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-03-05 | — | — | US | disclosed |
| US-20240067697-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-02-29 | — | — | US | disclosed |
| US-11912749-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11912748-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| EP-4324472-A2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | immatics biotechnologies GmbH (DE) | 2024-02-21 | — | — | EP | disclosed |
| US-11904003-B2 | Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-02-20 | — | — | US | disclosed |
| US-11905319-B2 | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-02-20 | — | — | US | disclosed |
| EP-4321529-A2 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | immatics biotechnologies GmbH (DE) | 2024-02-14 | — | — | EP | disclosed |
| EP-4321172-A2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | immatics biotechnologies GmbH (DE) | 2024-02-14 | — | — | EP | disclosed |
| US-11897936-B2 | Peptides, combination of peptides as targets and for use in immunotherapy | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-02-13 | — | — | US | disclosed |
| US-11897934-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-02-13 | — | — | US | disclosed |
| US-11897935-B2 | Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-02-13 | — | — | US | disclosed |
| EP-4316597-A2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | immatics biotechnologies GmbH (DE) | 2024-02-07 | — | — | EP | disclosed |
| US-11890333-B2 | Personalized immunotherapy against several neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-02-06 | — | — | US | disclosed |
| US-11891427-B2 | Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-02-06 | — | — | US | disclosed |
| US-11890334-B2 | Personalized immunotherapy against several neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-02-06 | — | — | US | disclosed |
| US-20240034769-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-02-01 | — | — | US | disclosed |
| US-11883462-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-30 | — | — | US | disclosed |
| US-20240024441-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240024440-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240016907-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-18 | — | — | US | disclosed |
| US-20240016912-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-18 | — | — | US | disclosed |
| US-20240016913-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-18 | — | — | US | disclosed |
| US-20240016911-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-18 | — | — | US | disclosed |
| US-20240016909-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-18 | — | — | US | disclosed |
| US-20240016908-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-18 | — | — | US | disclosed |
| US-20240016906-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-18 | — | — | US | disclosed |
| US-20240016910-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-18 | — | — | US | disclosed |
| US-11872270-B2 | A*03 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-11873329-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-11866473-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-09 | — | — | US | disclosed |
| US-11866517-B2 | Immunotherapy against several tumors including lung cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-09 | — | — | US | disclosed |
| US-11858978-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| US-11857624-B2 | Cancer therapeutic methods utilizing OPCML fragment | PAPYRUS THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11859017-B2 | Immunotherapy against several tumors including lung cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| US-20230414734-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-12-28 | — | — | US | disclosed |
| US-11850274-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-12-26 | — | — | US | disclosed |
| WO-2023240085-A1 | VIRAL PEPTIDES AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11840562-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-12-12 | — | — | US | disclosed |
| US-11839643-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-12-12 | — | — | US | disclosed |
| US-11833193-B2 | A*03 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-12-05 | — | — | US | disclosed |
| US-11833194-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-12-05 | — | — | US | disclosed |
| US-11833195-B2 | Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-12-05 | — | — | US | disclosed |
| US-20230382963-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382964-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-11-30 | — | — | US | disclosed |
| US-11826409-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-11-28 | — | — | US | disclosed |
| US-11826410-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-11-28 | — | — | US | disclosed |
| EP-3273986-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-11-22 | — | — | EP | disclosed |
| EP-4277649-A1 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | immatics biotechnologies GmbH (DE) | 2023-11-22 | — | — | EP | disclosed |
| US-11819518-B2 | Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-11-21 | — | — | US | disclosed |
| US-20230365651-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-11-16 | — | — | US | disclosed |
| US-11814446-B2 | Immunotherapy against several tumors including lung cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| US-11806366-B2 | Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-11-07 | — | — | US | disclosed |
| US-20230346837-A1 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348563-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| US-11801264-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-10-31 | — | — | US | disclosed |
| US-20230338489-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20230340046-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20230338488-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-10-26 | — | — | US | disclosed |
| US-11793843-B2 | Prostate neoantigens and their uses | JANSSEN BIOTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793866-B2 | Peptides and T cells for use in immunotherapeutic treatment of various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| US-20230331807-A1 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-10-19 | — | — | US | disclosed |
| US-11786583-B2 | Peptides and combination of peptides for use in immunotherapy against Hepatocellular carcinoma (HCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| US-11786584-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| US-11779606-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-10-10 | — | — | US | disclosed |
| US-11779605-B2 | Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-10-10 | — | — | US | disclosed |
| US-11779638-B2 | Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-10-10 | — | — | US | disclosed |
| US-20230312679-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR GENERATING SCAFFOLDS FOR THE USE AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-10-05 | — | — | US | disclosed |
| US-20230312680-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-10-05 | — | — | US | disclosed |
| EP-4253401-A2 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | immatics biotechnologies GmbH (DE) | 2023-10-04 | — | — | EP | disclosed |
| CN-116813705-A | Peptide compound, application thereof and composition containing peptide compound | 凯惠科技发展(上海)有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-11759507-B2 | Personalized immunotherapy against several neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-20230287069-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230285461-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230285458-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230285460-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230287071-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230285462-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230285525-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230279066-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230282304-A1 | OFF-TARGET PREDICTION METHOD FOR ANTIGEN-RECOGNITION MOLECULES BINDING TO MHC-PEPTIDE TARGETS | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11744882-B2 | Peptides and T cells for use in immunotherapeutic treatment of various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-09-05 | — | — | US | disclosed |
| US-20230263830-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-08-24 | — | — | US | disclosed |
| US-20230265158-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-08-24 | — | — | US | disclosed |
| US-20230265140-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-08-24 | — | — | US | disclosed |
| US-20230263873-A1 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-08-24 | — | — | US | disclosed |
| US-11732021-B2 | Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-08-22 | — | — | US | disclosed |
| CN-109206481-B | Peptide compound, application thereof and composition containing peptide compound | 尚华医药科技(江西)有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20230257442-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-08-17 | — | — | US | disclosed |
| EP-4221743-A2 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | Immatics Biotechnologies GmbH (DE) | 2023-08-09 | — | — | EP | disclosed |
| EP-4221741-A2 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | immatics Biotechnologies GmbH (DE) | 2023-08-09 | — | — | EP | disclosed |
| US-20230241111-A1 | NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20230241109-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20230242604-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20230241112-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20230241108-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20230241107-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20230241113-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20230241115-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20230241110-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20230241114-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20230241106-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| EP-4219524-A2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS | immatics biotechnologies GmbH (DE) | 2023-08-02 | — | — | EP | disclosed |
| US-20230235014-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-07-27 | — | — | US | disclosed |
| US-20230235016-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-07-27 | — | — | US | disclosed |
| US-20230233612-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-07-27 | — | — | US | disclosed |
| US-20230235015-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-07-27 | — | — | US | disclosed |
| US-20230227518-A1 | PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-07-20 | — | — | US | disclosed |
| US-20230226161-A1 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-07-20 | — | — | US | disclosed |
| US-20230227517-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-07-20 | — | — | US | disclosed |
| US-20230226162-A1 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-07-20 | — | — | US | disclosed |
| US-11702460-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-07-18 | — | — | US | disclosed |
| US-20230220045-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR GENERATING SCAFFOLDS FOR THE USE AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| US-20230212244-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20230203113-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203127-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230201259-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-06-29 | — | — | US | disclosed |
| WO-2023122621-A2 | OFF-TARGET PREDICTION METHOD FOR ANTIGEN-RECOGNITION MOLECULES BINDING TO MHC-PEPTIDE TARGETS | REGENERON PHARMACEUTICALS, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230203114-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-06-29 | — | — | US | disclosed |
| US-11685769-B2 | Peptides for use in immunotherapy against cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-06-27 | — | — | US | disclosed |
| US-20230190813-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230192791-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-06-22 | — | — | US | disclosed |
| US-11679147-B2 | Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-06-20 | — | — | US | disclosed |
| US-11680089-B2 | B*44 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-06-20 | — | — | US | disclosed |
| US-20230181707-A1 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-06-15 | — | — | US | disclosed |
| US-11672848-B2 | Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-06-13 | — | — | US | disclosed |
| US-11673917-B2 | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-06-13 | — | — | US | disclosed |
| US-20230174602-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-11667685-B2 | B*44 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| EP-3388075-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (SEQ ID 25 - MRAX5-003) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-05-24 | — | — | EP | disclosed |
| US-11655280-B2 | Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-05-23 | — | — | US | disclosed |
| US-11655281-B2 | Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-05-23 | — | — | US | disclosed |
| US-20230151076-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-05-18 | — | — | US | disclosed |
| US-11648276-B2 | Immunotherapy against neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-05-16 | — | — | US | disclosed |
| US-11648292-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-05-16 | — | — | US | disclosed |
| US-20230148369-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-05-11 | — | — | US | disclosed |
| EP-4175721-A1 | PROSTATE NEOANTIGENS AND THEIR USES | Janssen Biotech, Inc. (US) | 2023-05-10 | — | — | EP | disclosed |
| EP-4175664-A2 | PROSTATE NEOANTIGENS AND THEIR USES | Janssen Biotech, Inc. (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20230135413-A1 | CURABLE WATER-BASED COMPOSITION, ACTIVE-ENERGY-RAY-CURABLE WATER-BASED COMPOSITION, ACTIVE-ENERGY-RAY-CURABLE WATER-BASED INK, STORED CONTAINER, TWO-DIMENSIONAL OR THREE-DIMENSIONAL IMAGE FORMING APPARATUS, TWO-DIMENSIONAL OR THREE-DIMENSIONAL IMAGE FORMING METHOD, CURED PRODUCT, AND DECORATED BODY | RICOH COMPANY, LTD. (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230135413-A1 | CURABLE WATER-BASED COMPOSITION, ACTIVE-ENERGY-RAY-CURABLE WATER-BASED COMPOSITION, ACTIVE-ENERGY-RAY-CURABLE WATER-BASED INK, STORED CONTAINER, TWO-DIMENSIONAL OR THREE-DIMENSIONAL IMAGE FORMING APPARATUS, TWO-DIMENSIONAL OR THREE-DIMENSIONAL IMAGE FORMING METHOD, CURED PRODUCT, AND DECORATED BODY | RICOH COMPANY, LTD. (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230135413-A1 | CURABLE WATER-BASED COMPOSITION, ACTIVE-ENERGY-RAY-CURABLE WATER-BASED COMPOSITION, ACTIVE-ENERGY-RAY-CURABLE WATER-BASED INK, STORED CONTAINER, TWO-DIMENSIONAL OR THREE-DIMENSIONAL IMAGE FORMING APPARATUS, TWO-DIMENSIONAL OR THREE-DIMENSIONAL IMAGE FORMING METHOD, CURED PRODUCT, AND DECORATED BODY | RICOH COMPANY, LTD. (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230125179-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-04-27 | — | — | US | disclosed |
| US-11629177-B2 | B*44 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-04-18 | — | — | US | disclosed |
| CN-115968299-A | Novel antigens expressed in multiple myeloma and uses thereof | 詹森生物科技公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20230116279-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-04-13 | — | — | US | disclosed |
| US-20230113246-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-04-13 | — | — | US | disclosed |
| CN-109734777-B | Novel peptides, peptide compositions and scaffolds for immunotherapy of various cancers | 伊玛提克斯生物技术有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115925806-A | Novel peptides, peptide compositions and scaffolds for immunotherapy of various cancers | 伊玛提克斯生物技术有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20230109584-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-04-06 | — | — | US | disclosed |
| EP-3573647-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-04-05 | — | — | EP | disclosed |
| US-11618774-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-04-04 | — | — | US | disclosed |
| US-20230100686-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-03-30 | — | — | US | disclosed |
| US-20230094286-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-03-30 | — | — | US | disclosed |
| US-20230094790-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-03-30 | — | — | US | disclosed |
| US-20230094553-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-03-30 | — | — | US | disclosed |
| US-20230101093-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-03-30 | — | — | US | disclosed |
| US-20230088845-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-03-23 | — | — | US | disclosed |
| US-20230086100-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-03-23 | — | — | US | disclosed |
| US-20230087025-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-03-23 | — | — | US | disclosed |
| US-20230088740-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-03-23 | — | — | US | disclosed |
| US-20230086855-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-03-23 | — | — | US | disclosed |
| US-20230089882-A1 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-03-23 | — | — | US | disclosed |
| US-11608370-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-03-21 | — | — | US | disclosed |
| US-11607446-B2 | Personalized immunotherapy against several neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-03-21 | — | — | US | disclosed |
| US-20230077903-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-03-16 | — | — | US | disclosed |
| US-20230077371-A1 | CURABLE COMPOSITION, CURABLE INK, COMPOSITION CONTAINER, DEVICE FOR FORMING TWO-DIMENSIONAL OR THREE-DIMENSIONAL IMAGE, METHOD OF FORMING TWO-DIMENSIONAL OR THREE-DIMENSIONAL IMAGE, CURED MATTER, AND DECORATIVE OBJECT | RICOH COMPANY, LTD. (JP) | 2023-03-16 | — | — | US | disclosed |
| US-11603397-B2 | Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-03-14 | — | — | US | disclosed |
| CN-110041403-B | Novel immunotherapy against a variety of tumors, such as lung cancer including NSCLC | 伊玛提克斯生物技术有限公司 | 2023-03-10 | — | — | CN | disclosed |
| US-11597752-B2 | Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-03-07 | — | — | US | disclosed |
| US-20230065320-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-03-02 | — | — | US | disclosed |
| US-20230051523-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-02-16 | — | — | US | disclosed |
| US-20230046543-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-02-16 | — | — | US | disclosed |
| US-20230051035-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-02-16 | — | — | US | disclosed |
| US-11576954-B2 | Method for treating non-small lung cancer with a population of activated cells | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-02-14 | — | — | US | disclosed |
| US-11576956-B2 | Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-02-14 | — | — | US | disclosed |
| US-11576955-B2 | A*03 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-02-14 | — | — | US | disclosed |
| US-20230043654-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-02-09 | — | — | US | disclosed |
| US-20230042253-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-02-09 | — | — | US | disclosed |
| US-20230042461-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR GENERATING SCAFFOLDS FOR THE USE AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-02-09 | — | — | US | disclosed |
| US-20230040789-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-02-09 | — | — | US | disclosed |
| US-20230031307-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-02-02 | — | — | US | disclosed |
| US-20230029453-A1 | Prostate Neoantigens And Their Uses | JANSSEN BIOTECH, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20230035702-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-02-02 | — | — | US | disclosed |
| US-20230021673-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230023408-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230024133-A1 | Prostate Neoantigens And Their Uses | JANSSEN BIOTECH, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11559550-B2 | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-24 | — | — | US | disclosed |
| US-11560405-B2 | Peptides and combination thereof for use in the immunotherapy against cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-24 | — | — | US | disclosed |
| US-11559572-B2 | Peptides and T cells for use in immunotherapeutic treatment of various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-24 | — | — | US | disclosed |
| US-11559573-B2 | Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-24 | — | — | US | disclosed |
| US-11554164-B2 | A*03 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-17 | — | — | US | disclosed |
| US-20230012265-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-12 | — | — | US | disclosed |
| US-11547750-B2 | Peptides and T cells for use in immunotherapeutic treatment hepatocellular carcinoma | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-10 | — | — | US | disclosed |
| US-20230002474-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-05 | — | — | US | disclosed |
| US-20230002464-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-05 | — | — | US | disclosed |
| US-20230002462-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-05 | — | — | US | disclosed |
| US-20230002473-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-05 | — | — | US | disclosed |
| US-20230002463-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-05 | — | — | US | disclosed |
| US-20230002461-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-05 | — | — | US | disclosed |
| US-11541107-B2 | Peptides and T cells for use in immunotherapeutic treatment of various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-03 | — | — | US | disclosed |
| US-11542303-B2 | Peptides and combination thereof for use in the immunotherapy against cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-03 | — | — | US | disclosed |
| CN-115515623-A | Novel antigens expressed in ovarian cancer and uses thereof | 詹森生物科技公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-4103221-A1 | NEOANTIGENS EXPRESSED IN MULTIPLE MYELOMA AND THEIR USES | Janssen Biotech, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-4103222-A1 | NEOANTIGENS EXPRESSED IN OVARIAN CANCER AND THEIR USES | Janssen Biotech, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-11529401-B2 | Personalized immunotherapy against several neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-12-20 | — | — | US | disclosed |
| US-11529400-B1 | Personalized immunotherapy against several neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-12-20 | — | — | US | disclosed |
| US-11529302-B2 | Composition, artificial nail composition, nail decoration material, artificial nail, stored container, image forming apparatus, and image forming method | RICOH COMPANY, LTD. (JP) | 2022-12-20 | — | — | US | disclosed |
| US-11529302-B2 | Composition, artificial nail composition, nail decoration material, artificial nail, stored container, image forming apparatus, and image forming method | RICOH COMPANY, LTD. (JP) | 2022-12-20 | — | — | US | disclosed |
| US-11524059-B2 | Personalized immunotherapy against several neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-12-13 | — | — | US | disclosed |
| WO-2022256739-A2 | ANTIBODY SPECIFIC FOR BCL-6 AND METHODS OF USE | NONAGEN THERAPEUTICS CORPORATION (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20220387566-A1 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-12-08 | — | — | US | disclosed |
| US-20220389068-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-12-08 | — | — | US | disclosed |
| US-20220372104-A1 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-24 | — | — | US | disclosed |
| US-20220370583-A1 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-24 | — | — | US | disclosed |
| US-20220363729-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
| US-20220362302-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
| US-20220362364-A1 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
| US-20220363717-A1 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
| US-20220362363-A1 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
| US-20220363730-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
| US-20220362362-A1 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
| US-11498948-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-15 | — | — | US | disclosed |
| US-20220354936-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-10 | — | — | US | disclosed |
| US-20220356220-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-10 | — | — | US | disclosed |
| US-20220354939-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-10 | — | — | US | disclosed |
| US-20220356208-A1 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-10 | — | — | US | disclosed |
| US-20220356227-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-10 | — | — | US | disclosed |
| US-20220348622-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-03 | — | — | US | disclosed |
| US-20220348621-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-03 | — | — | US | disclosed |
| US-20220348630-A1 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-03 | — | — | US | disclosed |
| US-11485769-B2 | Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-01 | — | — | US | disclosed |
| US-11485765-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-01 | — | — | US | disclosed |
| US-20220339272-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-10-27 | — | — | US | disclosed |
| EP-4079316-A1 | PROCOAGULANT COMPOUNDS | Bioverativ Therapeutics Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| US-11479622-B2 | Active energy ray curable composition, active energy ray curable ink, composition accommodating container, two or three dimensional image forming apparatus, two or three dimensional image forming method, cured matter, decorative matter, artificial nail composition, nail decorative material, and artificial nail | RICOH COMPANY, LTD. (JP) | 2022-10-25 | — | — | US | disclosed |
| US-11479594-B2 | Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-10-25 | — | — | US | disclosed |
| US-11479589-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-10-25 | — | — | US | disclosed |
| US-20220331413-A1 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-10-20 | — | — | US | disclosed |
| US-20220332760-A1 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-10-20 | — | — | US | disclosed |
| US-20220324941-A1 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-10-13 | — | — | US | disclosed |
| US-20220323501-A1 | NOVEL PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-10-13 | — | — | US | disclosed |
| US-20220323502-A1 | NOVEL PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-10-13 | — | — | US | disclosed |
| US-20220323559-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-10-13 | — | — | US | disclosed |
| US-20220323560-A1 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-10-13 | — | — | US | disclosed |
| US-11466072-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-10-11 | — | — | US | disclosed |
| US-20220313807-A1 | NOVEL PEPTIDES & COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML & OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-10-06 | — | — | US | disclosed |
| US-20220313805-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-10-06 | — | — | US | disclosed |
| US-11459366-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-10-04 | — | — | US | disclosed |
| US-11459371-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-10-04 | — | — | US | disclosed |
| US-11459365-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-10-04 | — | — | US | disclosed |
| US-20220306721-A1 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-09-29 | — | — | US | disclosed |
| US-20220298207-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-09-22 | — | — | US | disclosed |
| US-20220289816-A1 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-09-15 | — | — | US | disclosed |
| US-20220289817-A1 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-09-15 | — | — | US | disclosed |
| US-11440947-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-09-13 | — | — | US | disclosed |
| US-20220280622-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-09-08 | — | — | US | disclosed |
| US-20220280623-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-09-08 | — | — | US | disclosed |
| US-20220281917-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-09-08 | — | — | US | disclosed |
| EP-3236985-B2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-09-07 | — | — | EP | disclosed |
| US-11433099-B2 | Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-09-06 | — | — | US | disclosed |
| US-11434274-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-09-06 | — | — | US | disclosed |
| US-11433124-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-09-06 | — | — | US | disclosed |
| US-11434273-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-09-06 | — | — | US | disclosed |
| CN-109748953-B | Novel immunotherapies for the treatment of various tumors (e.g., lung cancer including NSCLC) | 伊玛提克斯生物技术有限公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20220273783-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-09-01 | — | — | US | disclosed |
| US-11427622-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-30 | — | — | US | disclosed |
| US-11427614-B2 | Peptides and combination thereof for use in the immunotherapy against cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-30 | — | — | US | disclosed |
| US-20220265793-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-25 | — | — | US | disclosed |
| US-20220265794-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-25 | — | — | US | disclosed |
| US-20220265795-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-25 | — | — | US | disclosed |
| US-20220267391-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-25 | — | — | US | disclosed |
| US-20220267392-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-25 | — | — | US | disclosed |
| US-20220265764-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-25 | — | — | US | disclosed |
| US-20220267408-A1 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-25 | — | — | US | disclosed |
| CN-107428810-B | Novel peptides and peptide compositions for immunotherapy of pancreatic and other cancers | 伊玛提克斯生物技术有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20220257738-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-18 | — | — | US | disclosed |
| US-20220257736-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-18 | — | — | US | disclosed |
| US-20220259338-A1 | IMAGE FORMING DEVICE AND IMAGE FORMING METHOD | RICOH COMPANY, LTD. (JP) | 2022-08-18 | — | — | US | disclosed |
| US-20220257739-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-18 | — | — | US | disclosed |
| US-11414473-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-16 | — | — | US | disclosed |
| US-11414472-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-16 | — | — | US | disclosed |
| US-11414470-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-16 | — | — | US | disclosed |
| US-11414471-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-16 | — | — | US | disclosed |
| US-20220249630-A1 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-11 | — | — | US | disclosed |
| US-20220249632-A1 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-11 | — | — | US | disclosed |
| US-20220249633-A1 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-11 | — | — | US | disclosed |
| US-20220249635-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-11 | — | — | US | disclosed |
| US-11407808-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-09 | — | — | US | disclosed |
| US-11407810-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-09 | — | — | US | disclosed |
| US-11406693-B2 | Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-09 | — | — | US | disclosed |
| US-11407807-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-09 | — | — | US | disclosed |
| US-11407809-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-09 | — | — | US | disclosed |
| US-11407798-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-09 | — | — | US | disclosed |
| US-20220243189-A1 | PROCOAGULANT COMPOUNDS | BIOGEN MA INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220242925-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST SMALL CELL LUNG CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-04 | — | — | US | disclosed |
| EP-4035675-A2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2022-08-03 | — | — | EP | disclosed |
| US-11401310-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-08-02 | — | — | US | disclosed |
| US-11401319-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH | 2022-08-02 | — | — | US | disclosed |
| US-20220233664-A1 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-07-28 | — | — | US | disclosed |
| US-20220235107-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-07-28 | — | — | US | disclosed |
| US-20220233663-A1 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-07-28 | — | — | US | disclosed |
| CN-107921111-B | Novel peptides, peptide compositions and scaffolds for immunotherapy of various cancers | 伊玛提克斯生物技术有限公司 | 2022-07-26 | — | — | CN | disclosed |
| US-20220226450-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-07-21 | — | — | US | disclosed |
| WO-2022152880-A1 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-07-21 | — | — | WO | disclosed |
| US-20220226452-A1 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-07-21 | — | — | US | disclosed |
| US-20220226451-A1 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-07-21 | — | — | US | disclosed |
| US-20220226376-A1 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-07-21 | — | — | US | disclosed |
| US-11390660-B2 | Uterine cancer treatments | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-07-19 | — | — | US | disclosed |
| US-11384129-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-07-12 | — | — | US | disclosed |
| US-11384127-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-07-12 | — | — | US | disclosed |
| US-11384128-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-07-12 | — | — | US | disclosed |
| CN-109134610-B | Peptide compound, application thereof and composition containing peptide compound | 尚华医药科技(江西)有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220211833-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-07-07 | — | — | US | disclosed |
| US-20220213168-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-07-07 | — | — | US | disclosed |
| EP-3321333-B1 | CURABLE COMPOSITION, CURABLE INK, ACCOMMODATING CONTAINER, IMAGE FORMING DEVICE, IMAGE FORMING METHOD, CURED MATTER, AND ACRYLAMIDE COMPOUND | RICOH CO LTD (JP) | 2022-07-06 | — | — | EP | disclosed |
| US-11376281-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-07-05 | — | — | US | disclosed |
| US-11369636-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-06-28 | — | — | US | disclosed |
| US-11370817-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-06-28 | — | — | US | disclosed |
| US-20220194987-A1 | BK CHANNEL-MODULATING PEPTIDES AND THEIR USE | NATIONAL INSTITUTES OF HEALTH | 2022-06-23 | — | — | US | disclosed |
| US-20220193212-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-06-23 | — | — | US | disclosed |
| US-20220194984-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-06-23 | — | — | US | disclosed |
| US-11365234-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-06-21 | — | — | US | disclosed |
| US-11365235-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-06-21 | — | — | US | disclosed |
| US-20220184193-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-06-16 | — | — | US | disclosed |
| US-20220184194-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-06-16 | — | — | US | disclosed |
| US-11357797-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-06-14 | — | — | US | disclosed |
| US-11359003-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-06-14 | — | — | US | disclosed |
| US-20220175898-A1 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-06-09 | — | — | US | disclosed |
| US-11352401-B1 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-06-07 | — | — | US | disclosed |
| US-20220169692-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-06-02 | — | — | US | disclosed |
| US-20220169691-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-06-02 | — | — | US | disclosed |
| US-11345737-B1 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-31 | — | — | US | disclosed |
| US-20220162277-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-26 | — | — | US | disclosed |
| US-20220160851-A1 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-26 | — | — | US | disclosed |
| US-20220152175-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-19 | — | — | US | disclosed |
| US-20220153796-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-19 | — | — | US | disclosed |
| US-20220152171-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-19 | — | — | US | disclosed |
| US-11332512-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-17 | — | — | US | disclosed |
| US-20220143164-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20220143091-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20220143163-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20220143162-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
| US-11324812-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-10 | — | — | US | disclosed |
| US-20220133870-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-05 | — | — | US | disclosed |
| US-20220135648-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-05 | — | — | US | disclosed |
| US-20220135636-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-05 | — | — | US | disclosed |
| US-20220135647-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-05 | — | — | US | disclosed |
| US-20220135635-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-05 | — | — | US | disclosed |
| US-20220135646-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-05 | — | — | US | disclosed |
| US-20220125902-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| US-20220127320-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DK) | 2022-04-28 | — | — | US | disclosed |
| EP-3988563-A2 | NOVEL PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2022-04-27 | — | — | EP | disclosed |
| CN-114395013-A | Novel peptides and peptide compositions for immunotherapy of prostate and other cancers | 伊玛提克斯生物技术有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20220119484-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-21 | — | — | US | disclosed |
| US-20220119487-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-21 | — | — | US | disclosed |
| US-20220119486-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-21 | — | — | US | disclosed |
| US-20220118071-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-21 | — | — | US | disclosed |
| US-20220118016-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-21 | — | — | US | disclosed |
| US-20220119470-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-21 | — | — | US | disclosed |
| US-20220119485-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-21 | — | — | US | disclosed |
| US-20220112266-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-14 | — | — | US | disclosed |
| US-20220112254-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-14 | — | — | US | disclosed |
| US-20220111022-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-14 | — | — | US | disclosed |
| US-20220112253-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-14 | — | — | US | disclosed |
| US-11298404-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-12 | — | — | US | disclosed |
| US-20220106380-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-07 | — | — | US | disclosed |
| WO-2022069579-A2 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-07 | — | — | WO | disclosed |
| US-20220105165-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-07 | — | — | US | disclosed |
| WO-2022069557-A2 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-07 | — | — | WO | disclosed |
| US-20220106379-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-07 | — | — | US | disclosed |
| US-11292821-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-04-05 | — | — | US | disclosed |
| US-20220098276-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-03-31 | — | — | US | disclosed |
| US-20220098277-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-03-31 | — | — | US | disclosed |
| US-20220098269-A1 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-03-31 | — | — | US | disclosed |
| US-20220098275-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-03-31 | — | — | US | disclosed |
| US-11279741-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-03-22 | — | — | US | disclosed |
| US-11278571-B2 | Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-03-22 | — | — | US | disclosed |
| US-11279740-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-03-22 | — | — | US | disclosed |
| CN-107810193-B | Novel peptides and peptide compositions and scaffolds thereof for immunotherapy of colorectal cancer (CRC) and other cancers | 伊玛提克斯生物技术有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-107864654-B | Novel peptides and peptide compositions for immunotherapy and methods for the generation of scaffolds for pancreatic and other cancers | 伊玛提克斯生物技术有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-11273200-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-03-15 | — | — | US | disclosed |
| CN-114163501-A | Novel peptides and peptide compositions for immunotherapy of epithelial ovarian and other cancers | 伊玛提克斯生物技术有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-108026154-B | Novel peptides and peptide compositions for immunotherapy of ovarian and other cancers | 伊玛提克斯生物技术有限公司 | 2022-03-08 | — | — | CN | disclosed |
| US-20220064220-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-03-03 | — | — | US | disclosed |
| US-20220064241-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-03-03 | — | — | US | disclosed |
| EP-3693000-B1 | PROCOAGULANT COMPOUNDS | BIOVERATIV THERAPEUTICS INC (US) | 2022-03-02 | — | — | EP | disclosed |
| US-11261437-B2 | Procoagulant compounds | BIOVERATIV THERAPEUTICS INC. (US) | 2022-03-01 | — | — | US | disclosed |
| US-11261224-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-03-01 | — | — | US | disclosed |
| US-11260115-B1 | Peptides and combination of peptides for use in immunotherapy against CLL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-03-01 | — | — | US | disclosed |
| US-20220054612-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-24 | — | — | US | disclosed |
| US-20220056103-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-24 | — | — | US | disclosed |
| US-20220054613-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-24 | — | — | US | disclosed |
| CN-107912043-B | Novel peptides and peptide compositions for immunotherapy of esophageal and other cancers | 伊玛提克斯生物技术有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20220048964-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| US-11246917-B2 | A*03 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-15 | — | — | US | disclosed |
| US-11248035-B1 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-15 | — | — | US | disclosed |
| US-11246889-B2 | Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-15 | — | — | US | disclosed |
| CN-114040921-A | Peptides and peptide combinations of non-classical origin for immunotherapy of different types of cancer | 伊玛提克斯生物技术有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-114028549-A | Novel peptides and peptide compositions for immunotherapy of NHL and other cancers | 伊玛提克斯生物技术有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20220041689-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-10 | — | — | US | disclosed |
| US-20220033469-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-03 | — | — | US | disclosed |
| US-20220031824-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-03 | — | — | US | disclosed |
| US-11235042-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-01 | — | — | US | disclosed |
| US-11235041-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-01 | — | — | US | disclosed |
| US-20220023403-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-27 | — | — | US | disclosed |
| US-20220023404-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-27 | — | — | US | disclosed |
| US-11230581-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-25 | — | — | US | disclosed |
| US-20220017595-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-20 | — | — | US | disclosed |
| US-20220016209-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-20 | — | — | US | disclosed |
| US-20220016207-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-20 | — | — | US | disclosed |
| US-20220017598-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-20 | — | — | US | disclosed |
| US-20220016227-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-20 | — | — | US | disclosed |
| US-11224644-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-18 | — | — | US | disclosed |
| US-20220008471-A1 | IMMUNOTHERAPY WITH B*08 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-13 | — | — | US | disclosed |
| US-20220008472-A1 | IMMUNOTHERAPY WITH B*08 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-13 | — | — | US | disclosed |
| US-20220009982-A1 | IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-13 | — | — | US | disclosed |
| US-20220008506-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-13 | — | — | US | disclosed |
| US-20220009983-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-13 | — | — | US | disclosed |
| WO-2022009049-A1 | PROSTATE NEOANTIGENS AND THEIR USES | JANSSEN BIOTECH, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022009052-A2 | PROSTATE NEOANTIGENS AND THEIR USES | JANSSEN BIOTECH, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20220009995-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-13 | — | — | US | disclosed |
| EP-3431557-B1 | COMPOSITION, CURED PRODUCT, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | RICOH CO LTD (JP) | 2022-01-12 | — | — | EP | disclosed |
| CN-113912702-A | Novel peptides and peptide compositions and scaffolds for Renal Cell Carcinoma (RCC) immunotherapy | 伊玛提克斯生物技术有限公司 | 2022-01-11 | — | — | CN | disclosed |
| US-20220002378-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-06 | — | — | US | disclosed |
| US-20220002374-A1 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-06 | — | — | US | disclosed |
| US-20220000922-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-06 | — | — | US | disclosed |
| US-20220002366-A1 | IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-06 | — | — | US | disclosed |
| US-11214595-B2 | BK channel-modulating peptides and their use | UNIVERSITY OF SOUTH FLORIDA (US) | 2022-01-04 | — | — | US | disclosed |
| US-11214608-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-04 | — | — | US | disclosed |
| US-11214604-B2 | Peptides for use in immunotherapy against cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-01-04 | — | — | US | disclosed |
| CN-107624118-B | Novel peptides and peptide compositions for immunotherapy of lung cancer, including non-small cell lung cancer and other cancers | 伊玛提克斯生物技术有限公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-113880938-A | Novel peptides and peptide compositions for immunotherapy of esophageal and other cancers | 伊玛提克斯生物技术有限公司 | 2022-01-04 | — | — | CN | disclosed |
| US-20210401892-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-12-30 | — | — | US | disclosed |
| US-20210403531-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-12-30 | — | — | US | disclosed |
| US-20210401888-A1 | NOVEL PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-12-30 | — | — | US | disclosed |
| US-20210403530-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-12-30 | — | — | US | disclosed |
| US-20210403506-A1 | PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| US-11208434-B2 | Immunotherapy against several tumors including neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-12-28 | — | — | US | disclosed |
| US-11208516-B2 | Composition, cured product, storage container, image forming apparatus, and image forming method | RICOH COMPANY, LTD. (JP) | 2021-12-28 | — | — | US | disclosed |
| US-11208448-B2 | B*44 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-12-28 | — | — | US | disclosed |
| US-11208449-B2 | Peptides for use in immunotherapy against cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-12-28 | — | — | US | disclosed |
| US-11208516-B2 | Composition, cured product, storage container, image forming apparatus, and image forming method | RICOH COMPANY, LTD. (JP) | 2021-12-28 | — | — | US | disclosed |
| US-20210395334-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-12-23 | — | — | US | disclosed |
| US-20210395338-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-12-23 | — | — | US | disclosed |
| US-20210395337-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-12-23 | — | — | US | disclosed |
| US-20210393756-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-12-23 | — | — | US | disclosed |
| US-20210395335-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-12-23 | — | — | US | disclosed |
| US-20210393754-A1 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-12-23 | — | — | US | disclosed |
| US-20210395336-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-12-23 | — | — | US | disclosed |
| US-11197892-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-12-14 | — | — | US | disclosed |
| CN-107438619-B | Novel peptides and peptide compositions and scaffolds for Renal Cell Carcinoma (RCC) immunotherapy | 伊玛提克斯生物技术有限公司 | 2021-12-14 | — | — | CN | disclosed |
| US-20210380662-A1 | Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-12-09 | — | — | US | disclosed |
| EP-3919507-A2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2021-12-08 | — | — | EP | disclosed |
| US-20210369826-A1 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-12-02 | — | — | US | disclosed |
| EP-3915577-A1 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2021-12-01 | — | — | EP | disclosed |
| US-20210363208-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-25 | — | — | US | disclosed |
| US-20210363211-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-25 | — | — | US | disclosed |
| US-20210363221-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-25 | — | — | US | disclosed |
| US-20210363210-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-25 | — | — | US | disclosed |
| US-20210363209-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-25 | — | — | US | disclosed |
| US-11179418-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-23 | — | — | US | disclosed |
| US-11180532-B2 | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-23 | — | — | US | disclosed |
| US-20210355075-A1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID AMIDE COMPOUND, COMPOSITION, AND ACTIVE ENERGY RAY-CURABLE COMPOSITION | RICOH COMPANY, LTD. (JP) | 2021-11-18 | — | — | US | disclosed |
| US-20210353728-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-18 | — | — | US | disclosed |
| EP-3908311-A1 | PROSTATE NEOANTIGENS AND THEIR USES | Janssen Biotech, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-3909942-A1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID AMIDE COMPOUND, COMPOSITION, AND ACTIVE ENERGY RAY-CURABLE COMPOSITION | Ricoh Company, Ltd. (JP) | 2021-11-17 | — | — | EP | disclosed |
| US-20210346481-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-11 | — | — | US | disclosed |
| US-20210346466-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-11 | — | — | US | disclosed |
| US-20210346465-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-11 | — | — | US | disclosed |
| US-20210347822-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-11 | — | — | US | disclosed |
| US-11168122-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-09 | — | — | US | disclosed |
| US-20210340202-A1 | PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-04 | — | — | US | disclosed |
| US-20210338734-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-04 | — | — | US | disclosed |
| US-20210340216-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-04 | — | — | US | disclosed |
| US-20210338735-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-04 | — | — | US | disclosed |
| US-20210340204-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-04 | — | — | US | disclosed |
| US-20210340217-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-04 | — | — | US | disclosed |
| US-20210340203-A1 | PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-04 | — | — | US | disclosed |
| US-11161878-B2 | Immunotherapy against several tumors including lung cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-02 | — | — | US | disclosed |
| US-11161877-B2 | Immunotherapy against several tumors including lung cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-02 | — | — | US | disclosed |
| US-11161879-B2 | Immunotherapy against several tumors, such as lung cancer, including NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-02 | — | — | US | disclosed |
| US-11161880-B2 | Immunotherapy against several tumors, such as lung cancer, including NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-11-02 | — | — | US | disclosed |
| CN-113573729-A | Prostate novel antigen and uses thereof | 詹森生物科技公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-113563455-A | Novel peptides and peptide compositions for immunotherapy and methods for the generation of scaffolds for pancreatic and other cancers | 伊玛提克斯生物技术有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-113563456-A | Novel peptides and peptide compositions for immunotherapy of pancreatic and other cancers | 伊玛提克斯生物技术有限公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20210330771-A1 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-28 | — | — | US | disclosed |
| US-20210330708-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-28 | — | — | US | disclosed |
| US-20210330743-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-28 | — | — | US | disclosed |
| US-20210330772-A1 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-28 | — | — | US | disclosed |
| EP-3897698-A2 | IMMUNOTHERAPY WITH B*08 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | immatics Biotechnologies GmbH (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-11154576-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-26 | — | — | US | disclosed |
| US-11155590-B2 | B*44 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-26 | — | — | US | disclosed |
| US-11155597-B2 | Relaxin1 derived peptides for use in immunotherapy | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-26 | — | — | US | disclosed |
| CN-113527421-A | Novel peptides and peptide compositions and scaffolds thereof for immunotherapy of colorectal cancer (CRC) and other cancers | 伊玛提克斯生物技术有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20210322478-A1 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-21 | — | — | US | disclosed |
| US-20210322527-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-21 | — | — | US | disclosed |
| EP-3456339-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-20 | — | — | EP | disclosed |
| US-11147839-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-19 | — | — | US | disclosed |
| US-11147838-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-19 | — | — | US | disclosed |
| US-20210317175-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-14 | — | — | US | disclosed |
| EP-3616706-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-13 | — | — | EP | disclosed |
| US-11141437-B2 | Peptides and combination of peptides of non- canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-12 | — | — | US | disclosed |
| US-11142556-B2 | Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-12 | — | — | US | disclosed |
| CN-113480635-A | Novel peptides and peptide compositions for immunotherapy of various tumors | 伊玛提克斯生物技术有限公司 | 2021-10-08 | — | — | CN | disclosed |
| CN-113480604-A | Novel peptides and peptide compositions for immunotherapy of ovarian and other cancers | 伊玛提克斯生物技术有限公司 | 2021-10-08 | — | — | CN | disclosed |
| US-20210309715-A1 | UTERINE CANCER TREATMENTS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-07 | — | — | US | disclosed |
| US-20210309771-A1 | COMPOSITION, ARTIFICIAL NAIL COMPOSITION, NAIL DECORATION MATERIAL, ARTIFICIAL NAIL, STORED CONTAINER, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | RICOH COMPANY, LTD. (JP) | 2021-10-07 | — | — | US | disclosed |
| US-20210309771-A1 | COMPOSITION, ARTIFICIAL NAIL COMPOSITION, NAIL DECORATION MATERIAL, ARTIFICIAL NAIL, STORED CONTAINER, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | RICOH COMPANY, LTD. (JP) | 2021-10-07 | — | — | US | disclosed |
| US-11136352-B2 | Immunotherapy against several tumors including neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-05 | — | — | US | disclosed |
| US-11135246-B2 | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20210300968-A1 | UTERINE CANCER TREATMENTS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| EP-3885356-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NHL AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2021-09-29 | — | — | EP | disclosed |
| CN-113444148-A | Use of A03-restricted peptides in anti-cancer immunotherapy and related methods | 伊玛提克斯生物技术有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20210292367-A1 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-23 | — | — | US | disclosed |
| US-20210290743-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-23 | — | — | US | disclosed |
| US-20210290745-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-23 | — | — | US | disclosed |
| US-20210290744-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-23 | — | — | US | disclosed |
| US-20210292365-A1 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-23 | — | — | US | disclosed |
| US-11123370-B2 | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-21 | — | — | US | disclosed |
| US-20210283231-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-16 | — | — | US | disclosed |
| US-20210284704-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST SMALL CELL LUNG CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-16 | — | — | US | disclosed |
| US-20210283230-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-16 | — | — | US | disclosed |
| US-11117941-B2 | B*44 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-14 | — | — | US | disclosed |
| US-11117951-B2 | Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-14 | — | — | US | disclosed |
| US-11116826-B2 | Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-14 | — | — | US | disclosed |
| US-20210275655-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-09 | — | — | US | disclosed |
| US-20210277086-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-09 | — | — | US | disclosed |
| US-20210277087-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-09 | — | — | US | disclosed |
| US-20210275656-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-09 | — | — | US | disclosed |
| US-20210275634-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-09 | — | — | US | disclosed |
| US-20210277080-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-09 | — | — | US | disclosed |
| US-20210275653-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-09 | — | — | US | disclosed |
| US-20210277088-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-09 | — | — | US | disclosed |
| US-20210275654-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-09 | — | — | US | disclosed |
| US-20210275652-A1 | PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-09 | — | — | US | disclosed |
| US-20210277081-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-09 | — | — | US | disclosed |
| EP-3875467-A2 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2021-09-08 | — | — | EP | disclosed |
| EP-3626729-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-08 | — | — | EP | disclosed |
| EP-3626731-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-08 | — | — | EP | disclosed |
| US-11111281-B2 | B*44 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-07 | — | — | US | disclosed |
| US-11111280-B2 | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-09-07 | — | — | US | disclosed |
| CN-105026419-B | Vaccine composition quantification | 勃林格殷格翰动物保健美国有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-20210252064-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-08-19 | — | — | US | disclosed |
| US-20210253640-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-08-19 | — | — | US | disclosed |
| US-20210253637-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-08-19 | — | — | US | disclosed |
| WO-2021161244-A1 | NEOANTIGENS EXPRESSED IN OVARIAN CANCER AND THEIR USES | JANSSEN BIOTECH, INC. (US) | 2021-08-19 | — | — | WO | disclosed |
| US-20210252065-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-08-19 | — | — | US | disclosed |
| WO-2021161245-A1 | NEOANTIGENS EXPRESSED IN MULTIPLE MYELOMA AND THEIR USES | JANSSEN BIOTECH, INC. (US) | 2021-08-19 | — | — | WO | disclosed |
| US-20210252061-A1 | NOVEL PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-08-19 | — | — | US | disclosed |
| US-20210252066-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-08-19 | — | — | US | disclosed |
| CN-113260376-A | B08 restricted peptides and peptide compositions for anticancer immunotherapy and related methods | 伊玛提克斯生物技术有限公司 | 2021-08-13 | — | — | CN | disclosed |
| US-20210244765-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-08-12 | — | — | US | disclosed |
| US-20210246181-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-08-12 | — | — | US | disclosed |
| US-11084940-B2 | Composition, cured product, storage container, image forming apparatus, and image forming method | RICOH COMPANY, LTD. (JP) | 2021-08-10 | — | — | US | disclosed |
| US-11084940-B2 | Composition, cured product, storage container, image forming apparatus, and image forming method | RICOH COMPANY, LTD. (JP) | 2021-08-10 | — | — | US | disclosed |
| US-11083784-B2 | Peptides and combination of peptides for use in immunotherapy against CLL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-08-10 | — | — | US | disclosed |
| US-20210238227-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-08-05 | — | — | US | disclosed |
| US-20210238243-A1 | IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-08-05 | — | — | US | disclosed |
| US-11077142-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-08-03 | — | — | US | disclosed |
| CN-109280116-B | Composition, cured product, image forming apparatus, and image forming method | 株式会社理光 | 2021-08-03 | — | — | CN | disclosed |
| US-11077171-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-08-03 | — | — | US | disclosed |
| US-11078253-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-08-03 | — | — | US | disclosed |
| CN-109701091-B | Covering material for skin care | 王丽娟 | 2021-07-30 | — | — | CN | disclosed |
| US-20210228697-A1 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-29 | — | — | US | disclosed |
| US-20210228698-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-29 | — | — | US | disclosed |
| US-20210230240-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-29 | — | — | US | disclosed |
| EP-3854801-A2 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | immatics biotechnologies GmbH (DE) | 2021-07-28 | — | — | EP | disclosed |
| EP-3853243-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | Immatics Biotechnologies GmbH (DE) | 2021-07-28 | — | — | EP | disclosed |
| EP-3852787-A1 | IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | immatics Biotechnologies GmbH (DE) | 2021-07-28 | — | — | EP | disclosed |
| US-11071773-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| US-11071756-B2 | Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| CN-113150115-A | Peptides for anticancer immunotherapy | 伊玛提克斯生物技术有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113164569-A | A01 restricted peptides and peptide compositions for use in anticancer immunotherapy and related methods | 伊玛提克斯生物技术有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3545965-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-21 | — | — | EP | disclosed |
| US-11065279-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-20 | — | — | US | disclosed |
| US-11065316-B2 | Peptides and T cells for use in immunother[[r]]apeutic treatment of various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-20 | — | — | US | disclosed |
| US-11065314-B2 | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-20 | — | — | US | disclosed |
| US-11065315-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-20 | — | — | US | disclosed |
| US-20210213065-A1 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-15 | — | — | US | disclosed |
| US-20210213064-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-15 | — | — | US | disclosed |
| US-11058726-B2 | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-13 | — | — | US | disclosed |
| US-11058727-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-13 | — | — | US | disclosed |
| US-11058754-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-13 | — | — | US | disclosed |
| US-11058755-B2 | A*03 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-13 | — | — | US | disclosed |
| US-11059985-B2 | Composition, cured product, storage container, image forming apparatus, and image forming method | RICOH COMPANY, LTD. (JP) | 2021-07-13 | — | — | US | disclosed |
| US-11059985-B2 | Composition, cured product, storage container, image forming apparatus, and image forming method | RICOH COMPANY, LTD. (JP) | 2021-07-13 | — | — | US | disclosed |
| US-11052114-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-06 | — | — | US | disclosed |
| US-11052113-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-06 | — | — | US | disclosed |
| US-11053296-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-07-06 | — | — | US | disclosed |
| EP-3842446-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | immatics biotechnologies GmbH (DE) | 2021-06-30 | — | — | EP | disclosed |
| CN-113045642-A | Novel peptides and peptide compositions for immunotherapy of lung cancer, including non-small cell lung cancer and other cancers | 伊玛提克斯生物技术有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20210188944-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-06-24 | — | — | US | disclosed |
| US-20210188943-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-06-24 | — | — | US | disclosed |
| US-11040069-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-06-22 | — | — | US | disclosed |
| US-20210179691-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-06-17 | — | — | US | disclosed |
| US-11033585-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-06-15 | — | — | US | disclosed |
| US-11033583-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-06-15 | — | — | US | disclosed |
| US-20210172961-A1 | METHODS FOR IDENTIFYING RNA EDITING-DERIVED EPITOPES THAT ELICIT IMMUNE RESPONSES IN CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-06-10 | — | — | US | disclosed |
| EP-3829720-A1 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | immatics Biotechnologies GmbH (DE) | 2021-06-09 | — | — | EP | disclosed |
| EP-3829386-A1 | COMPOSITION, ARTIFICIAL NAIL COMPOSITION, NAIL DECORATION MATERIAL, ARTIFICIAL NAIL, STORED CONTAINER, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | Ricoh Company, Ltd. (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-11026977-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-06-08 | — | — | US | disclosed |
| CN-112920257-A | Peptides and peptide combinations of non-classical origin for immunotherapy of different types of cancer | 伊玛提克斯生物技术有限公司 | 2021-06-08 | — | — | CN | disclosed |
| US-11028280-B2 | Composition, cured product, composition stored container, image forming apparatus, and image forming method | RICOH COMPANY, LTD. (JP) | 2021-06-08 | — | — | US | disclosed |
| US-11027002-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-06-08 | — | — | US | disclosed |
| US-20210162004-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-06-03 | — | — | US | disclosed |
| US-20210161962-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-06-03 | — | — | US | disclosed |
| US-11020432-B2 | Peptides and combination thereof for use in the immunotherapy against cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| US-11020433-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| US-11020434-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| US-20210154284-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NHL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-27 | — | — | US | disclosed |
| US-20210155814-A1 | ACTIVE-ENERGY-RAY-CURABLE AQUEOUS COMPOSITION, ACTIVE-ENERGY-RAY-CURABLE AQUEOUS INK, STORED CONTAINER, IMAGE FORMING APPARATUS, IMAGE FORMING METHOD, CURED PRODUCT, AND DECORATED PRODUCT | RICOH COMPANY, LTD. (JP) | 2021-05-27 | — | — | US | disclosed |
| US-20210155814-A1 | ACTIVE-ENERGY-RAY-CURABLE AQUEOUS COMPOSITION, ACTIVE-ENERGY-RAY-CURABLE AQUEOUS INK, STORED CONTAINER, IMAGE FORMING APPARATUS, IMAGE FORMING METHOD, CURED PRODUCT, AND DECORATED PRODUCT | RICOH COMPANY, LTD. (JP) | 2021-05-27 | — | — | US | disclosed |
| US-11013766-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-25 | — | — | US | disclosed |
| US-11013769-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-25 | — | — | US | disclosed |
| US-11013768-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-25 | — | — | US | disclosed |
| US-11014972-B2 | B*44 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-25 | — | — | US | disclosed |
| US-20210145952-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20210145887-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20210145886-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20210145888-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| US-11007257-B2 | Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-18 | — | — | US | disclosed |
| US-11007258-B2 | Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-18 | — | — | US | disclosed |
| US-11007223-B2 | Peptides and combination thereof for use in the immunotherapy against cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-18 | — | — | US | disclosed |
| US-20210137986-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-13 | — | — | US | disclosed |
| US-20210137985-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-13 | — | — | US | disclosed |
| US-20210138052-A1 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-13 | — | — | US | disclosed |
| US-11001617-B2 | Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| US-11001616-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| CN-112789285-A | Use of B44 restricted peptides in anticancer immunotherapy and related methods | 伊玛提克斯生物技术有限公司 | 2021-05-11 | — | — | CN | disclosed |
| US-20210128708-A1 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-06 | — | — | US | disclosed |
| US-20210128707-A1 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-06 | — | — | US | disclosed |
| EP-3813873-A1 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | immatics Biotechnologies GmbH (DE) | 2021-05-05 | — | — | EP | disclosed |
| EP-3815712-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | immatics biotechnologies GmbH (DE) | 2021-05-05 | — | — | EP | disclosed |
| US-10993964-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-04 | — | — | US | disclosed |
| US-10993963-B2 | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-04 | — | — | US | disclosed |
| US-10993962-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-05-04 | — | — | US | disclosed |
| US-20210113619-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
| CN-112679604-A | Novel peptides and peptide compositions for immunotherapy of lung cancer, including non-small cell lung cancer and other cancers | 伊玛提克斯生物技术有限公司 | 2021-04-20 | — | — | CN | disclosed |
| CN-112661838-A | Novel peptides and peptide compositions for immunotherapy of lung cancer, including non-small cell lung cancer and other cancers | 伊玛提克斯生物技术有限公司 | 2021-04-16 | — | — | CN | disclosed |
| US-20210107941-A1 | NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-04-15 | — | — | US | disclosed |
| US-20210106624-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-04-15 | — | — | US | disclosed |
| US-20210106623-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-04-15 | — | — | US | disclosed |
| CN-112646021-A | Novel peptides and peptide compositions for immunotherapy of hepatocellular carcinoma (HCC) and other cancers | 伊玛提克斯生物技术有限公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-112646025-A | Novel peptides and peptide compositions for immunotherapy of hepatocellular carcinoma (HCC) and other cancers | 伊玛提克斯生物技术有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-20210101958-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-04-08 | — | — | US | disclosed |
| US-20210101957-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-04-08 | — | — | US | disclosed |
| US-20210100845-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-04-08 | — | — | US | disclosed |
| EP-3394084-B1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-04-07 | — | — | EP | disclosed |
| US-10967053-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-04-06 | — | — | US | disclosed |
| US-20210094992-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-04-01 | — | — | US | disclosed |
| US-20210093702-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-04-01 | — | — | US | disclosed |
| US-20210085767-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-25 | — | — | US | disclosed |
| EP-3793592-A1 | PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS | immatics Biotechnologies GmbH (DE) | 2021-03-24 | — | — | EP | disclosed |
| CN-112538109-A | Novel peptides and peptide compositions for immunotherapy of hepatocellular carcinoma (HCC) and other cancers | 伊玛提克斯生物技术有限公司 | 2021-03-23 | — | — | CN | disclosed |
| US-10954281-B2 | Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-23 | — | — | US | disclosed |
| CN-112521478-A | Peptides and peptide compositions for immunotherapy of leukemia and other cancers | 伊玛提克斯生物技术有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-10946081-B2 | *03 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| US-10947294-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| US-10947286-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| CN-112512639-A | B × 07 restricted peptides and peptide combinations for anticancer immunotherapy and related methods | 伊玛提克斯生物技术有限公司 | 2021-03-16 | — | — | CN | disclosed |
| US-10946064-B2 | Personalized immunotherapy against several neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| US-10947293-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| US-20210069251-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-11 | — | — | US | disclosed |
| US-20210069250-A1 | NOVEL PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-11 | — | — | US | disclosed |
| US-10941181-B2 | Immunotherapy against several tumors including neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-09 | — | — | US | disclosed |
| CN-112469306-A | Composition, artificial nail composition, nail decorating material, artificial nail, storage container, image forming apparatus, and image forming method | 株式会社理光 | 2021-03-09 | — | — | CN | disclosed |
| CN-112457390-A | Novel immunotherapy for several tumors including gastrointestinal and gastric cancers | 伊玛提克斯生物技术有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20210061929-A1 | ACTIVE-ENERGY-RAY-CURABLE COMPOSITION, ACTIVE-ENERGY-RAY-CURABLE INK, COMPOSITION STORED CONTAINER, TWO-DIMENSIONAL OR THREE-DIMENSIONAL IMAGE FORMING METHOD AND APPARATUS, CURED PRODUCT, AND DECORATED PRODUCT | RICOH COMPANY, LTD. (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20210061929-A1 | ACTIVE-ENERGY-RAY-CURABLE COMPOSITION, ACTIVE-ENERGY-RAY-CURABLE INK, COMPOSITION STORED CONTAINER, TWO-DIMENSIONAL OR THREE-DIMENSIONAL IMAGE FORMING METHOD AND APPARATUS, CURED PRODUCT, AND DECORATED PRODUCT | RICOH COMPANY, LTD. (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20210060077-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-04 | — | — | US | disclosed |
| US-20210060074-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-04 | — | — | US | disclosed |
| US-20210060078-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-04 | — | — | US | disclosed |
| CN-112430255-A | Novel immunotherapy for several tumors including gastrointestinal and gastric cancers | 伊玛提克斯生物技术有限公司 | 2021-03-02 | — | — | CN | disclosed |
| US-10934338-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-02 | — | — | US | disclosed |
| US-10933118-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-02 | — | — | US | disclosed |
| US-10934333-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-02 | — | — | US | disclosed |
| US-10934339-B2 | Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-02 | — | — | US | disclosed |
| US-10933125-B2 | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-03-02 | — | — | US | disclosed |
| CN-112409453-A | Novel immunotherapy for several tumors including gastrointestinal and gastric cancers | 伊玛提克斯生物技术有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-112409451-A | Novel immunotherapy for several tumors including gastrointestinal and gastric cancers | 伊玛提克斯生物技术有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-112409452-A | Novel immunotherapy for several tumors including gastrointestinal and gastric cancers | 伊玛提克斯生物技术有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20210052651-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-02-25 | — | — | US | disclosed |
| US-20210052653-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-02-25 | — | — | US | disclosed |
| US-20210052652-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-02-25 | — | — | US | disclosed |
| US-20210052654-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-02-25 | — | — | US | disclosed |
| US-10925949-B2 | Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-02-23 | — | — | US | disclosed |
| US-10925948-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-02-23 | — | — | US | disclosed |
| US-10925947-B2 | A*03 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-02-23 | — | — | US | disclosed |
| CN-112399853-A | Use of A03-restricted peptides in anti-cancer immunotherapy and related methods | 伊玛提克斯生物技术有限公司 | 2021-02-23 | — | — | CN | disclosed |
| EP-3331900-B1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-02-17 | — | — | EP | disclosed |
| EP-3291830-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-02-17 | — | — | EP | disclosed |
| US-10919931-B2 | Immunotherapy against several tumors including neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-02-16 | — | — | US | disclosed |
| US-10919933-B2 | Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-02-16 | — | — | US | disclosed |
| US-20210030854-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-02-04 | — | — | US | disclosed |
| US-10905741-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-02-02 | — | — | US | disclosed |
| US-10906938-B2 | Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-02-02 | — | — | US | disclosed |
| US-10905719-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-02-02 | — | — | US | disclosed |
| US-10905720-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-02-02 | — | — | US | disclosed |
| US-10906936-B2 | Immunotherapy against several tumors including neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-02-02 | — | — | US | disclosed |
| US-20210023189-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, SUCH AS ACUTE MYELOID LEUKEMIA (AML) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| US-20210024609-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| US-20210023190-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NHL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| US-10899806-B2 | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10899794-B2 | Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10898557-B2 | Method of treating with a peptide | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10899814-B2 | Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10898562-B1 | Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10898546-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10899808-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10899809-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10899819-B2 | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10898518-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10898558-B2 | Method of treating with a peptide | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10899807-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10898560-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10898561-B2 | Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10899810-B2 | B*44 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10898519-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10899813-B2 | Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10899811-B2 | B*44 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10899820-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10898559-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10899812-B2 | Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-26 | — | — | US | disclosed |
| US-10894064-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20210009654-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-14 | — | — | US | disclosed |
| US-20210008189-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, SUCH AS ACUTE MYELOID LEUKEMIA (AML) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-14 | — | — | US | disclosed |
| US-10888586-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| US-10888587-B2 | Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| US-10889617-B2 | Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| US-10888582-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| US-10888585-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| US-10888583-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| US-10888584-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| US-20210002340-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-07 | — | — | US | disclosed |
| EP-3760225-A2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2021-01-06 | — | — | EP | disclosed |
| US-10881690-B2 | Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2021-01-05 | — | — | US | disclosed |
| US-20200405830-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-31 | — | — | US | disclosed |
| US-20200405831-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-31 | — | — | US | disclosed |
| EP-3755708-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | immatics Biotechnologies GmbH (DE) | 2020-12-30 | — | — | EP | disclosed |
| US-10874696-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-29 | — | — | US | disclosed |
| US-10875892-B2 | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-29 | — | — | US | disclosed |
| US-10874695-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-29 | — | — | US | disclosed |
| CN-112135629-A | Peptides for anticancer immunotherapy | 伊玛提克斯生物技术有限公司 | 2020-12-25 | — | — | CN | disclosed |
| US-20200397878-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-24 | — | — | US | disclosed |
| US-20200399334-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-24 | — | — | US | disclosed |
| US-20200397880-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-24 | — | — | US | disclosed |
| US-20200397879-A1 | METHOD OF TREATING WITH A PEPTIDE | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-24 | — | — | US | disclosed |
| EP-3753570-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | Immatics Biotechnologies GmbH (DE) | 2020-12-23 | — | — | EP | disclosed |
| US-10869892-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-22 | — | — | US | disclosed |
| US-10870685-B2 | Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-22 | — | — | US | disclosed |
| US-10869897-B2 | Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-22 | — | — | US | disclosed |
| US-10869895-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-22 | — | — | US | disclosed |
| US-10869893-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-22 | — | — | US | disclosed |
| US-10869891-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-22 | — | — | US | disclosed |
| US-10869894-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-22 | — | — | US | disclosed |
| US-10869890-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-22 | — | — | US | disclosed |
| US-10869917-B2 | A*03 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-22 | — | — | US | disclosed |
| US-10869896-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-22 | — | — | US | disclosed |
| US-20200392194-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-17 | — | — | US | disclosed |
| EP-3750559-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2020-12-16 | — | — | EP | disclosed |
| EP-3750557-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2020-12-16 | — | — | EP | disclosed |
| EP-3750558-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2020-12-16 | — | — | EP | disclosed |
| US-20200384093-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-10 | — | — | US | disclosed |
| US-10858527-B2 | Composition, cured product, image forming apparatus, and image forming method | RICOH COMPANY, LTD. (JP) | 2020-12-08 | — | — | US | disclosed |
| US-20200376103-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-12-03 | — | — | US | disclosed |
| US-10842817-B2 | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-11-24 | — | — | US | disclosed |
| US-20200360433-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-11-19 | — | — | US | disclosed |
| EP-3738606-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | Immatics Biotechnologies GmbH (DE) | 2020-11-18 | — | — | EP | disclosed |
| US-10835587-B2 | Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-11-17 | — | — | US | disclosed |
| US-10835586-B2 | Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-11-17 | — | — | US | disclosed |
| US-10835588-B2 | Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-11-17 | — | — | US | disclosed |
| US-10836806-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-11-17 | — | — | US | disclosed |
| US-20200353080-A1 | CANCER METHODS | GABRA HANI (GB) | 2020-11-12 | — | — | US | disclosed |
| EP-3736283-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | immatics biotechnologies GmbH (DE) | 2020-11-11 | — | — | EP | disclosed |
| US-10829537-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| US-10829631-B2 | Composition, accommodating unit, image forming device, and image forming method | RICOH COMPANY, LTD. (JP) | 2020-11-10 | — | — | US | disclosed |
| US-10829631-B2 | Composition, accommodating unit, image forming device, and image forming method | RICOH COMPANY, LTD. (JP) | 2020-11-10 | — | — | US | disclosed |
| US-10828357-B2 | A*03 restricted peptides for use in immunotherapy against cancers and related methods | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| US-20200345777-A1 | NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-11-05 | — | — | US | disclosed |
| US-10822376-B2 | Biologically active peptides | Baxalta GmbH (CH) | 2020-11-03 | — | — | US | disclosed |
| US-10822390-B2 | Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-11-03 | — | — | US | disclosed |
| US-20200338126-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-29 | — | — | US | disclosed |
| US-20200339658-A1 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-29 | — | — | US | disclosed |
| US-20200339657-A1 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-29 | — | — | US | disclosed |
| US-20200339630-A1 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-29 | — | — | US | disclosed |
| US-20200338175-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-29 | — | — | US | disclosed |
| US-20200339644-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-29 | — | — | US | disclosed |
| US-20200339656-A1 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-29 | — | — | US | disclosed |
| US-20200339646-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-29 | — | — | US | disclosed |
| US-20200339645-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-29 | — | — | US | disclosed |
| EP-3319985-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-10813985-B2 | Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-27 | — | — | US | disclosed |
| US-10813986-B2 | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-27 | — | — | US | disclosed |
| US-10813953-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-27 | — | — | US | disclosed |
| US-20200330552-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-22 | — | — | US | disclosed |
| EP-3725327-A2 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | Immatics Biotechnologies GmbH (DE) | 2020-10-21 | — | — | EP | disclosed |
| CN-105001339-B | Novel immunotherapy for several tumors including gastrointestinal and gastric cancers | 伊玛提克斯生物技术有限公司 | 2020-10-16 | — | — | CN | disclosed |
| US-20200325195-A1 | IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200325197-A1 | IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200323913-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200325199-A1 | IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200325192-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200325198-A1 | IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200323910-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200323912-A1 | NOVEL PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200323907-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200325194-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200323918-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200323915-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200323969-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200323916-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200323967-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200323906-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200325207-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200325174-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200325193-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200325206-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200323909-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200323914-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200323968-A1 | METHOD OF TREATING WITH A PEPTIDE | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200323911-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200325196-A1 | IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200323970-A1 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200323919-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200325191-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-10799570-B2 | Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| US-10799537-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| US-10799571-B2 | Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| US-10800823-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| US-10799569-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHOLOGIES GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| US-20200316127-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-08 | — | — | US | disclosed |
| US-20200316182-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-08 | — | — | US | disclosed |
| US-20200317748-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-08 | — | — | US | disclosed |
| US-20200316125-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-08 | — | — | US | disclosed |
| US-20200316183-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-08 | — | — | US | disclosed |
| US-20200316126-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-08 | — | — | US | disclosed |
| US-10792350-B2 | Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-10792308-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-10793602-B2 | Immunotherapy against several tumors, such as lung cancer, including NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-10792307-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-20200308250-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-01 | — | — | US | disclosed |
| US-20200306305-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-01 | — | — | US | disclosed |
| US-20200308227-A1 | NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-01 | — | — | US | disclosed |
| US-20200308226-A1 | NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-01 | — | — | US | disclosed |
| US-20200306308-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-01 | — | — | US | disclosed |
| US-20200308225-A1 | NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-01 | — | — | US | disclosed |
| US-20200306311-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-10-01 | — | — | US | disclosed |
| EP-3317296-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-30 | — | — | EP | disclosed |
| EP-3715357-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2020-09-30 | — | — | EP | disclosed |
| US-20200297801-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| US-20200299346-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| US-20200297831-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NHL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| US-20200297772-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| US-20200297770-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| US-20200299425-A1 | ACTIVE ENERGY RAY CURABLE COMPOSITION, ACTIVE ENERGY RAY CURABLE INK, COMPOSITION ACCOMMODATING CONTAINER, TWO OR THREE DIMENSIONAL IMAGE FORMING APPARATUS, TWO OR THREE DIMENSIONAL IMAGE FORMING METHOD, CURED MATTER, DECORATIVE MATTER, ARTIFICIAL NAIL COMPOSITION, NAIL DECORATIVE MATERIAL, AND ARTIFICIAL NAIL | RICOH COMPANY, LTD. (JP) | 2020-09-24 | — | — | US | disclosed |
| US-20200299425-A1 | ACTIVE ENERGY RAY CURABLE COMPOSITION, ACTIVE ENERGY RAY CURABLE INK, COMPOSITION ACCOMMODATING CONTAINER, TWO OR THREE DIMENSIONAL IMAGE FORMING APPARATUS, TWO OR THREE DIMENSIONAL IMAGE FORMING METHOD, CURED MATTER, DECORATIVE MATTER, ARTIFICIAL NAIL COMPOSITION, NAIL DECORATIVE MATERIAL, AND ARTIFICIAL NAIL | RICOH COMPANY, LTD. (JP) | 2020-09-24 | — | — | US | disclosed |
| US-20200297771-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| US-10780122-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-22 | — | — | US | disclosed |
| US-10780125-B2 | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-22 | — | — | US | disclosed |
| US-10781325-B2 | Curable composition, curable ink, accommodating container, image forming device, image forming method, cured matter, and acrylamide compound | RICOH COMPANY, LTD. (JP) | 2020-09-22 | — | — | US | disclosed |
| US-10780123-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-22 | — | — | US | disclosed |
| US-10781244-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-22 | — | — | US | disclosed |
| US-10780124-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-22 | — | — | US | disclosed |
| US-10781233-B2 | Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-22 | — | — | US | disclosed |
| US-20200291084-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-17 | — | — | US | disclosed |
| US-20200291088-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-17 | — | — | US | disclosed |
| US-20200289632-A1 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-17 | — | — | US | disclosed |
| US-20200289631-A1 | METHOD OF TREATING WITH A PEPTIDE | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-17 | — | — | US | disclosed |
| EP-3708185-A2 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL) | Immatics Biotechnologies GmbH (DE) | 2020-09-16 | — | — | EP | disclosed |
| US-10772915-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-15 | — | — | US | disclosed |
| CN-111647062-A | Peptides and peptide compositions thereof for cancer immunotherapy | 伊玛提克斯生物技术有限公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-3705491-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2020-09-09 | — | — | EP | disclosed |
| US-10765730-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-08 | — | — | US | disclosed |
| US-10766944-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | INMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-09-08 | — | — | US | disclosed |
| US-10767213-B2 | Quantification of vaccine compositions | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200268861-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-27 | — | — | US | disclosed |
| US-20200268862-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, SUCH AS ACUTE MYELOID LEUKEMIA (AML) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-27 | — | — | US | disclosed |
| US-20200268800-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-27 | — | — | US | disclosed |
| US-20200268799-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-27 | — | — | US | disclosed |
| US-20200268863-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-27 | — | — | US | disclosed |
| US-20200268798-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-27 | — | — | US | disclosed |
| US-10751369-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20200261505-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-20 | — | — | US | disclosed |
| US-20200261506-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-20 | — | — | US | disclosed |
| US-20200261504-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-20 | — | — | US | disclosed |
| US-10745460-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-18 | — | — | US | disclosed |
| CN-111548406-A | Peptides and peptide compositions thereof for cancer immunotherapy | 伊玛提克斯生物技术有限公司 | 2020-08-18 | — | — | CN | disclosed |
| CN-111548405-A | Peptides and peptide compositions thereof for cancer immunotherapy | 伊玛提克斯生物技术有限公司 | 2020-08-18 | — | — | CN | disclosed |
| CN-111548404-A | Peptides and peptide compositions thereof for cancer immunotherapy | 伊玛提克斯生物技术有限公司 | 2020-08-18 | — | — | CN | disclosed |
| CN-111533797-A | Peptides and peptide compositions thereof for cancer immunotherapy | 伊玛提克斯生物技术有限公司 | 2020-08-14 | — | — | CN | disclosed |
| CN-111533798-A | Peptides and peptide compositions thereof for cancer immunotherapy | 伊玛提克斯生物技术有限公司 | 2020-08-14 | — | — | CN | disclosed |
| CN-111528539-A | Peptides and peptide compositions thereof for cancer immunotherapy | 伊玛提克斯生物技术有限公司 | 2020-08-14 | — | — | CN | disclosed |
| CN-111533799-A | Peptides and peptide compositions for immunotherapy of leukemia and other cancers | 伊玛提克斯生物技术有限公司 | 2020-08-14 | — | — | CN | disclosed |
| CN-111533796-A | Peptides and peptide compositions thereof for cancer immunotherapy | 伊玛提克斯生物技术有限公司 | 2020-08-14 | — | — | CN | disclosed |
| US-20200254017-A1 | NOVEL PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-13 | — | — | US | disclosed |
| US-20200255490-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST SMALL CELL LUNG CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-13 | — | — | US | disclosed |
| US-20200254078-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, SUCH AS ACUTE MYELOID LEUKEMIA (AML) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-13 | — | — | US | disclosed |
| US-20200255491-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST SMALL CELL LUNG CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-13 | — | — | US | disclosed |
| US-20200254022-A1 | NOVEL PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-13 | — | — | US | disclosed |
| EP-3693000-A1 | PROCOAGULANT COMPOUNDS | Bioverativ Therapeutics Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10738094-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-11 | — | — | US | disclosed |
| US-10738100-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-11 | — | — | US | disclosed |
| EP-3363456-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-05 | — | — | EP | disclosed |
| US-10729755-B1 | Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-04 | — | — | US | disclosed |
| US-10730910-B2 | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-08-04 | — | — | US | disclosed |
| US-10722566-B2 | Peptides and combination of peptides for use in immunotherapy against CLL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-28 | — | — | US | disclosed |
| US-10722536-B1 | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-28 | — | — | US | disclosed |
| US-10723781-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-28 | — | — | US | disclosed |
| US-10722565-B2 | Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-28 | — | — | US | disclosed |
| US-10722538-B2 | Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-28 | — | — | US | disclosed |
| US-20200230222-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-23 | — | — | US | disclosed |
| EP-3120869-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-22 | — | — | EP | disclosed |
| WO-2020144615-A1 | PROSTATE NEOANTIGENS AND THEIR USES | JANSSEN BIOTECH, INC. (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020144614-A1 | PROSTATE NEOANTIGENS AND THEIR USES | JANSSEN BIOTECH, INC. (US) | 2020-07-16 | — | — | WO | disclosed |
| US-20200222465-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-16 | — | — | US | disclosed |
| US-20200223900-A1 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-16 | — | — | US | disclosed |
| US-20200222478-A1 | PROSTATE NEOANTIGENS AND THEIR USES | JANSSEN BIOTECH, INC. | 2020-07-16 | — | — | US | disclosed |
| US-10709737-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-14 | — | — | US | disclosed |
| US-10709735-B2 | Immunotherapy against neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-14 | — | — | US | disclosed |
| US-10709738-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-14 | — | — | US | disclosed |
| US-10709736-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-14 | — | — | US | disclosed |
| US-10711048-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-14 | — | — | US | disclosed |
| US-10702592-B2 | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-07 | — | — | US | disclosed |
| US-10702553-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-07 | — | — | US | disclosed |
| US-10702593-B2 | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-07 | — | — | US | disclosed |
| US-10703795-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-07 | — | — | US | disclosed |
| US-20200206268-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-02 | — | — | US | disclosed |
| US-20200207832-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-02 | — | — | US | disclosed |
| US-20200207831-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-07-02 | — | — | US | disclosed |
| US-10695411-B2 | Method of treating with a peptide | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-10695377-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-10695373-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-10695375-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-10695376-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-10695374-B2 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| WO-2020127546-A2 | IMMUNOTHERAPY WITH B*08 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-25 | — | — | WO | disclosed |
| US-20200199194-A1 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-25 | — | — | US | disclosed |
| US-20200199193-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-25 | — | — | US | disclosed |
| US-20200197441-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-25 | — | — | US | disclosed |
| US-20200199195-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-25 | — | — | US | disclosed |
| EP-3329933-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-24 | — | — | EP | disclosed |
| US-10688131-B2 | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-23 | — | — | US | disclosed |
| CN-111303244-A | Personalized immunotherapy for several neuronal and brain tumors | 伊玛提克斯生物技术有限公司 | 2020-06-19 | — | — | CN | disclosed |
| US-20200188438-A1 | IMMUNOTHERAPY WITH B*08 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-18 | — | — | US | disclosed |
| US-20200190160-A1 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-18 | — | — | US | disclosed |
| US-10683337-B2 | Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-16 | — | — | US | disclosed |
| US-20200179454-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-11 | — | — | US | disclosed |
| US-20200179453-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-11 | — | — | US | disclosed |
| US-20200181233-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-11 | — | — | US | disclosed |
| EP-3322717-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-10 | — | — | EP | disclosed |
| US-10675338-B1 | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | INMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-09 | — | — | US | disclosed |
| US-20200171091-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-04 | — | — | US | disclosed |
| US-10668100-B1 | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-02 | — | — | US | disclosed |
| US-10669325-B2 | Uterine cancer treatments | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-02 | — | — | US | disclosed |
| US-10669326-B2 | Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-02 | — | — | US | disclosed |
| US-10668137-B2 | Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-02 | — | — | US | disclosed |
| US-10668138-B1 | Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-06-02 | — | — | US | disclosed |
| US-20200163996-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-28 | — | — | US | disclosed |
| US-20200164053-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-28 | — | — | US | disclosed |
| US-10662233-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-26 | — | — | US | disclosed |
| US-10660955-B2 | Cancer methods | GABRA HANI (GB) | 2020-05-26 | — | — | US | disclosed |
| US-20200157162-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-21 | — | — | US | disclosed |
| US-20200155603-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-21 | — | — | US | disclosed |
| US-20200157148-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-21 | — | — | US | disclosed |
| US-20200155605-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-21 | — | — | US | disclosed |
| US-20200155645-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-21 | — | — | US | disclosed |
| US-20200157176-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-21 | — | — | US | disclosed |
| US-20200155604-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-21 | — | — | US | disclosed |
| US-20200155602-A1 | NOVEL PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-21 | — | — | US | disclosed |
| US-20200157177-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR GENERATING SCAFFOLDS FOR THE USE AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-21 | — | — | US | disclosed |
| US-10653761-B2 | Peptides and combination of peptides for use in immunotherapy against CLL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-19 | — | — | US | disclosed |
| US-10653762-B2 | Peptides and combination of peptides for use in immunotherapy against CLL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-19 | — | — | US | disclosed |
| US-10654903-B2 | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-19 | — | — | US | disclosed |
| US-10654904-B2 | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-19 | — | — | US | disclosed |
| US-20200147192-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-14 | — | — | US | disclosed |
| US-20200147190-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-14 | — | — | US | disclosed |
| EP-3648790-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2020-05-13 | — | — | EP | disclosed |
| US-20200138924-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-07 | — | — | US | disclosed |
| EP-3647319-A1 | PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME | XDCExplorer (Shanghai) Co., Ltd. (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-10640547-B2 | Immunotherapy against melanoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-05 | — | — | US | disclosed |
| US-10639332-B2 | Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-05 | — | — | US | disclosed |
| US-10639331-B2 | Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-05-05 | — | — | US | disclosed |
| EP-3157549-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-3124043-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-04-29 | — | — | EP | disclosed |
| US-10626162-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-04-21 | — | — | US | disclosed |
| US-10618948-B2 | Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-04-14 | — | — | US | disclosed |
| US-10618945-B2 | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-04-14 | — | — | US | disclosed |
| US-20200108097-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-04-09 | — | — | US | disclosed |
| EP-3120868-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-04-08 | — | — | EP | disclosed |
| US-20200102360-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-04-02 | — | — | US | disclosed |
| US-20200102359-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-04-02 | — | — | US | disclosed |
| EP-3106175-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-04-01 | — | — | EP | disclosed |
| EP-3120870-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-04-01 | — | — | EP | disclosed |
| CN-110944660-A | Peptides and peptide compositions for immunotherapy of leukemia and other cancers | 伊玛提克斯生物技术有限公司 | 2020-03-31 | — | — | CN | disclosed |
| US-20200093905-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, SUCH AS ACUTE MYELOID LEUKEMIA (AML) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-26 | — | — | US | disclosed |
| US-20200093906-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-26 | — | — | US | disclosed |
| US-20200093862-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-26 | — | — | US | disclosed |
| WO-2020058285-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020058360-A1 | IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-26 | — | — | WO | disclosed |
| EP-3626729-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | immatics Biotechnologies GmbH (DE) | 2020-03-25 | — | — | EP | disclosed |
| EP-3626730-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | immatics Biotechnologies GmbH (DE) | 2020-03-25 | — | — | EP | disclosed |
| EP-3626731-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | immatics Biotechnologies GmbH (DE) | 2020-03-25 | — | — | EP | disclosed |
| US-10596243-B2 | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-24 | — | — | US | disclosed |
| US-10596240-B2 | Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-24 | — | — | US | disclosed |
| US-10597433-B2 | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-24 | — | — | US | disclosed |
| US-10597434-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-24 | — | — | US | disclosed |
| US-10596241-B2 | Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-24 | — | — | US | disclosed |
| US-10596196-B2 | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-24 | — | — | US | disclosed |
| US-10597432-B2 | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-24 | — | — | US | disclosed |
| US-20200085874-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-19 | — | — | US | disclosed |
| US-20200087378-A1 | RELAXIN1 DERIVED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-19 | — | — | US | disclosed |
| US-20200087363-A1 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-19 | — | — | US | disclosed |
| US-20200087364-A1 | IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-19 | — | — | US | disclosed |
| US-20200085873-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-19 | — | — | US | disclosed |
| US-20200078439-A1 | NOVEL AND POWERFUL MHC-CLASS II PEPTIDES DERIVED FROM SURVIVIN | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-12 | — | — | US | disclosed |
| EP-3620168-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | immatics Biotechnologies GmbH (DE) | 2020-03-11 | — | — | EP | disclosed |
| US-10584147-B2 | Procoagulant fusion compound | Biovertiv Therapeutics Inc. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20200071379-A1 | UTERINE CANCER TREATMENTS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-05 | — | — | US | disclosed |
| EP-3616706-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | immatics Biotechnologies GmbH (DE) | 2020-03-04 | — | — | EP | disclosed |
| EP-3616711-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER INCLUDING NSCLC | Immatics Biotechnologies GmbH (DE) | 2020-03-04 | — | — | EP | disclosed |
| EP-3616712-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER INCLUDING NSCLC | Immatics Biotechnologies GmbH (DE) | 2020-03-04 | — | — | EP | disclosed |
| EP-3616707-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER INCLUDING NSCLC | Immatics Biotechnologies GmbH (DE) | 2020-03-04 | — | — | EP | disclosed |
| EP-3616709-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER INCLUDING NSCLC | Immatics Biotechnologies GmbH (DE) | 2020-03-04 | — | — | EP | disclosed |
| EP-3616710-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER INCLUDING NSCLC | Immatics Biotechnologies GmbH (DE) | 2020-03-04 | — | — | EP | disclosed |
| EP-3616708-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER INCLUDING NSCLC | Immatics Biotechnologies GmbH (DE) | 2020-03-04 | — | — | EP | disclosed |
| US-10576135-B2 | Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-03 | — | — | US | disclosed |
| US-10576132-B2 | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-03 | — | — | US | disclosed |
| US-10577402-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-03-03 | — | — | US | disclosed |
| US-20200061170-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-27 | — | — | US | disclosed |
| EP-3613427-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER INCLUDING NSCLC | Immatics Biotechnologies GmbH (DE) | 2020-02-26 | — | — | EP | disclosed |
| US-10568909-B2 | Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-25 | — | — | US | disclosed |
| US-10568950-B1 | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-25 | — | — | US | disclosed |
| US-10570175-B2 | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-25 | — | — | US | disclosed |
| US-20200054727-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-20 | — | — | US | disclosed |
| US-20200055898-A1 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-20 | — | — | US | disclosed |
| US-20200055899-A1 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-20 | — | — | US | disclosed |
| US-20200054729-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-20 | — | — | US | disclosed |
| EP-3609530-A1 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | Immatics Biotechnologies GmbH (DE) | 2020-02-19 | — | — | EP | disclosed |
| EP-3609531-A2 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS | immatics biotechnologies GmbH (DE) | 2020-02-19 | — | — | EP | disclosed |
| US-10561718-B2 | Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-18 | — | — | US | disclosed |
| US-20200046819-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-13 | — | — | US | disclosed |
| US-20200048320-A1 | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-13 | — | — | US | disclosed |
| CN-110785183-A | Novel peptides and peptide compositions for immunotherapy of lung cancer, including NSCLC, SCLC and other cancers | 伊玛提克斯生物技术有限公司 | 2020-02-11 | — | — | CN | disclosed |
| CN-105793280-B | Personalized immunotherapy for several neuronal and brain tumors | 伊玛提克斯生物技术有限公司 | 2020-02-11 | — | — | CN | disclosed |
| US-20200040060-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-06 | — | — | US | disclosed |
| US-20200038310-A1 | COMPOSITION, ARTIFICIAL NAIL COMPOSITION, NAIL DECORATION MATERIAL, ARTIFICIAL NAIL, STORED CONTAINER, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | RICOH COMPANY, LTD. (JP) | 2020-02-06 | — | — | US | disclosed |
| US-20200038310-A1 | COMPOSITION, ARTIFICIAL NAIL COMPOSITION, NAIL DECORATION MATERIAL, ARTIFICIAL NAIL, STORED CONTAINER, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | RICOH COMPANY, LTD. (JP) | 2020-02-06 | — | — | US | disclosed |
| US-20200040050-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-06 | — | — | US | disclosed |
| US-20200040057-A1 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-06 | — | — | US | disclosed |
| US-20200038447-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-06 | — | — | US | disclosed |
| US-20200038446-A1 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-06 | — | — | US | disclosed |
| US-20200038448-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-06 | — | — | US | disclosed |
| US-20200038309-A1 | COMPOSITION, ARTIFICIAL NAIL COMPOSITION, NAIL DECORATION MATERIAL, ARTIFICIAL NAIL, STORED CONTAINER, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | RICOH COMPANY, LTD. (JP) | 2020-02-06 | — | — | US | disclosed |
| US-20200038309-A1 | COMPOSITION, ARTIFICIAL NAIL COMPOSITION, NAIL DECORATION MATERIAL, ARTIFICIAL NAIL, STORED CONTAINER, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | RICOH COMPANY, LTD. (JP) | 2020-02-06 | — | — | US | disclosed |
| WO-2020025576-A1 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020026675-A1 | COMPOSITION, ARTIFICIAL NAIL COMPOSITION, NAIL DECORATION MATERIAL, ARTIFICIAL NAIL, STORED CONTAINER, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | RICOH COMPANY, LTD. (JP) | 2020-02-06 | — | — | WO | disclosed |
| EP-3604327-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, SUCH AS ACUTE MYELOID LEUKEMIA (AML) | immatics Biotechnologies GmbH (DE) | 2020-02-05 | — | — | EP | disclosed |
| US-10550167-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-04 | — | — | US | disclosed |
| US-10548958-B2 | Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-02-04 | — | — | US | disclosed |
| US-20200031867-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-01-30 | — | — | US | disclosed |
| US-20200031969-A1 | COMPOSITION, CURED PRODUCT, STORAGE CONTAINER, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | RICOH COMPANY, LTD. (JP) | 2020-01-30 | — | — | US | disclosed |
| US-20200031969-A1 | COMPOSITION, CURED PRODUCT, STORAGE CONTAINER, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | RICOH COMPANY, LTD. (JP) | 2020-01-30 | — | — | US | disclosed |
| US-20200031869-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-01-30 | — | — | US | disclosed |
| US-20200031868-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-01-30 | — | — | US | disclosed |
| US-20200032068-A1 | COMPOSITION, CURED PRODUCT, STORAGE CONTAINER, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | RICOH COMPANY, LTD. (JP) | 2020-01-30 | — | — | US | disclosed |
| US-20200032068-A1 | COMPOSITION, CURED PRODUCT, STORAGE CONTAINER, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | RICOH COMPANY, LTD. (JP) | 2020-01-30 | — | — | US | disclosed |
| WO-2020023845-A2 | METHODS FOR IDENTIFYING RNA EDITING-DERIVED EPITOPES THAT ELICIT IMMUNE RESPONSES IN CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20200031899-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-01-30 | — | — | US | disclosed |
| US-20200031870-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-01-30 | — | — | US | disclosed |
| US-20200032089-A1 | COMPOSITION, CURED PRODUCT, STORAGE CONTAINER, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | RICOH COMPANY, LTD. (JP) | 2020-01-30 | — | — | US | disclosed |
| US-20200032089-A1 | COMPOSITION, CURED PRODUCT, STORAGE CONTAINER, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | RICOH COMPANY, LTD. (JP) | 2020-01-30 | — | — | US | disclosed |
| US-20200017551-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2020-01-16 | — | — | US | disclosed |
| US-10513547-B2 | Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-12-24 | — | — | US | disclosed |
| US-10487116-B2 | Immunotherapy against several tumors, such as lung cancer, including NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-11-26 | — | — | US | disclosed |
| US-20190352359-A1 | PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-11-21 | — | — | US | disclosed |
| US-10479823-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-11-19 | — | — | US | disclosed |
| US-10478481-B2 | Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (GH) | 2019-11-19 | — | — | US | disclosed |
| US-10478471-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-11-19 | — | — | US | disclosed |
| US-10479818-B2 | Immunotherapy against several tumors, such as lung cancer, including NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-11-19 | — | — | US | disclosed |
| US-10478480-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-11-19 | — | — | US | disclosed |
| US-10472407-B2 | Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-11-12 | — | — | US | disclosed |
| US-10472401-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-11-12 | — | — | US | disclosed |
| US-10472402-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-11-12 | — | — | US | disclosed |
| US-20190338006-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-11-07 | — | — | US | disclosed |
| US-20190338005-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-11-07 | — | — | US | disclosed |
| US-20190336590-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NHL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-11-07 | — | — | US | disclosed |
| US-10463696-B2 | Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-11-05 | — | — | US | disclosed |
| US-10464978-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-11-05 | — | — | US | disclosed |
| US-10464991-B2 | Immunotherapy against melanoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-11-05 | — | — | US | disclosed |
| US-10464990-B2 | Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-11-05 | — | — | US | disclosed |
| US-20190330274-A1 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-31 | — | — | US | disclosed |
| US-20190328856-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-31 | — | — | US | disclosed |
| EP-3132801-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-10457712-B2 | Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-29 | — | — | US | disclosed |
| US-20190321442-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-20190322721-A1 | IMMUNOTHERAPY AGAINST MELANOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-20190322715-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST SMALL CELL LUNG CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-20190322716-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST SMALL CELL LUNG CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-20190322722-A1 | IMMUNOTHERAPY AGAINST MELANOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-20190322783-A1 | POLYMER PARTICLES WITH A GRADIENT COMPOSITION AND METHODS OF PRODUCTION THEREOF | WATERS TECHNOLOGIES CORPORATION | 2019-10-24 | — | — | US | disclosed |
| US-20190322703-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-20190321405-A1 | NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-10450357-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-22 | — | — | US | disclosed |
| US-10450346-B2 | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-22 | — | — | US | disclosed |
| US-10449240-B2 | Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-22 | — | — | US | disclosed |
| US-10449239-B1 | Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-22 | — | — | US | disclosed |
| US-10449238-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-22 | — | — | US | disclosed |
| US-10450362-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-22 | — | — | US | disclosed |
| US-20190314473-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-17 | — | — | US | disclosed |
| US-20190314477-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-17 | — | — | US | disclosed |
| US-20190315832-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-17 | — | — | US | disclosed |
| US-20190315833-A1 | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-17 | — | — | US | disclosed |
| US-20190314474-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NHL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-17 | — | — | US | disclosed |
| US-20190314476-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-17 | — | — | US | disclosed |
| US-20190314475-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-17 | — | — | US | disclosed |
| US-10442844-B2 | Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-15 | — | — | US | disclosed |
| US-20190307801-A1 | Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-10 | — | — | US | disclosed |
| US-20190309280-A1 | PROCOAGULANT COMPOUNDS | BIOGEN MA INC. | 2019-10-10 | — | — | US | disclosed |
| EP-3030255-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-09 | — | — | EP | disclosed |
| US-10435448-B2 | Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-08 | — | — | US | disclosed |
| US-10435449-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | INMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-08 | — | — | US | disclosed |
| US-10434120-B2 | Immunotherapy against neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-08 | — | — | US | disclosed |
| US-10434159-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-08 | — | — | US | disclosed |
| US-10435455-B1 | Immunotherapy against melanoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-08 | — | — | US | disclosed |
| US-10435454-B2 | Immunotherapy against melanoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-08 | — | — | US | disclosed |
| US-10434136-B2 | Powerful MHC-class II peptides derived from survivin | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-08 | — | — | US | disclosed |
| US-20190300595-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-10-03 | — | — | US | disclosed |
| EP-3545965-A2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | immatics Biotechnologies GmbH (DE) | 2019-10-02 | — | — | EP | disclosed |
| US-20190290727-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-26 | — | — | US | disclosed |
| EP-3236985-B1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-25 | — | — | EP | disclosed |
| US-10420800-B2 | Immunotherapy against neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-24 | — | — | US | disclosed |
| US-10420816-B1 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-24 | — | — | US | disclosed |
| US-20190284236-A1 | NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-19 | — | — | US | disclosed |
| US-20190284234-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-19 | — | — | US | disclosed |
| US-20190284233-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-19 | — | — | US | disclosed |
| US-20190284235-A1 | NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-19 | — | — | US | disclosed |
| US-20190284256-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-19 | — | — | US | disclosed |
| US-20190284409-A1 | COMPOSITION, CURED PRODUCT, COMPOSITION STORED CONTAINER, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | RICOH COMPANY, LTD. (JP) | 2019-09-19 | — | — | US | disclosed |
| US-20190284250-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-19 | — | — | US | disclosed |
| EP-3539979-A2 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | Immatics Biotechnologies GmbH (DE) | 2019-09-18 | — | — | EP | disclosed |
| US-20190275131-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-12 | — | — | US | disclosed |
| US-20190275129-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-12 | — | — | US | disclosed |
| US-20190275130-A1 | Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-12 | — | — | US | disclosed |
| US-20190269770-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-05 | — | — | US | disclosed |
| US-20190270784-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-05 | — | — | US | disclosed |
| US-20190269767-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-05 | — | — | US | disclosed |
| US-10400011-B2 | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-03 | — | — | US | disclosed |
| US-10398766-B2 | Peptides and combination of peptides for use in immunotherapy against CLL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-03 | — | — | US | disclosed |
| WO-2019162110-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-29 | — | — | WO | disclosed |
| US-20190262444-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-29 | — | — | US | disclosed |
| US-20190262445-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-29 | — | — | US | disclosed |
| US-10392427-B1 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| US-20190255164-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-22 | — | — | US | disclosed |
| US-20190255110-A1 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-22 | — | — | US | disclosed |
| US-20190255112-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-22 | — | — | US | disclosed |
| US-20190255113-A1 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-22 | — | — | US | disclosed |
| EP-3527218-A1 | PRO-COAGULANT COMPOUNDS AND METHODS OF USE THEREOF | Bioverativ Therapeutics Inc. (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10385111-B2 | Immunotherapy against melanoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-20 | — | — | US | disclosed |
| US-10385105-B1 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-20 | — | — | US | disclosed |
| US-10383896-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-20 | — | — | US | disclosed |
| US-10385109-B2 | Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-20 | — | — | US | disclosed |
| US-10385110-B2 | Immunotherapy against melanoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-20 | — | — | US | disclosed |
| US-10383930-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-20 | — | — | US | disclosed |
| US-20190248857-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-15 | — | — | US | disclosed |
| US-10377802-B2 | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| US-10377797-B2 | Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| US-10377803-B1 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| US-10377811-B2 | Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| US-10376542-B2 | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| US-10376569-B2 | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| US-10376568-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| US-20190241631-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-08 | — | — | US | disclosed |
| US-20190240305-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-08 | — | — | US | disclosed |
| US-20190241630-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-08 | — | — | US | disclosed |
| US-10370429-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-06 | — | — | US | disclosed |
| US-20190233488-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-20190233489-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| EP-3517128-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | immatics Biotechnologies GmbH (DE) | 2019-07-31 | — | — | EP | disclosed |
| EP-3517127-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | immatics Biotechnologies GmbH (DE) | 2019-07-31 | — | — | EP | disclosed |
| EP-3517126-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | immatics Biotechnologies GmbH (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-10364282-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-30 | — | — | US | disclosed |
| US-10364281-B2 | Immunotherapy against melanoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-30 | — | — | US | disclosed |
| US-10363295-B2 | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-30 | — | — | US | disclosed |
| US-10363296-B2 | Peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-30 | — | — | US | disclosed |
| US-10364271-B2 | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-30 | — | — | US | disclosed |
| US-20190225648-A1 | BIOLOGICALLY ACTIVE PEPTIDES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-25 | — | — | US | disclosed |
| EP-3195873-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-10357550-B2 | Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-23 | — | — | US | disclosed |
| US-10357540-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-23 | — | — | US | disclosed |
| US-10357551-B2 | Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-23 | — | — | US | disclosed |
| US-10357552-B2 | Peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers | IMMAICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-23 | — | — | US | disclosed |
| US-20190218254-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-18 | — | — | US | disclosed |
| US-20190209670-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-11 | — | — | US | disclosed |
| EP-3140319-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, SUCH AS ACUTE MYELOID LEUKEMIA (AML) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-10 | — | — | EP | disclosed |
| US-10342859-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-09 | — | — | US | disclosed |
| EP-3504228-A1 | NOVEL PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2019-07-03 | — | — | EP | disclosed |
| US-10335471-B2 | Method for treating cancer with activated T cells | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-02 | — | — | US | disclosed |
| US-10335475-B2 | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-02 | — | — | US | disclosed |
| US-10336809-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-02 | — | — | US | disclosed |
| US-10335474-B2 | Peptides and combination of peptides for use in immunotherapy against CLL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-07-02 | — | — | US | disclosed |
| US-20190192567-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
| US-20190192571-A1 | NOVEL PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
| US-20190194289-A1 | UTERINE CANCER TREATMENTS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
| EP-3115370-B1 | BIOLOGICALLY ACTIVE PEPTIDES | Baxalta GmbH (CH) | 2019-06-26 | — | — | EP | disclosed |
| US-20190185540-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| US-10323065-B1 | Immunotherapy against several tumors, such as lung cancer, including NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-06-18 | — | — | US | disclosed |
| US-20190177383-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-06-13 | — | — | US | disclosed |
| US-20190177368-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-06-13 | — | — | US | disclosed |
| US-20190177397-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-06-13 | — | — | US | disclosed |
| US-20190177369-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-06-13 | — | — | US | disclosed |
| US-10314896-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-06-11 | — | — | US | disclosed |
| US-10314898-B2 | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-06-11 | — | — | US | disclosed |
| US-10314897-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-06-11 | — | — | US | disclosed |
| US-10314899-B2 | Peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-06-11 | — | — | US | disclosed |
| US-10316063-B1 | Immunotherapy against several tumors, such as lung cancer, including NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-06-11 | — | — | US | disclosed |
| US-10316062-B1 | Immunotherapy against several tumors, such as lung cancer, including NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-06-11 | — | — | US | disclosed |
| US-20190169233-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-06-06 | — | — | US | disclosed |
| US-20190161526-A1 | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-05-30 | — | — | US | disclosed |
| US-20190153066-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-05-23 | — | — | US | disclosed |
| US-10294288-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-05-21 | — | — | US | disclosed |
| US-10293036-B2 | Peptides and combination of peptides for use in immunotherapy against NHL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-05-21 | — | — | US | disclosed |
| US-10286052-B2 | Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-05-14 | — | — | US | disclosed |
| US-10287564-B2 | Procoagulant compounds | BIOVERATIV THERAPEUTICS INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10287319-B2 | Biologically active peptides | BAXALTA INCORPORATED (US) | 2019-05-14 | — | — | US | disclosed |
| US-10280205-B2 | Method for treating cancer with an activated T lymphocyte that selectively recognizes a cancer cell consisting of specific peptide | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-05-07 | — | — | US | disclosed |
| US-10279022-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-05-07 | — | — | US | disclosed |
| US-10272114-B1 | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-04-30 | — | — | US | disclosed |
| US-10273282-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-04-30 | — | — | US | disclosed |
| US-20190117693-A1 | NOVEL PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-04-25 | — | — | US | disclosed |
| US-20190119351-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-04-25 | — | — | US | disclosed |
| US-20190119352-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-04-25 | — | — | US | disclosed |
| US-20190119342-A1 | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-04-25 | — | — | US | disclosed |
| US-10266581-B2 | Uterine cancer treatments | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-04-23 | — | — | US | disclosed |
| US-20190111081-A1 | NOVEL PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| US-20190112347-A1 | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| US-20190112339-A1 | BK CHANNEL-MODULATING PEPTIDES AND THEIR USE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-04-18 | — | — | US | disclosed |
| EP-3463425-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2019-04-10 | — | — | EP | disclosed |
| EP-2961766-B1 | QUANTIFICATION OF VACCINE COMPOSITIONS | BOEHRINGER INGELHEIM VETMEDICA INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10253077-B2 | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-10253076-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-20190100566-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-04-04 | — | — | US | disclosed |
| EP-3461494-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | Immatics Biotechnologies GmbH (DE) | 2019-04-03 | — | — | EP | disclosed |
| EP-3066115-B1 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-04-03 | — | — | EP | disclosed |
| US-20190091311-A1 | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-28 | — | — | US | disclosed |
| US-20190092823-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-28 | — | — | US | disclosed |
| US-20190091313-A1 | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-28 | — | — | US | disclosed |
| US-20190091312-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-28 | — | — | US | disclosed |
| US-20190092824-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-28 | — | — | US | disclosed |
| US-20190091314-A1 | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-28 | — | — | US | disclosed |
| US-10239932-B2 | Uterine cancer treatments | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-26 | — | — | US | disclosed |
| US-10238728-B2 | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-26 | — | — | US | disclosed |
| US-10238727-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-26 | — | — | US | disclosed |
| US-10239931-B2 | Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-26 | — | — | US | disclosed |
| US-10238691-B1 | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-26 | — | — | US | disclosed |
| US-10239925-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-26 | — | — | US | disclosed |
| US-10238726-B2 | Peptides and combination of peptides for use in immunotherapy against CLL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-26 | — | — | US | disclosed |
| US-10238725-B2 | Peptides and combination of peptides for use in immunotherapy against CLL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-26 | — | — | US | disclosed |
| US-10239930-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-26 | — | — | US | disclosed |
| US-10238724-B2 | Peptides and combination of peptides for use in immunotherapy against CLL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-26 | — | — | US | disclosed |
| EP-3456347-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | Immatics Biotechnologies GmbH (DE) | 2019-03-20 | — | — | EP | disclosed |
| EP-3456339-A2 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER INCLUDING NSCLC | immatics biotechnologies GmbH (DE) | 2019-03-20 | — | — | EP | disclosed |
| US-20190076476-A1 | NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-14 | — | — | US | disclosed |
| US-20190077832-A1 | NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-14 | — | — | US | disclosed |
| US-20190076513-A1 | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-14 | — | — | US | disclosed |
| US-20190076477-A1 | NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-14 | — | — | US | disclosed |
| US-20190076514-A1 | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-14 | — | — | US | disclosed |
| US-10227388-B2 | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-12 | — | — | US | disclosed |
| US-10227381-B2 | Immunotherapy against several tumors including neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-12 | — | — | US | disclosed |
| US-20190070279-A1 | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-07 | — | — | US | disclosed |
| US-10221229-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | INMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-05 | — | — | US | disclosed |
| US-10220069-B2 | Compositions and methods for treating diabetes | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221225-B2 | Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-03-05 | — | — | US | disclosed |
| US-20190054160-A1 | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-02-21 | — | — | US | disclosed |
| US-20190055302-A1 | UTERINE CANCER TREATMENTS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-02-21 | — | — | US | disclosed |
| US-20190055301-A1 | UTERINE CANCER TREATMENTS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-02-21 | — | — | US | disclosed |
| US-20190055286-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-02-21 | — | — | US | disclosed |
| EP-3440095-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2019-02-13 | — | — | EP | disclosed |
| US-10202437-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-02-12 | — | — | US | disclosed |
| US-10202436-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-02-12 | — | — | US | disclosed |
| US-20190040114-A1 | Immunotherapy against melanoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-02-07 | — | — | US | disclosed |
| US-20190040115-A1 | Immunotherapy against melanoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-02-07 | — | — | US | disclosed |
| US-20190040112-A1 | IMMUNOTHERAPY AGAINST MELANOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-02-07 | — | — | US | disclosed |
| US-20190040113-A1 | Immunotherapy against melanoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-02-07 | — | — | US | disclosed |
| US-10196422-B2 | Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-02-05 | — | — | US | disclosed |
| US-10196432-B2 | Tumor-associated peptides binding to human leukocyte antigen (HLA) class II molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-02-05 | — | — | US | disclosed |
| US-10195232-B1 | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-02-05 | — | — | US | disclosed |
| US-20190030075-A1 | NOVEL PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-31 | — | — | US | disclosed |
| US-10189886-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-29 | — | — | US | disclosed |
| US-20190022201-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-24 | — | — | US | disclosed |
| US-20190023924-A1 | COMPOSITION, CURED PRODUCT, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | RICOH COMPANY, LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| US-20190023763-A1 | UTERINE CANCER TREATMENTS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-24 | — | — | US | disclosed |
| US-20190023762-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-24 | — | — | US | disclosed |
| EP-3431557-A1 | COMPOSITION, CURED PRODUCT, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | Ricoh Company, Limited (JP) | 2019-01-23 | — | — | EP | disclosed |
| US-10183972-B2 | BK channel-modulating peptides and their use | UNIVERSITY OF SOUTH FLORIDA (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183982-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-22 | — | — | US | disclosed |
| US-20190016779-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-17 | — | — | US | disclosed |
| US-20190015492-A1 | Novel Peptides and Combination of Peptides for Use In Immunotherapy Against Various Cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-17 | — | — | US | disclosed |
| EP-3426281-A1 | UTERINE CANCER TREATMENTS | Immatics Biotechnologies GmbH (DE) | 2019-01-16 | — | — | EP | disclosed |
| CN-109206481-A | Peptide compound, application thereof and composition containing peptide compound | 凯惠科技发展(上海)有限公司 | 2019-01-15 | — | — | CN | disclosed |
| US-10179165-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-15 | — | — | US | disclosed |
| US-20190010190-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-10 | — | — | US | disclosed |
| US-20190010209-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-10 | — | — | US | disclosed |
| WO-2019007974-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-10 | — | — | WO | disclosed |
| US-20190010208-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-10 | — | — | US | disclosed |
| US-20190010198-A1 | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-10 | — | — | US | disclosed |
| EP-3423085-A1 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2019-01-09 | — | — | EP | disclosed |
| US-10174089-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-08 | — | — | US | disclosed |
| CN-109134610-A | A kind of peptides, its application and the composition containing it | 凯惠科技发展(上海)有限公司 | 2019-01-04 | — | — | CN | disclosed |
| US-20190002525-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-03 | — | — | US | disclosed |
| US-20190002524-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-03 | — | — | US | disclosed |
| US-20190000947-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-03 | — | — | US | disclosed |
| US-20190002526-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-03 | — | — | US | disclosed |
| US-20190002497-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-03 | — | — | US | disclosed |
| US-20190002504-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-03 | — | — | US | disclosed |
| US-10167331-B1 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-01 | — | — | US | disclosed |
| US-10166278-B2 | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-01 | — | — | US | disclosed |
| US-10167317-B1 | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-01-01 | — | — | US | disclosed |
| EP-3416980-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NHL AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2018-12-26 | — | — | EP | disclosed |
| US-10159726-B2 | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-25 | — | — | US | disclosed |
| US-10160786-B1 | Immunotherapy against several tumors, such as lung cancer, including NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-25 | — | — | US | disclosed |
| US-20180360936-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-20 | — | — | US | disclosed |
| US-20180360937-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-20 | — | — | US | disclosed |
| EP-2717898-B1 | PRO-COAGULANT COMPOUNDS AND METHODS OF USE THEREOF | BIOVERATIV THERAPEUTICS INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-10155032-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-18 | — | — | US | disclosed |
| US-10155801-B1 | Peptides and combination of peptides for use in immunotherapy against various tumors | immatics biotechnology GmbH (DE) | 2018-12-18 | — | — | US | disclosed |
| US-20180353584-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-13 | — | — | US | disclosed |
| US-20180353583-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-13 | — | — | US | disclosed |
| US-20180353585-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-13 | — | — | US | disclosed |
| US-20180353586-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-13 | — | — | US | disclosed |
| US-20180344826-A1 | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-06 | — | — | US | disclosed |
| US-20180346548-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-06 | — | — | US | disclosed |
| US-20180344825-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-06 | — | — | US | disclosed |
| US-20180346538-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-06 | — | — | US | disclosed |
| US-20180344827-A1 | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-06 | — | — | US | disclosed |
| US-10143731-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-04 | — | — | US | disclosed |
| US-10143733-B2 | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-04 | — | — | US | disclosed |
| US-10143732-B2 | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-04 | — | — | US | disclosed |
| US-10144763-B2 | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-04 | — | — | US | disclosed |
| US-10143730-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-12-04 | — | — | US | disclosed |
| US-20180340019-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-11-29 | — | — | US | disclosed |
| US-10138287-B2 | Uterine cancer treatments | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-11-27 | — | — | US | disclosed |
| US-10138288-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-11-27 | — | — | US | disclosed |
| US-10131703-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | INMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-11-20 | — | — | US | disclosed |
| US-10130693-B2 | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-11-20 | — | — | US | disclosed |
| US-20180327474-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-11-15 | — | — | US | disclosed |
| US-20180327475-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-11-15 | — | — | US | disclosed |
| EP-2291395-B2 | NOVEL AND POWERFUL MHC-CLASS II PEPTIDES DERIVED FROM SURVIVIN | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-11-14 | — | — | EP | disclosed |
| EP-3069728-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-11-14 | — | — | EP | disclosed |
| US-10117916-B2 | Peptides and combination of peptides for use in immunotherapy against CLL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-11-06 | — | — | US | disclosed |
| US-10117917-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-11-06 | — | — | US | disclosed |
| US-20180311330-A1 | Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-11-01 | — | — | US | disclosed |
| EP-3394084-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2018-10-31 | — | — | EP | disclosed |
| EP-3111952-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-10-31 | — | — | EP | disclosed |
| US-20180303919-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-20180303921-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-20180303920-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10106593-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-10-23 | — | — | US | disclosed |
| US-10106594-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-10-23 | — | — | US | disclosed |
| US-10105428-B2 | Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-10-23 | — | — | US | disclosed |
| WO-2018189152-A2 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018189148-A1 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-10-18 | — | — | WO | disclosed |
| EP-3387008-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2018-10-17 | — | — | EP | disclosed |
| EP-3388079-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (SEQ ID 253 - RAD54B) | Immatics Biotechnologies GmbH (DE) | 2018-10-17 | — | — | EP | disclosed |
| EP-3388080-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (SEQ ID 243 - SPC25-001) | Immatics Biotechnologies GmbH (DE) | 2018-10-17 | — | — | EP | disclosed |
| EP-3388075-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (SEQ ID 25 - MRAX5-003) | Immatics Biotechnologies GmbH (DE) | 2018-10-17 | — | — | EP | disclosed |
| EP-3388077-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (SEQ ID 245 - MAGEA4-003) | Immatics Biotechnologies GmbH (DE) | 2018-10-17 | — | — | EP | disclosed |
| EP-3388076-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (SEQ ID 274 - IGF-004) | Immatics Biotechnologies GmbH (DE) | 2018-10-17 | — | — | EP | disclosed |
| EP-3388078-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (SEQ ID 23 - MMP-002) | Immatics Biotechnologies GmbH (DE) | 2018-10-17 | — | — | EP | disclosed |
| US-10098938-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-10-16 | — | — | US | disclosed |
| US-10100085-B2 | Immunotherapy against several tumors including neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-10-16 | — | — | US | disclosed |
| US-10098937-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-10-16 | — | — | US | disclosed |
| US-20180291083-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-10-11 | — | — | US | disclosed |
| US-20180291082-A1 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-10-11 | — | — | US | disclosed |
| US-10093715-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-10-09 | — | — | US | disclosed |
| US-20180282393-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-10-04 | — | — | US | disclosed |
| US-20180282394-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-10-04 | — | — | US | disclosed |
| US-10081664-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-25 | — | — | US | disclosed |
| US-10081665-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-25 | — | — | US | disclosed |
| US-10076560-B2 | Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-18 | — | — | US | disclosed |
| US-20180258150-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-13 | — | — | US | disclosed |
| US-20180258155-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-13 | — | — | US | disclosed |
| US-20180256693-A1 | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-13 | — | — | US | disclosed |
| US-10071148-B2 | Immunotherapy against several tumors, such as lung cancer, including NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-11 | — | — | US | disclosed |
| US-10072063-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-11 | — | — | US | disclosed |
| US-20180250373-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-06 | — | — | US | disclosed |
| US-20180251507-A1 | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-06 | — | — | US | disclosed |
| US-20180250374-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-06 | — | — | US | disclosed |
| US-20180251520-A1 | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-06 | — | — | US | disclosed |
| US-20180251516-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-06 | — | — | US | disclosed |
| US-20180251518-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-06 | — | — | US | disclosed |
| US-20180251517-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-06 | — | — | US | disclosed |
| US-20180251506-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-06 | — | — | US | disclosed |
| US-20180251519-A1 | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-06 | — | — | US | disclosed |
| EP-2258720-B1 | MULTIPLE TARGET T CELL RECEPTOR | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN MDC BERLIN BUCH (DE) | 2018-09-05 | — | — | EP | disclosed |
| US-10064913-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-04 | — | — | US | disclosed |
| US-10064928-B2 | Peptides and combination of peptides for use in immunotherapy against CLL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-04 | — | — | US | disclosed |
| US-10064924-B2 | Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-04 | — | — | US | disclosed |
| US-10064929-B2 | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-04 | — | — | US | disclosed |
| US-10064926-B2 | Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-04 | — | — | US | disclosed |
| US-10066003-B1 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-09-04 | — | — | US | disclosed |
| US-20180244722-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-08-30 | — | — | US | disclosed |
| US-20180244741-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-08-30 | — | — | US | disclosed |
| US-10059755-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-08-28 | — | — | US | disclosed |
| US-10058598-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-08-28 | — | — | US | disclosed |
| US-20180237494-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-08-23 | — | — | US | disclosed |
| US-20180237493-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-08-23 | — | — | US | disclosed |
| EP-3363456-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | immatics Biotechnologies GmbH (DE) | 2018-08-22 | — | — | EP | disclosed |
| US-20180222961-A1 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-08-09 | — | — | US | disclosed |
| WO-2018138257-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-08-02 | — | — | WO | disclosed |
| US-10035838-B2 | Immunotherapy against melanoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-07-31 | — | — | US | disclosed |
| US-20180208641-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20180207253-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20180207252-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20180208640-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20180207251-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20180193439-A1 | Immunotherapy against melanoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-07-12 | — | — | US | disclosed |
| EP-2183278-B1 | NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-07-04 | — | — | EP | disclosed |
| EP-3042914-B1 | NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-07-04 | — | — | EP | disclosed |
| EP-3341014-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | Immatics Biotechnologies GmbH (DE) | 2018-07-04 | — | — | EP | disclosed |
| US-10011645-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-07-03 | — | — | US | disclosed |
| US-10005828-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-06-26 | — | — | US | disclosed |
| US-10004792-B2 | Peptides and combination of peptides for use in immunotherapy against various cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-06-26 | — | — | US | disclosed |
| US-10000533-B2 | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-10000547-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | immatics biotechnology GmbH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-10000539-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| EP-3331900-A2 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2018-06-13 | — | — | EP | disclosed |
| US-9993539-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9994628-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9993523-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9993536-B2 | Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9993540-B2 | Immunotherapy against several tumors including neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| EP-3329933-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | Immatics Biotechnologies GmbH (DE) | 2018-06-06 | — | — | EP | disclosed |
| US-9988432-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| EP-3325498-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | Immatics Biotechnologies GmbH (DE) | 2018-05-30 | — | — | EP | disclosed |
| US-9982030-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-05-29 | — | — | US | disclosed |
| US-9982031-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-05-29 | — | — | US | disclosed |
| US-20180141993-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-05-24 | — | — | US | disclosed |
| EP-3322717-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | immatics biotechnologies GmbH (DE) | 2018-05-23 | — | — | EP | disclosed |
| EP-3319985-A2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2018-05-16 | — | — | EP | disclosed |
| US-20180127473-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-05-10 | — | — | US | disclosed |
| US-20180127607-A1 | CURABLE COMPOSITION, CURABLE INK, ACCOMMODATING CONTAINER, IMAGE FORMING DEVICE, IMAGE FORMING METHOD, CURED MATTER, AND ACRYLAMIDE COMPOUND | RICOH COMPANY, LTD. (JP) | 2018-05-10 | — | — | US | disclosed |
| US-20180127607-A1 | CURABLE COMPOSITION, CURABLE INK, ACCOMMODATING CONTAINER, IMAGE FORMING DEVICE, IMAGE FORMING METHOD, CURED MATTER, AND ACRYLAMIDE COMPOUND | RICOH COMPANY, LTD. (JP) | 2018-05-10 | — | — | US | disclosed |
| US-20180125929-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-05-10 | — | — | US | disclosed |
| EP-3317296-A2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2018-05-09 | — | — | EP | disclosed |
| US-20180117085-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-05-03 | — | — | US | disclosed |
| EP-3313860-A2 | NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNO-THERAPY OF MYELOMA AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-3310806-A2 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR GENERATING SCAFFOLDS FOR THE USE AGAINST PANCREATIC CANCER AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2018-04-25 | — | — | EP | disclosed |
| US-9950048-B2 | Immunogenic epitopes for immunotherapy | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9951119-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9943579-B2 | Immunotherapy against several tumors, such as lung cancer, including NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-04-17 | — | — | US | disclosed |
| US-20180100005-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-04-12 | — | — | US | disclosed |
| US-20180094043-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
| US-9931388-B2 | Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-04-03 | — | — | US | disclosed |
| US-9932384-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-04-03 | — | — | US | disclosed |
| EP-3291830-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2018-03-14 | — | — | EP | disclosed |
| US-20180066032-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-03-08 | — | — | US | disclosed |
| US-20180064796-A1 | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-03-08 | — | — | US | disclosed |
| US-9908922-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-03-06 | — | — | US | disclosed |
| US-9908920-B2 | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-03-06 | — | — | US | disclosed |
| WO-2018037085-A1 | NOVEL PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-03-01 | — | — | WO | disclosed |
| US-20180055883-A1 | Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-03-01 | — | — | US | disclosed |
| EP-3285801-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-9901629-B2 | Immunotherapy against melanoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| US-9895415-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-02-20 | — | — | US | disclosed |
| US-9889159-B2 | Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| US-20180037627-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| US-20180037629-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| US-20180037628-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| US-20180037626-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| EP-3277310-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2018-02-07 | — | — | EP | disclosed |
| US-20180030113-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-02-01 | — | — | US | disclosed |
| EP-3273986-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | Immatics Biotechnologies GmbH (DE) | 2018-01-31 | — | — | EP | disclosed |
| EP-3270952-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2018-01-24 | — | — | EP | disclosed |
| US-20180016303-A1 | BK CHANNEL-MODULATING PEPTIDES AND THEIR USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-01-18 | — | — | US | disclosed |
| US-20180015163-A1 | CANCER METHODS | GABRA HANI (GB) | 2018-01-18 | — | — | US | disclosed |
| US-20180009858-A9 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-01-11 | — | — | US | disclosed |
| US-9862756-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| US-20180000896-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2018-01-04 | — | — | US | disclosed |
| US-9840548-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-12-12 | — | — | US | disclosed |
| US-20170342125-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-11-30 | — | — | US | disclosed |
| WO-2017202806-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-11-30 | — | — | WO | disclosed |
| EP-2119726-B2 | Novel and powerful MHC-class II peptides derived from survivin and neurocan | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-11-29 | — | — | EP | disclosed |
| US-20170326215-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-11-16 | — | — | US | disclosed |
| US-20170326217-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-11-16 | — | — | US | disclosed |
| US-20170326216-A1 | Immunotherapy against melanoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-11-16 | — | — | US | disclosed |
| US-20170320913-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-11-09 | — | — | US | disclosed |
| US-20170319675-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-11-09 | — | — | US | disclosed |
| US-20170312336-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313760-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| EP-3236985-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2017-11-01 | — | — | EP | disclosed |
| US-9802997-B2 | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-20170305993-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20170305982-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20170304399-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-10-26 | — | — | US | disclosed |
| WO-2017182395-A1 | IMMUNOTHERAPY AGAINST MELANOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-10-26 | — | — | WO | disclosed |
| US-20170305992-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20170305991-A1 | Immunotherapy against melanoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20170296640-A1 | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-10-19 | — | — | US | disclosed |
| US-20170290897-A1 | Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-10-12 | — | — | US | disclosed |
| WO-2017174645-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-10-12 | — | — | WO | disclosed |
| US-20170260249-A1 | Uterine cancer treatments | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-09-14 | — | — | US | disclosed |
| WO-2017153247-A1 | UTERINE CANCER TREATMENTS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-09-14 | — | — | WO | disclosed |
| US-20170253908-A1 | QUANTIFICATION OF VACCINE COMPOSITIONS | Boehringer Ingelheim Animal Health USA Inc. | 2017-09-07 | — | — | US | disclosed |
| US-20170253633-A1 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-09-07 | — | — | US | disclosed |
| WO-2017140897-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NHL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-08-24 | — | — | WO | disclosed |
| US-9717774-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-08-01 | — | — | US | disclosed |
| EP-3195873-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | immatics biotechnologies GmbH (DE) | 2017-07-26 | — | — | EP | disclosed |
| US-20170202937-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-07-20 | — | — | US | disclosed |
| EP-2923708-B1 | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-07-12 | — | — | EP | disclosed |
| US-20170189511-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-07-06 | — | — | US | disclosed |
| US-20170189506-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-07-06 | — | — | US | disclosed |
| US-20170189510-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-07-06 | — | — | US | disclosed |
| US-20170189505-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-07-06 | — | — | US | disclosed |
| US-20170189509-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-07-06 | — | — | US | disclosed |
| US-20170189504-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-07-06 | — | — | US | disclosed |
| US-20170189513-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-07-06 | — | — | US | disclosed |
| US-20170189507-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-07-06 | — | — | US | disclosed |
| US-20170189512-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-07-06 | — | — | US | disclosed |
| US-20170189508-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-07-06 | — | — | US | disclosed |
| WO-2017108345-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-06-29 | — | — | WO | disclosed |
| US-20170173132-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20170174724-A1 | BIOLOGICALLY ACTIVE PEPTIDES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170173131-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| WO-2017097699-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017097602-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-06-15 | — | — | WO | disclosed |
| US-20170165340-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-06-15 | — | — | US | disclosed |
| US-20170165339-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-06-15 | — | — | US | disclosed |
| US-20170165335-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-06-15 | — | — | US | disclosed |
| US-20170165337-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-06-15 | — | — | US | disclosed |
| US-20170165338-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-06-15 | — | — | US | disclosed |
| US-20170158750-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-06-08 | — | — | US | disclosed |
| US-20170145073-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-05-25 | — | — | US | disclosed |
| US-20170145072-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-05-25 | — | — | US | disclosed |
| US-20170136108-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-05-18 | — | — | US | disclosed |
| US-9649378-B2 | Cancer methods | GABRA HANI (GB) | 2017-05-16 | — | — | US | disclosed |
| EP-3157549-A2 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL) | immatics biotechnologies GmbH (DE) | 2017-04-26 | — | — | EP | disclosed |
| US-9624527-B2 | Quantification of vaccine compositions | BOEHRINGER INGELHEIM VETMEDICA, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| WO-2017060169-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST SMALL CELL LUNG CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-04-13 | — | — | WO | disclosed |
| US-20170096461-A1 | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170080070-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| US-9598464-B2 | Biologically active peptides | BAXALTA INCORPORATED (US) | 2017-03-21 | — | — | US | disclosed |
| EP-3140319-A2 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, SUCH AS ACUTE MYELOID LEUKEMIA (AML) | Immatics Biotechnologies GmbH (DE) | 2017-03-15 | — | — | EP | disclosed |
| WO-2017036936-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-03-09 | — | — | WO | disclosed |
| EP-2845604-B1 | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-03-08 | — | — | EP | disclosed |
| US-20170056488-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170056486-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170058005-A1 | VACCINE COMPOSITION COMPRISING ANTHRAX LETHAL FACTOR POLYPEPTIDE | IMP INNOVATIONS LTD (GB) | 2017-03-02 | — | — | US | disclosed |
| US-20170056487-A1 | NOVEL PEPTIDES, COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-03-02 | — | — | US | disclosed |
| EP-3132801-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | Immatics Biotechnologies GmbH (DE) | 2017-02-22 | — | — | EP | disclosed |
| US-20170037092-A1 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-02-09 | — | — | US | disclosed |
| US-20170037096-A1 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-02-09 | — | — | US | disclosed |
| US-20170035807-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-02-09 | — | — | US | disclosed |
| US-20170037111-A1 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-02-09 | — | — | US | disclosed |
| US-20170037095-A1 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-02-09 | — | — | US | disclosed |
| US-20170037107-A1 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-02-09 | — | — | US | disclosed |
| US-20170037093-A1 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-02-09 | — | — | US | disclosed |
| US-20170037094-A1 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-02-09 | — | — | US | disclosed |
| WO-2017021527-A2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-02-09 | — | — | WO | disclosed |
| US-20170037097-A1 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-02-09 | — | — | US | disclosed |
| US-20170037089-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | immatics biotechnology GmbH (DE) | 2017-02-09 | — | — | US | disclosed |
| US-20170037098-A1 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-02-09 | — | — | US | disclosed |
| US-20170037110-A1 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-02-09 | — | — | US | disclosed |
| US-20170029486-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-02-02 | — | — | US | disclosed |
| EP-3124043-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | Immatics Biotechnologies GmbH (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-20170022251-A1 | NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH | 2017-01-26 | — | — | US | disclosed |
| EP-3120869-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | Immatics Biotechnologies GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-3120868-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | Immatics Biotechnologies GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-3120870-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | Immatics Biotechnologies GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| WO-2017009400-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-01-19 | — | — | WO | disclosed |
| WO-2017005733-A2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-01-12 | — | — | WO | disclosed |
| US-20170007666-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | THE JOHNS HOPKINS UNIVERSITY | 2017-01-12 | — | — | US | disclosed |
| EP-3115370-A1 | BIOLOGICALLY ACTIVE PEPTIDES | Baxalta GmbH (CH) | 2017-01-11 | — | — | EP | disclosed |
| US-20170002055-A1 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-01-05 | — | — | US | disclosed |
| WO-2017001491-A2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2017-01-05 | — | — | WO | disclosed |
| EP-3111952-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | Immatics Biotechnologies GmbH (DE) | 2017-01-04 | — | — | EP | disclosed |
| US-20160376317-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-12-29 | — | — | US | disclosed |
| US-20160376314-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-12-29 | — | — | US | disclosed |
| US-20160376313-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-12-29 | — | — | US | disclosed |
| US-20160376315-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-12-29 | — | — | US | disclosed |
| WO-2016207164-A2 | NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNO-THERAPY OF MYELOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-12-29 | — | — | WO | disclosed |
| US-20160376312-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-12-29 | — | — | US | disclosed |
| US-20160376316-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-12-29 | — | — | US | disclosed |
| US-20160368965-A1 | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-12-22 | — | — | US | disclosed |
| WO-2016202963-A2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR GENERATING SCAFFOLDS FOR THE USE AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-12-22 | — | — | WO | disclosed |
| EP-3106175-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | Immatics Biotechnologies GmbH (DE) | 2016-12-21 | — | — | EP | disclosed |
| US-20160355550-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-12-08 | — | — | US | disclosed |
| US-9511128-B2 | Immunogenic epitopes for immunotherapy | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20160346371-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-12-01 | — | — | US | disclosed |
| US-20160347808-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-12-01 | — | — | US | disclosed |
| US-20160339092-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| US-9498512-B2 | Powerful MHC-class II peptides derived from survivin | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| WO-2016177784-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-11-10 | — | — | WO | disclosed |
| US-9486507-B2 | Pro-coagulant compounds and methods of use thereof | BIOGEN MA INC. (US) | 2016-11-08 | — | — | US | disclosed |
| WO-2016170139-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016156230-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016156202-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-10-06 | — | — | WO | disclosed |
| US-20160289273-A1 | PROCOAGULANT FUSION COMPOUND | BIOGEN MA INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160287687-A1 | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160289296-A1 | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-10-06 | — | — | US | disclosed |
| EP-2172212-B1 | Novel immunotherapy against several tumors including neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-20160279218-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-09-29 | — | — | US | disclosed |
| US-20160280760-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH | 2016-09-29 | — | — | US | disclosed |
| US-20160280758-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH | 2016-09-29 | — | — | US | disclosed |
| US-20160279215-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH | 2016-09-29 | — | — | US | disclosed |
| US-20160279214-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH | 2016-09-29 | — | — | US | disclosed |
| US-20160280759-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH | 2016-09-29 | — | — | US | disclosed |
| US-20160279216-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH | 2016-09-29 | — | — | US | disclosed |
| US-20160279217-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH | 2016-09-29 | — | — | US | disclosed |
| US-20160280752-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH | 2016-09-29 | — | — | US | disclosed |
| US-20160280738-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-09-29 | — | — | US | disclosed |
| US-20160280757-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | IMMATICS BIOTECHNOLOGIES GMBH | 2016-09-29 | — | — | US | disclosed |
| WO-2016146751-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-09-22 | — | — | WO | disclosed |
| EP-3069728-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | Immatics Biotechnologies GmbH (DE) | 2016-09-21 | — | — | EP | disclosed |
| EP-3066115-A2 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | Immatics Biotechnologies GmbH (DE) | 2016-09-14 | — | — | EP | disclosed |
| EP-3065769-A1 | PROCOAGULANT FUSION COMPOUND | Biogen MA Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160250307-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-09-01 | — | — | US | disclosed |
| EP-3058947-A2 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | immatics biotechnologies GmbH (DE) | 2016-08-24 | — | — | EP | disclosed |
| US-20160222080-A1 | MULTIPLE TARGET T CELL RECEPTOR | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2016-08-04 | — | — | US | disclosed |
| US-20160213812-A1 | BIODEGRADABLE POLYMER AND TISSUE COMBINATIONS | PATHAK HOLDINGS LLC | 2016-07-28 | — | — | US | disclosed |
| EP-3042914-A1 | NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY | immatics biotechnologies GmbH (DE) | 2016-07-13 | — | — | EP | disclosed |
| EP-2279200-B1 | BIOLOGICALLY ACTIVE PEPTIDES | Baxalta GmbH (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-9388216-B2 | Methods of treating reproductive cancer | MEDICAL RESEARCH COUNCIL (GB) | 2016-07-12 | — | — | US | disclosed |
| WO-2016102272-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-06-30 | — | — | WO | disclosed |
| US-20160175357-A1 | NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-06-23 | — | — | US | disclosed |
| US-20160168200-A1 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| EP-3030255-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | immatics biotechnologies GmbH (DE) | 2016-06-15 | — | — | EP | disclosed |
| US-9334487-B2 | Methods for diagnosing rheumatoid arthritis | IMPERIAL INNOVATIONS LIMITED (GB) | 2016-05-10 | — | — | US | disclosed |
| EP-2341927-B1 | Composition comprising tumor associated peptides and a vaccine for treatment of glioblastoma and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-05-04 | — | — | EP | disclosed |
| US-20160115212-A1 | TUMOR-ASSOCIATED PEPTIDES BINDING PROMISCUOUSLY TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS II MOLECULES | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-04-28 | — | — | US | disclosed |
| CN-105524163-A | BIOLOGICALLY ACTIVE PEPTIDES | BAXTER INT | 2016-04-27 | — | — | CN | disclosed |
| CN-105440119-A | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules | IMMATICS BIOTECHOLOGIES GMBH | 2016-03-30 | — | — | CN | disclosed |
| US-20160060295-A1 | BIOLOGICALLY ACTIVE PEPTIDES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
| CN-105377290-A | Novel immunotherapies for the treatment of various tumors (e.g., lung cancer including NSCLC) | IMMATICS BIOTECHNOLOGIES GMBH | 2016-03-02 | — | — | CN | disclosed |
| US-20160051654-A1 | NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-02-25 | — | — | US | disclosed |
| EP-2211891-B1 | ANTAGONISTS OF KISSPEPTIN AND USES THEREOF | MEDICAL RES COUNCIL (GB) | 2016-02-24 | — | — | EP | disclosed |
| CN-102007140-B | biologically active peptides | BAXTER INTERNATIONAL INC. (US) | 2016-02-24 | — | — | CN | disclosed |
| EP-2961766-A2 | QUANTIFICATION OF VACCINE COMPOSITIONS | Boehringer Ingelheim Vetmedica, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20150368502-A1 | METHOD FOR COATING A SUBSTRATE WITH A POLY(IONIC-LIQUID) AND COATED SUBSTRATE MADE BY THE PROCESS | SURFACE INNOVATIONS LTD (GB) | 2015-12-24 | — | — | US | disclosed |
| US-20150368298-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-12-24 | — | — | US | disclosed |
| WO-2015193359-A2 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-12-23 | — | — | WO | disclosed |
| US-9206234-B2 | Biologically active peptides | BAXALTA INCORPORATED (US) | 2015-12-08 | — | — | US | disclosed |
| EP-2945982-A2 | THREE DIMENSIONAL POROUS STRUCTURES | Spheritech Ltd (GB) | 2015-11-25 | — | — | EP | disclosed |
| US-20150328620-A1 | METHOD OF CAPTURING HEAVY METALS BY A CHEMICALLY FUNCTIONALIZED SURFACE | SURFACE INNOVATIONS LIMITED (GB) | 2015-11-19 | — | — | US | disclosed |
| WO-2015169945-A2 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, SUCH AS ACUTE MYELOID LEUKEMIA (AML) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-11-12 | — | — | WO | disclosed |
| US-20150320848-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, SUCH AS ACUTE MYELOID LEUKEMIA (AML) | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-11-12 | — | — | US | disclosed |
| WO-2015166250-A1 | VACCINE COMPOSITION COMPRISING ANTHRAX LETHAL FACTOR POLYPEPTIDE | IMPERIAL INNOVATIONS LTD (GB) | 2015-11-05 | — | — | WO | disclosed |
| US-9175040-B2 | Immunotherapeutic peptides against neuronal and brain tumors and related methods and compositions | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-20150306277-A1 | BIODEGRADABLE TISSUE COMPOSITION WITH BIODEGRADABLE CROSS-LINKERS | PATHAK HOLDINGS LLC | 2015-10-29 | — | — | US | disclosed |
| CN-103059104-B | Be incorporated into the tumor-associated peptides of human leucocyte antigen (HLA) II quasi-molecule with mixing | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-10-28 | — | — | CN | disclosed |
| EP-2562184-B1 | Novel immunogenic epitopes for immunotherapy | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| EP-2562183-B1 | Novel immunogenic epitopes for immunotherapy | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| EP-2562182-B1 | Novel immunogenic epitopes for immunotherapy | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| EP-2105501-B1 | Novel immunotherapy against neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| EP-2565204-B1 | Novel immunogenic epitopes for immunotherapy | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| EP-2923708-A1 | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer | Immatics Biotechnologies GmbH (DE) | 2015-09-30 | — | — | EP | disclosed |
| EP-2338907-B1 | Novel immunogenic epitopes for immunotherapy | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-09-30 | — | — | EP | disclosed |
| US-9133264-B2 | Epitope-tag surface expressed proteins and nucleic acids thereof | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (MDC) BERLIN-BUCH (DE) | 2015-09-15 | — | — | US | disclosed |
| EP-2029618-B1 | AGENTS, METHODS AND USES | MEDICAL RES COUNCIL (GB) | 2015-08-12 | — | — | EP | disclosed |
| EP-2291395-B1 | NOVEL AND POWERFUL MHC-CLASS II PEPTIDES DERIVED FROM SURVIVIN | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-08-12 | — | — | EP | disclosed |
| US-9101585-B2 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| US-9096756-B2 | Process for obtaining low free monomer levels in a block copolymer emulsion prepared with (reverse) iodine transfer polymerisation | DSM IP ASSETS B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| WO-2015112703-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-07-30 | — | — | WO | disclosed |
| EP-2899206-A1 | Novel and powerful MHC-class II peptides derived from survivin | immatics biotechnologies GmbH (DE) | 2015-07-29 | — | — | EP | disclosed |
| US-9089535-B2 | Anti-virus therapy for respiratory diseases | IMPERIAL INNOVATIONS LIMITED (GB) | 2015-07-28 | — | — | US | disclosed |
| CN-102977188-B | GNRH (gonadotropin-releasing hormone) peptide variants | MEDICAL RES COUNCIL | 2015-07-15 | — | — | CN | disclosed |
| CN-102630240-B | Three-dimensional porous structure | SPHERITECH LTD | 2015-07-08 | — | — | CN | disclosed |
| US-9072814-B2 | Biodegradable tissue compositions with biodegradable cross-linkers | PATHAK HOLDINGS LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150184142-A1 | PROCOAGULANT COMPOUNDS | BIOGEN IDEC MA INC. (US) | 2015-07-02 | — | — | US | disclosed |
| US-9056069-B2 | Cancer therapy based on tumor associated antigens derived from cyclin D1 | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-06-16 | — | — | US | disclosed |
| EP-2660248-B1 | Novel immunotherapy against brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-06-10 | — | — | EP | disclosed |
| EP-2183361-B1 | Novel immunotherapy against brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-06-10 | — | — | EP | disclosed |
| EP-2547354-B1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-06-03 | — | — | EP | disclosed |
| US-20150147347-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-05-28 | — | — | US | disclosed |
| CN-102630241-B | hollow particle body | SPHERITECH LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2041171-B1 | EPITOPE-TAG FOR SURFACE-EXPRESSED PROTEINS AND USES THEREOF | MAX DELBRÜCK CT FÜR MOLEKULARE MEDIZIN MDC (DE) | 2015-05-20 | — | — | EP | disclosed |
| WO-2015070014-A1 | PROCOAGULANT FUSION COMPOUND | BIOGEN IDEC MA INC. (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20150125478-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-05-07 | — | — | US | disclosed |
| US-20150125477-A1 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-05-07 | — | — | US | disclosed |
| WO-2015063302-A2 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-05-07 | — | — | WO | disclosed |
| EP-2866950-A1 | METHOD FOR COATING A SUBSTRATE WITH A POLY(IONIC-LIQUID) AND COATED SUBSTRATE MADE BY THE PROCESS | Surface Innovations Limited (GB) | 2015-05-06 | — | — | EP | disclosed |
| US-9023379-B2 | Biodegradable tissue composition with biodegradable cross-linkers | PATHAK HOLDINGS LLC (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023803-B2 | Cancer therapy based on tumor associated antigens derived from cyclin D1 | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| EP-2845604-A2 | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer | immatics biotechnologies GmbH (DE) | 2015-03-11 | — | — | EP | disclosed |
| US-20150057430-A1 | COMPOUND, USE AND METHOD | MEDICAL RESEARCH COUNCIL (GB) | 2015-02-26 | — | — | US | disclosed |
| US-8961985-B2 | Immunotherapy against several tumors including neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-02-24 | — | — | US | disclosed |
| US-8961845-B2 | Optical compensation film, and polarizing plate and liquid crystal display employing the same | KONICA MINOLTA OPTO, INC. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8961845-B2 | Optical compensation film, and polarizing plate and liquid crystal display employing the same | KONICA MINOLTA OPTO, INC. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8956612-B2 | Peptide associated with rheumatic fever (PARF) and its use as a diagnostic marker | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2015-02-17 | — | — | US | disclosed |
| US-20150045498-A1 | METHOD FOR PRODUCING A SURFACE - FUNCTIONALISED OBJECT | BADYAL JAS PAL S (GB) | 2015-02-12 | — | — | US | disclosed |
| WO-2015018805-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-02-12 | — | — | WO | disclosed |
| US-20150038676-A1 | Biologically Active Peptides | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-05 | — | — | US | disclosed |
| EP-2119726-B1 | Novel and powerful MHC-class II peptides derived from survivin and neurocan | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2014-12-24 | — | — | EP | disclosed |
| US-8916681-B2 | Compound, use and method | MEDICAL RESEARCH COUNCIL (GB) | 2014-12-23 | — | — | US | disclosed |
| US-8906404-B2 | Three dimensional porous polymeric structure having a pore-size range of 1/10 to 10 times the average pore size | SPHERITECH LTD. (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20140315780-A1 | PRODUCT | UNIVERSITY OF DURHAM (GB) | 2014-10-23 | — | — | US | disclosed |
| EP-2029624-B1 | PEPTIDE ASSOCIATED WITH RHEUMATIC FEVER (PARF) AND ITS USE AS A DIAGNOSTIC MARKER | Helmholtz Zentrum für Infektionsforschung GmbH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-20140303084-A1 | Pro-Coagulant Compounds and Methods of Use Thereof | BIOGEN IDEC MA INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140271692-A1 | NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| WO-2014134561-A2 | QUANTIFICATION OF VACCINE COMPOSITIONS | BOEHRINGER INGELHEIM VETMEDICA, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| US-20140248603-A1 | QUANTIFICATION OF VACCINE COMPOSITIONS | BOEHRINGER INGELHEIM VETMEDICA, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-8822638-B2 | Procoagulant peptides | BAXTER INTERNATIONAL INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140243440-A1 | METHOD | UNIVERSITY OF DURHAM (GB) | 2014-08-28 | — | — | US | disclosed |
| US-8791053-B2 | Spatially encoded polymer matrix | MPM-HOLDING APS (DK) | 2014-07-29 | — | — | US | disclosed |
| WO-2014108681-A1 | A METHOD OF CAPTURING HEAVY METALS BY A CHEMICALLY FUNCTIONALIZED SURFACE | SURFACE INNOVATIONS LIMITED (GB) | 2014-07-17 | — | — | WO | disclosed |
| CN-101861160-B | Kisspeptin antagonists and uses thereof | MEDICAL RES COUNCIL | 2014-07-16 | — | — | CN | disclosed |
| EP-2734578-A2 | METHOD FOR PRODUCING A POROUS POLYMER STRUCTURE | Surface Innovations Limited (GB) | 2014-05-28 | — | — | EP | disclosed |
| EP-2734351-A1 | METHOD FOR PRODUCING A SURFACE - FUNCTIONALISED OBJECT | Surface Innovations Limited (GB) | 2014-05-28 | — | — | EP | disclosed |
| US-20140127242-A1 | NOVEL AND POWERFUL MHC-CLASS II PEPTIDES DERIVED FROM SURVIVIN | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2014-05-08 | — | — | US | disclosed |
| EP-2717898-A2 | PRO-COAGULANT COMPOUNDS AND METHODS OF USE THEREOF | Biogen Idec MA Inc. (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20140086943-A1 | NOVEL AND POWERFUL MHC-CLASS II PEPTIDES DERIVED FROM SURVIVIN | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| EP-2707535-A2 | PRODUCT FOR THE RELEASE OF ACTIVE SUBSTANCES | Surface Innovations Limited (GB) | 2014-03-19 | — | — | EP | disclosed |
| US-8669230-B2 | Immunogenic epitopes for immunotherapy | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2014-03-11 | — | — | US | disclosed |
| US-20140050689-A1 | TISSUE GRAFTED WITH A BIODEGRADABLE POLYMER | PATHAK HOLDINGS LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-8647629-B2 | Powerful MHC-class II peptides derived from survivin | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| CN-103495154-A | Antagonists of kisspeptin and uses thereof | MEDICAL RES COUNCIL | 2014-01-08 | — | — | CN | disclosed |
| WO-2014001808-A1 | METHOD FOR COATING A SUBSTRATE WITH A POLY(IONIC-LIQUID) AND COATED SUBSTRATE MADE BY THE PROCESS | SURFACE INNOVATIONS LIMITED (GB) | 2014-01-03 | — | — | WO | disclosed |
| US-20130323272-A1 | NOVEL AND POWERFUL MHC-CLASS II PEPTIDES DERIVED FROM SURVIVIN | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2013-12-05 | — | — | US | disclosed |
| EP-2660248-A1 | Novel immunotherapy against neuronal and brain tumors | Immatics Biotechnologies GmbH (DE) | 2013-11-06 | — | — | EP | disclosed |
| US-20130285280-A1 | OPTICAL COMPENSATION FILM, AND POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY EMPLOYING THE SAME | KONICA MINOLTA OPTO, INC. (JP) | 2013-10-31 | — | — | US | disclosed |
| US-20130285280-A1 | OPTICAL COMPENSATION FILM, AND POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY EMPLOYING THE SAME | KONICA MINOLTA OPTO, INC. (JP) | 2013-10-31 | — | — | US | disclosed |
| US-8563688-B2 | Procoagulant peptides | BAXTER INTERNATIONAL INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8529904-B2 | Immunotherapeutic methods using epitopes of WT-1 and GATA-1 | GANYMED PHARMACEUTICALS AG (DE) | 2013-09-10 | — | — | US | disclosed |
| US-20130209399-A1 | ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASES | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2013-08-15 | — | — | US | disclosed |
| US-20130177525-A1 | CANCER THERAPY BASED ON TUMOR ASSOCIATED ANTIGENS DERIVED FROM CYCLIN D1 | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2013-07-11 | — | — | US | disclosed |
| US-20130171133-A1 | CANCER METHODS | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-07-04 | — | — | US | disclosed |
| US-20130149387-A1 | BIODEGRADABLE TISSUE COMPOSITION WITH BIODEGRADABLE CROSS-LINKERS | PATHAK HOLDINGS LLC (US) | 2013-06-13 | — | — | US | disclosed |
| EP-1492882-B1 | METHODS AND REAGENTS FOR ASSAYING PROTEIN KINASE ACTIVITY | UNIV DUNDEE (GB) | 2013-04-24 | — | — | EP | disclosed |
| CN-103059104-A | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules | IMMATICS BIOTECHNOLOGIES GMBH | 2013-04-24 | — | — | CN | disclosed |
| EP-2575850-A1 | IMPROVED CANCER THERAPY BASED ON TUMOR ASSOCIATED ANTIGENS DERIVED FROM CYCLIN D1 | Immatics Biotechnologies GmbH (DE) | 2013-04-10 | — | — | EP | disclosed |
| US-20130078654-A1 | Methods For Diagnosing Rheumatoid Arthritis | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-03-28 | — | — | US | disclosed |
| WO-2013039883-A1 | ARTIFICIAL NK CELLS AND USES THEREOF | ABBVIE BIOTHERAPEUTICS INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| EP-2565204-A1 | Novel immunogenic epitopes for immunotherapy | Immatics Biotechnologies GmbH (DE) | 2013-03-06 | — | — | EP | disclosed |
| EP-2562182-A1 | Novel immunogenic epitopes for immunotherapy | Immatics Biotechnologies GmbH (DE) | 2013-02-27 | — | — | EP | disclosed |
| EP-2562183-A1 | Novel immunogenic epitopes for immunotherapy | Immatics Biotechnologies GmbH (DE) | 2013-02-27 | — | — | EP | disclosed |
| EP-2562184-A1 | Novel immunogenic epitopes for immunotherapy | Immatics Biotechnologies GmbH (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-20130045191-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2013-02-21 | — | — | US | disclosed |
| EP-2558114-A2 | CANCER METHODS | Imperial Innovations Limited (GB) | 2013-02-20 | — | — | EP | disclosed |
| CN-101287754-B | Tumor associated peptides that promiscuously bind to Human Leukocyte Antigen (HLA) class II molecules | IMMATICS BIOTECHOLOGIES GMBH | 2013-02-13 | — | — | CN | disclosed |
| US-20130030118-A1 | PROCESS FOR OBTAINING LOW FREE MONOMER LEVELS IN A BLOCK COPOLYMER EMULSION PREPARED WITH (REVERSE) IODINE TRANSFER POLYMERISATION | DSM IP ASSETS B.V. (NL) | 2013-01-31 | — | — | US | disclosed |
| WO-2013011303-A1 | METHOD FOR PRODUCING A SURFACE - FUNCTIONALISED OBJECT | SURFACE INNOVATIONS LIMITED (GB) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013011302-A2 | METHOD | SURFACE INNOVATIONS LIMITED (GB) | 2013-01-24 | — | — | WO | disclosed |
| EP-2547354-A2 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | Immatics Biotechnologies GmbH (DE) | 2013-01-23 | — | — | EP | disclosed |
| CN-101365474-B | Interferon lambda therapy for treatment of respiratory diseases | IMP INNOVATIONS LTD | 2012-12-19 | — | — | CN | disclosed |
| WO-2012170969-A2 | PRO-COAGULANT COMPOUNDS AND METHODS OF USE THEREOF | BIOGEN IDEC MA INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309053-A1 | THREE DIMENSIONAL POROUS STRUCTURES | SPHERITECH LTD (GB) | 2012-12-06 | — | — | US | disclosed |
| WO-2012150459-A2 | PRODUCT | SURFACE INNOVATIONS LIMITED (GB) | 2012-11-08 | — | — | WO | disclosed |
| EP-2158237-B1 | PROCESS FOR OBTAINING LOW FREE MONOMER LEVELS IN A BLOCK COPOLYMER EMULSION PREPARED WITH (REVERSE) IODINE TRANSFER POLYMERISATION | DSM IP ASSETS BV (NL) | 2012-10-24 | — | — | EP | disclosed |
| US-8273342-B2 | Anti-virus therapy for respiratory diseases | UNIVERSITY OF SOUTHAMPTON (GB) | 2012-09-25 | — | — | US | disclosed |
| US-8273403-B2 | Generation of surface coating diversity | BIO-LAYER PTY LTD. (AU) | 2012-09-25 | — | — | US | disclosed |
| US-8273403-B2 | Generation of surface coating diversity | BIO-LAYER PTY LTD. (AU) | 2012-09-25 | — | — | US | disclosed |
| US-20120237606-A1 | HOLLOW PARTICULATE BODY | SPHERITECH LTD (GB) | 2012-09-20 | — | — | US | disclosed |
| US-8258260-B2 | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| EP-1922081-B1 | INTERFERON LAMBDA THERAPY FOR TREATMENT OF RESPIRATORY DISEASES | IMP INNOVATIONS LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| EP-2115134-B1 | citrullinated enolase peptides | IMP INNOVATIONS LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196142-A1 | RESIN FILM, POLARIZER PROTECTIVE FILM, POLARIZER, AND LIQUID-CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20120196142-A1 | RESIN FILM, POLARIZER PROTECTIVE FILM, POLARIZER, AND LIQUID-CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| EP-2478045-A2 | HOLLOW PARTICULATE BODY | Spheritech Ltd (GB) | 2012-07-25 | — | — | EP | disclosed |
| US-8216584-B2 | Using endothelial cell-specific polypeptide for use in detection and treatment of abnormal menstral bleeding, cell proliferative and skin disorders | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-07-10 | — | — | US | disclosed |
| US-8211999-B2 | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2012-07-03 | — | — | US | disclosed |
| US-8212000-B2 | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2012-07-03 | — | — | US | disclosed |
| US-20120141517-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-8193337-B2 | Oxidation process | AVECIA BIOTECHNOLOGY, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-1343802-B1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | AVECIA BIOTECHNOLOGY INC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20120077749-A1 | Biologically Active Peptides | BAXTER HEALTHCARE S.A. (CH) | 2012-03-29 | — | — | US | disclosed |
| US-8119139-B2 | Immunotherapy against several tumors including neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20120027684-A1 | CANCER THERAPY BASED ON TUMOR ASSOCIATED ANTIGENS DERIVED FROM CYCLIN D1 | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20110312613-A1 | CARRIERS FOR COMBINATORIAL COMPOUND LIBRARIES | NANOMICS BIOSYSTEMS PTY LTD (AU) | 2011-12-22 | — | — | US | disclosed |
| US-8080634-B2 | Immunogenic epitope for immunotherapy | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2011-12-20 | — | — | US | disclosed |
| WO-2011151403-A1 | IMPROVED CANCER THERAPY BASED ON TUMOR ASSOCIATED ANTIGENS DERIVED FROM CYCLIN D1 | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2011-12-08 | — | — | WO | disclosed |
| US-8067529-B2 | Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| EP-2135878-B1 | Tumor-associated peptide binding promiscuously to human leukocyte antigen (HLA) class II molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2011-11-09 | — | — | EP | disclosed |
| WO-2011128701-A2 | CANCER METHODS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-10-20 | — | — | WO | disclosed |
| EP-1534755-B1 | GENERATION OF SURFACE COATING DIVERSITY | BIO LAYER PTY LTD (AU) | 2011-10-12 | — | — | EP | disclosed |
| US-20110229504-A1 | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| WO-2011113819-A2 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011113882-A1 | DIAGNOSIS AND TREATMENT OF CANCER BASED ON AVL9 | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2011-09-22 | — | — | WO | disclosed |
| US-20110229505-A1 | Methods for the diagnosis and treatment of cancer based on AVL9 | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110189141-A1 | MULTIPLE TARGET T CELL RECEPTOR | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2011-08-04 | — | — | US | disclosed |
| US-20110177150-A1 | IMPLANTABLE TISSUE COMPOSITIONS AND METHOD | PATHAK HOLDINGS, LLC | 2011-07-21 | — | — | US | disclosed |
| US-7981427-B2 | has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (eg Quebec and LY138) and human coronavirus strain OC43 | THE ROYAL VETERINARY COLLEGE (GB) | 2011-07-19 | — | — | US | disclosed |
| EP-2341927-A2 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | Immatics Biotechnologies GmbH (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2338907-A1 | Novel immunogenic epitopes for immunotherapy | Immatics Biotechnologies GmbH (DE) | 2011-06-29 | — | — | EP | disclosed |
| US-7968097-B2 | Identification of Hla-A2-presented T-cell epitopes derived from the oncofoetal antigen-immature laminin receptor protein and uses thereof | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20110150849-A1 | Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2011-06-23 | — | — | US | disclosed |
| US-20110142865-A1 | Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2011-06-16 | — | — | US | disclosed |
| US-20110142842-A1 | POLYPEPTIDES | MEDINNOVA AS | 2011-06-16 | — | — | US | disclosed |
| US-20110142867-A1 | IMMUNOTHERAPEUTIC METHODS AND SYSTEMS | LARCHE MARK | 2011-06-16 | — | — | US | disclosed |
| US-20110142864-A1 | Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2011-06-16 | — | — | US | disclosed |
| EP-2332954-A2 | Process for the preparation of phosphorothionate oligonucleotides | Avecia Biotechnology, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| EP-1717245-B1 | T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2011-06-08 | — | — | EP | disclosed |
| US-20110117117-A1 | NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-7919112-B2 | Implantable tissue compositions and method | PATHAK HOLDINGS, LLC (US) | 2011-04-05 | — | — | US | disclosed |
| WO-2011032703-A2 | HOLLOW PARTICULATE SUPPORT | SPHERITECH LTD (GB) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011032704-A2 | HOLLOW PARTICULATE BODY | SPHERITECH LTD (GB) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011032705-A2 | THREE DIMENSIONAL POROUS STRUCTURES | SPHERITECH LTD (GB) | 2011-03-24 | — | — | WO | disclosed |
| EP-2291395-A1 | NOVEL AND POWERFUL MHC-CLASS II PETPTIDES DERIVED FROM SURVIVIN | Immatics Biotechnologies GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20110046068-A1 | Compound, Use and Method | MEDICAL RESEARCH COUNCIL (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2279200-A1 | BIOLOGICALLY ACTIVE PEPTIDES | Baxter International Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-7869011-B2 | Apparatus and methods for analysis and sorting of particles such as polymer beads | NOVO NORKISK A/S (DK) | 2011-01-11 | — | — | US | disclosed |
| EP-1922334-B1 | TUMOR-ASSOCIATED PEPTIDES BINDING TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I OR II MOLECULES AND RELATED ANTI-CANCER VACCINE | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2011-01-05 | — | — | EP | disclosed |
| EP-1525313-B1 | CANINE RESPIRATORY CORONAVIRUS (CRCV) SPIKE PROTEIN, POLYMERASE AND HEMAGGLLUTININ/ESTERASE | ROYAL VETERINARY COLLEGE (GB) | 2010-12-15 | — | — | EP | disclosed |
| EP-2258719-A1 | Multiple target T cell receptor | Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258720-A1 | Multiple target T cell receptor | Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; (DE) | 2010-12-08 | — | — | EP | disclosed |
| US-7842488-B2 | Polynucleotides encoding a human 3-phosphoinositide- dependent protein kinase | MEDICAL RESEARCH COUNCIL (GB) | 2010-11-30 | — | — | US | disclosed |
| US-7833969-B2 | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2010-11-16 | — | — | US | disclosed |
| US-7833970-B2 | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2010-11-16 | — | — | US | disclosed |
| EP-1575975-B1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | AVECIA BIOTECHNOLOGY INC (US) | 2010-10-27 | — | — | EP | disclosed |
| CN-101861160-A | Kisspeptin antagonists and uses thereof | MEDICAL RES COUNCIL | 2010-10-13 | — | — | CN | disclosed |
| US-7811789-B2 | Expression vector comprising nucleotide sequences coding migration stimulation factor for use in identifying modulator for treatment and prevention of cell proliferative disorders; wound healing agents | UNIVERSITY OF DUNDEE (GB) | 2010-10-12 | — | — | US | disclosed |
| US-20100256299-A1 | PROCESS FOR OBTAINING LOW FREE MONOMER LEVELS IN A BLOCK COPOLYMER EMULSION PREPARED WITH (REVERSE) IODINE TRANSFER POLYMERISATION | DSM IP ASSETS B.V. (NL) | 2010-10-07 | — | — | US | disclosed |
| EP-1385877-B1 | TAPP2 POLYPEPTIDES | MEDICAL RES COUNCIL (GB) | 2010-10-06 | — | — | EP | disclosed |
| US-7807642-B2 | Tumor-associated peptides binding promiscuosly to human leukocyte antigen (HLA) class II molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2010-10-05 | — | — | US | disclosed |
| US-20100234303-A1 | AGENTS, METHODS AND USES | MEDICAL RESEARCH COUNCIL (GB) | 2010-09-16 | — | — | US | disclosed |
| EP-1790728-B1 | Imaging, diagnosis and treatment of disease | CANCER REC TECH LTD (GB) | 2010-09-08 | — | — | EP | disclosed |
| US-20100221457-A1 | OPTICAL COMPENSATION FILM, AND POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY EMPLOYING THE SAME | KONICA MINOLTA OPTO, INC. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-20100221457-A1 | OPTICAL COMPENSATION FILM, AND POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY EMPLOYING THE SAME | KONICA MINOLTA OPTO, INC. (JP) | 2010-09-02 | — | — | US | disclosed |
| EP-2217623-A2 | T-CELL RECEPTOR PEPTIDES SPECIFIC FOR PART OF CD20 , USES THEREOF, AND METHODS OF PREPARING CYTOTOXIC T-CELLS | MEDINNOVA AS (NO) | 2010-08-18 | — | — | EP | disclosed |
| US-7776340-B2 | Canine respiratory coronavirus (CRCV) spike protein, polymerase and hemagglutinin/esterase | THE ROYAL VETERINARY COLLEGE (GB) | 2010-08-17 | — | — | US | disclosed |
| EP-2211891-A2 | ANTAGONISTS OF KISSPEPTIN AND USES THEREOF | Medical Research Council (GB) | 2010-08-04 | — | — | EP | disclosed |
| US-20100158931-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2010-06-24 | — | — | US | disclosed |
| US-7740830-B2 | Imaging, diagnosis and treatment of disease | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-06-22 | — | — | US | disclosed |
| US-20100150929-A1 | Peptide Associated with Rheumatic Fever (PARF) and Its Use as a Diagnostic Marker | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2010-06-17 | — | — | US | disclosed |
| US-20100136246-A1 | METHOD FOR PRODUCING SURFACES AND SUBSTRATES HAVING SAID SURFACES SO FORMED | SURFACE INNOVATIONS LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20100137572-A1 | OXIDATION PROCESS | NITTO DENKO AVECIA, INC. | 2010-06-03 | — | — | US | disclosed |
| US-7727950-B2 | Methods and reagents for assaying protein kinase activity | THE UNIVERSITY OF DUNDEE (GB) | 2010-06-01 | — | — | US | disclosed |
| EP-1794190-B9 | IMMUNOGENIC T-HELPER EPITOPES FROM HUMAN TUMOUR ANTIGENS AND IMMUNOTHERAPEUTIC METHODS USING SAID EPITOPES | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2010-05-19 | — | — | EP | disclosed |
| EP-2183278-A2 | NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY | Immatics Biotechnologies GmbH (DE) | 2010-05-12 | — | — | EP | disclosed |
| EP-2183361-A1 | NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS | Immatics Biotechnologies GmbH (DE) | 2010-05-12 | — | — | EP | disclosed |
| EP-2182066-A2 | Canine respiratory coronavirus (crcv) spike protein, polymerase and hemaggllutinin/esterase | The Royal Veterinary College (GB) | 2010-05-05 | — | — | EP | disclosed |
| US-20100104775-A1 | ULTRAVIOLET ABSORBING POLYMER, CELLULOSE ESTER OPTICAL FILM, METHOD OF PRODUCING CELLULOSE ESTER OPTICAL FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY | KONICA MINOLTA OPTO, INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100104775-A1 | ULTRAVIOLET ABSORBING POLYMER, CELLULOSE ESTER OPTICAL FILM, METHOD OF PRODUCING CELLULOSE ESTER OPTICAL FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY | KONICA MINOLTA OPTO, INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100104556-A1 | EPITOPE-TAG FOR SURFACE-EXPRESSED PROTEINS AND USES THEREOF | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (MED) BERLIN-BUCH (DE) | 2010-04-29 | — | — | US | disclosed |
| US-7700559-B2 | Gonadotropin releasing hormone analogues conjugates with steroid hormones | MEDICAL RESEARCH COUNCIL (GB) | 2010-04-20 | — | — | US | disclosed |
| US-20100093027-A1 | Enzyme | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2010-04-15 | — | — | US | disclosed |
| WO-2010037514-A2 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2010-04-08 | — | — | WO | disclosed |
| EP-2172212-A2 | Novel immunotherapy against several tumors including neuronal and brain tumors | Immatics Biotechnologies GmbH (DE) | 2010-04-07 | — | — | EP | disclosed |
| US-7691968-B2 | Process for the synthesis of peptides amides by side-chain attachment to a solid phase | AVECIA BIOLOGICS LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| EP-1806358-B1 | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2010-03-17 | — | — | EP | disclosed |
| EP-1806359-B1 | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2010-03-17 | — | — | EP | disclosed |
| EP-2158237-A1 | PROCESS FOR OBTAINING LOW FREE MONOMER LEVELS IN A BLOCK COPOLYMER EMULSION PREPARED WITH (REVERSE) IODINE TRANSFER POLYMERISATION | DSM IP Assets B.V. (NL) | 2010-03-03 | — | — | EP | disclosed |
| US-20100047256-A1 | METHODS | IMPERIAL INNOVATIONS LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100047823-A1 | Polypeptides | MEDICAL RESEARCH COUNCIL (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100040590-A1 | Tumor-associated peptides binding to human leukocyte antigen (HLA) class II molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100040806-A1 | CELLULOSE ESTER OPTICAL FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY USING THE CELLULOSE ESTER OPTICAL FILM, AND METHOD FOR PRODUCING CELLULOSE ESTER OPTICAL FILM | KONICA MINOLTA OPTO, INC. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100040806-A1 | CELLULOSE ESTER OPTICAL FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY USING THE CELLULOSE ESTER OPTICAL FILM, AND METHOD FOR PRODUCING CELLULOSE ESTER OPTICAL FILM | KONICA MINOLTA OPTO, INC. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100029571-A1 | NOVEL AND POWERFUL MHC-CLASS II PEPTIDES DERIVED FROM SURVIVIN | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100022445-A1 | BIOLOGICALLY ACTIVE PEPTIDES | BAXTER INTERNATIONAL INC. (US) | 2010-01-28 | — | — | US | disclosed |
| EP-2138509-A1 | Tumor-associated peptide binding promiscuously to human leukocyte antigen (HLA) class II molecules | Immatics Biotechnologies GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20090317395-A1 | Antimicrobial Peptide Derived from Galanin Message Associated Peptide (GMAP) | AUSTRIA WIRTSCHAFTSSERVICE GESELLSCHAFT MBH (AT) | 2009-12-24 | — | — | US | disclosed |
| US-20090317428-A1 | Immunogenic T-Helper Epitopes From Human Tumour Antigens and Immunotherapeutic Methods Using Said Epitopes | IMMATICS BIOTECHNOLOGIES GMBH | 2009-12-24 | — | — | US | disclosed |
| EP-2135878-A1 | Tumor-associated peptide binding promiscuously to human leukocyte antigen (HLA) class II molecules | Immatics Biotechnologies GmbH (DE) | 2009-12-23 | — | — | EP | disclosed |
| US-7635772-B2 | Process for the preparation of oligonucleotides | AVECIA BIOTECHNOLOGY INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-1922335-B1 | TUMOR-ASSOCIATED PEPTIDES BINDING PROMISCUOUSLY TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS II MOLECULES | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2009-12-09 | — | — | EP | disclosed |
| US-20090286435-A1 | Method for Producing, and a Substrate with, a Surface with Specific Characteristics | SURFACE INNOVATIONS LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| WO-2009138236-A1 | NOVEL AND POWERFUL MHC-CLASS II PETPTIDES DERIVED FROM SURVIVIN | IMMATICS BIOTECHNOLOGIES GMBH | 2009-11-19 | — | — | WO | disclosed |
| EP-2119726-A1 | Novel and powerful MHC-class II peptides derived from survivin and neurocan | Immatics Biotechnologies GmbH (DE) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009137256-A1 | BIOLOGICALLY ACTIVE PEPTIDES | BAXTER INTERNATIONAL INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-2115134-A1 | METHODS | Imperial Innovations Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| US-20090274714-A1 | TUMOUR-ASSOCIATED PEPTIDES BINDING TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I OR II MOLECULES AND RELATED ANTI-CANCER VACCINE | IMMATICS BOITECHNOLOGIES GMHH (DE) | 2009-11-05 | — | — | US | disclosed |
| US-20090257980-A1 | ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASES | IMPERIAL INNOVATIONS LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| EP-2105501-A1 | Novel immunotherapy against neuronal and brain tumors | Immatics Biotechnologies GmbH (DE) | 2009-09-30 | — | — | EP | disclosed |
| US-7582440-B2 | A binding protein is encoded from nucleic acids, is used to diagnose or prognose disorders of vascular endothelium, detecting tumor or tumour neovasculature or cardiac disease or endometriosis or artherosclerosis | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| US-20090210165-A1 | Identification of encoded beads | CARLSBERG A/S (DK) | 2009-08-20 | — | — | US | disclosed |
| EP-1760089-B1 | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2009-08-19 | — | — | EP | disclosed |
| EP-1794190-B1 | IMMUNOGENIC T-HELPER EPITOPES FROM HUMAN TUMOUR ANTIGENS AND IMMUNOTHERAPEUTIC METHODS USING SAID EPITOPES | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2009-08-12 | — | — | EP | disclosed |
| US-7569216-B2 | Anti-virus therapy for respiratory diseases | UNIVERSITY OF SOUTHAMPTON (GB) | 2009-08-04 | — | — | US | disclosed |
| US-20090191572-A1 | Imaging, diagnosis and treatment of disease | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090181115-A1 | Method of Screening for Compounds That Alter Skin and/or Hair Pigmentation | CONOPCO INC., D/B/A UNILEVER | 2009-07-16 | — | — | US | disclosed |
| EP-2076549-A2 | A METHOD FOR PRODUCING SURFACES AND SUBSTRATES HAVING SAID SURFACES SO FORMED | UNIVERSITY OF DURHAM (GB) | 2009-07-08 | — | — | EP | disclosed |
| US-20090136528-A1 | NOVEL IMMUNOGENIC EPITOPE FOR IMMUNOTHERAPY | IMMATICS BIOTECHNOLOGIES GMHH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-20090130162-A2 | IMPLANTABLE TISSUE COMPOSITIONS AND METHOD | PATHAK CHANDRASKEKHAR | 2009-05-21 | — | — | US | disclosed |
| US-20090123489-A1 | NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMHH (DE) | 2009-05-14 | — | — | US | disclosed |
| WO-2009059804-A2 | T-CELL RECEPTOR PEPTIDES SPECIFIC FOR PART OF CD20, USES THEREOF, AND METHODS OF PREPARING CYTOTOXIC T-CELLS | MEDINNOVA AS (NO) | 2009-05-14 | — | — | WO | disclosed |
| EP-2051803-A1 | SOLID SUPPORT | Chromatide Ltd (GB) | 2009-04-29 | — | — | EP | disclosed |
| WO-2009047513-A2 | ANTAGONISTS OF KISSPEPTIN AND USES THEREOF | MEDICAL RESEARCH COUNCIL (GB) | 2009-04-16 | — | — | WO | disclosed |
| EP-2046825-A1 | ANTIMICROBIAL PEPTIDE DERIVED FROM GALANIN MESSAGE ASSOCIATED PEPTIDE (GMAP) | Austria Wirtschaftsservice Gesellschaft mbH (AT) | 2009-04-15 | — | — | EP | disclosed |
| EP-2041171-A2 | EPITOPE-TAG FOR SURFACE-EXPRESSED PROTEINS AND USES THEREOF | Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-20090081780-A1 | CANINE RESPIRATORY CORONAVIRUS (CRCV) SPIKE PROTEIN, POLYMERASE AND HEMAGGLUTININ/ESTERASE | THE ROYAL VETERINARY COLLEGE (GB) | 2009-03-26 | — | — | US | disclosed |
| EP-2029618-A2 | AGENTS, METHODS AND USES | Ardana Bioscience Limited (GB) | 2009-03-04 | — | — | EP | disclosed |
| EP-2029624-A1 | PEPTIDE ASSOCIATED WITH RHEUMATIC FEVER (PARF) AND ITS USE AS A DIAGNOSTIC MARKER | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2009-03-04 | — | — | EP | disclosed |
| US-7498034-B2 | Imaging, diagnosis and treatment of disease | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-20090041794-A1 | Identification of Hla-A2-Presented T-Cell Epitopes Derived from the Oncofoetal Antigen-Immature Laminin Receptor Protein and Uses Thereof | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-2021791-A2 | METHOD OF SCREENING FOR COMPOUNDS THAT ALTER SKIN AND/OR HAIR PIGMENTATION | UNILEVER N.V. (NL) | 2009-02-11 | — | — | EP | disclosed |
| EP-1042466-B1 | POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF | UNIV DUNDEE (GB) | 2009-02-11 | — | — | EP | disclosed |
| CN-101365474-A | Interferon lambda therapy for treatment of respiratory diseases | IMP INNOVATIONS LTD (GB) | 2009-02-11 | — | — | CN | disclosed |
| WO-2009015842-A2 | NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009015843-A1 | NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2009-02-05 | — | — | WO | disclosed |
| US-20090025489-A1 | Apparatus and methods for analysis and sorting of particles such as polymer beads | VERSAMATRIX A/S (DK) | 2009-01-29 | — | — | US | disclosed |
| EP-1642905-B1 | Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2009007736-A1 | OXIDATION PROCESS | AVECIA BIOTECHNOLOGY INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008155324-A1 | PROCESS FOR OBTAINING LOW FREE MONOMER LEVELS IN A BLOCK COPOLYMER EMULSION PREPARED WITH (REVERSE) IODINE TRANSFER POLYMERISATION | DSM IP ASSETS B.V. (NL) | 2008-12-24 | — | — | WO | disclosed |
| EP-1002069-B1 | PEPTIDES CONTAINING THE MOTIF IGD AND THEIR USE AS CELL MIGRATION MODULATORS | UNIV DUNDEE (GB) | 2008-12-10 | — | — | EP | disclosed |
| EP-1453539-B1 | IMMUNOTHERAPEUTIC METHODS AND SYSTEMS | CIRCASSIA LTD (GB) | 2008-11-19 | — | — | EP | disclosed |
| US-20080274045-A9 | Imaging, diagnosis and treatment of disease | CANCER RESEARCH TECHNOLOGY LIMITED, A UNITED KINGDOM CORPORATION | 2008-11-06 | — | — | US | disclosed |
| EP-1613357-B1 | GONADOTROPIN RELEASING HORMONE ANALOGUE CONJUGATES WITH STEROID HORMONES | MEDICAL RES COUNCIL (GB) | 2008-10-15 | — | — | EP | disclosed |
| CN-101287754-A | Tumor associated peptides that promiscuously bind to Human Leukocyte Antigen (HLA) class II molecules | IMMATICS BIOTECHOLOGIES GMBH (DE) | 2008-10-15 | — | — | CN | disclosed |
| EP-0764047-B2 | POLYMERIC MICROBEADS AND METHOD OF PREPARATION | SUNSTORM RES CORP (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20080219924-A1 | Imaging, diagnosis and treatment of disease | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| US-20080207520-A1 | Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080206217-A1 | Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080206218-A1 | Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080206216-A1 | Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1619202-B1 | immunotherapeutic methods using epitopes of wt-1 and gata-1 | GANYMED PHARMACEUTICALS AG (DE) | 2008-08-20 | — | — | EP | disclosed |
| US-20080187962-A1 | POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF | UNIVERSITY OF DUNDEE (GB) | 2008-08-07 | — | — | US | disclosed |
| WO-2008090360-A1 | METHODS | IMPERIAL INNOVATIONS LIMITED (GB) | 2008-07-31 | — | — | WO | disclosed |
| US-20080159993-A1 | Antigenic peptide comprising sequenc simimlarity to wilm's tumor-1 gene a nd gata-1 transcription factor for use as targeting tools in treatment of cell proliferative disorders; tissue targeted therapy | GANYMED PHARMACEUTICALS, AG | 2008-07-03 | — | — | US | disclosed |
| US-20080145359-A1 | Imaging, diagnosis and treatment of disease | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| EP-0891551-B1 | PROTEIN PHOSPHATASE-1 CATALYTIC SUBUNIT INTERACTIONS | MEDICAL RES COUNCIL (GB) | 2008-06-11 | — | — | EP | disclosed |
| EP-1066315-B1 | USE OF INHIBITORS OF MAMMALIAN ASPARAGINYL ENDOPEPTIDASE FOR MODULATING THE IMMUNE SYSTEM | UNIV DUNDEE (GB) | 2008-05-28 | — | — | EP | disclosed |
| EP-1922335-A2 | TUMOR-ASSOCIATED PEPTIDES BINDING PROMISCUOUSLY TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS II MOLECULES | Immatics Biotechnologies GmbH (DE) | 2008-05-21 | — | — | EP | disclosed |
| EP-1922081-A2 | INTERFERON LAMBDA THERAPY FOR TREATMENT OF RESPIRATORY DISEASES | Imperial Innovations Limited (GB) | 2008-05-21 | — | — | EP | disclosed |
| EP-1922334-A1 | TUMOR-ASSOCIATED PEPTIDES BINDING TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I OR II MOLECULES AND RELATED ANTI-CANCER VACCINE | Immatics Biotechnologies GmbH (DE) | 2008-05-21 | — | — | EP | disclosed |
| WO-2008050122-A2 | A METHOD FOR PRODUCING SURFACES AND SUBSTRATES HAVING SAID SURFACES SO FORMED | UNIVERSITY OF DURHAM (GB) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007028574-A9 | TUMOR-ASSOCIATED PEPTIDES BINDING PROMISCUOUSLY TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS II MOLECULES | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007028573-A9 | TUMOR-ASSOCIATED PEPTIDES BINDING TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I OR II MOLECULES AND RELATED ANTI-CANCER VACCINE | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2008-05-02 | — | — | WO | disclosed |
| US-7351810-B1 | Polypeptides, polynucleotides and uses thereof | UNIVERSITY OF DUNDEE (GB) | 2008-04-01 | — | — | US | disclosed |
| US-7344870-B2 | 3-phosphoinositide-dependent protein kinase | MEDICAL RESEARCH COUNCIL (GB) | 2008-03-18 | — | — | US | disclosed |
| EP-1760088-B1 | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1534735-A4 | CODED NUCLEIC ACID CARRIERS | GENERA BIOSYSTEMS PTY LTD (AU) | 2008-02-06 | — | — | EP | disclosed |
| US-7326767-B1 | Peptide derived from the amino acid sequence of human WT-1 containing the amino acid sequence RMFPNAPYL that is processed by HLA-A0201-positive antigen presenting cells (APC) to produce the HLA-A0201 bound RMFPNAPYL sequence; cancer vaccine | GANYMED PHARMACEUTICALS, AG (DE) | 2008-02-05 | — | — | US | disclosed |
| WO-2008012064-A1 | SOLID SUPPORT | CHROMATIDE LTD (GB) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008006467-A1 | ANTIMICROBIAL PEPTIDE DERIVED FROM GALANIN MESSAGE ASSOCIATED PEPTIDE (GMAP) | AUSTRIA WIRTSCHAFTSSERVICE GESELLSCHAFT MBH (AT) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006458-A2 | EPITOPE-TAG FOR SURFACE-EXPRESSED T-CELL RECEPTOR PROTEINS, USES THEREOF AND METHOD OF SELECTING HOST CELLS EXPRESSING THEM | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) BERLIN-BUCH (DE) | 2008-01-17 | — | — | WO | disclosed |
| EP-1878744-A1 | Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them | Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) | 2008-01-16 | — | — | EP | disclosed |
| EP-1874810-A1 | T-CELL EPITOPES FROM THE ONCOFETAL ANTIGEN-IMMATURE LAMININ RECEPTOR PROTEIN AND MEDICAL USES THEREOF | Immatics Biotechnologies GmbH (DE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1868739-A2 | METHOD FOR PRODUCING, AND A SUBSTRATE WITH, A SURFACE WITH SPECIFIC CHARACTERISTICS | UNIVERSITY OF DURHAM (GB) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007144554-A2 | GNRH (GONADOTROPIN-RELEASING HORMONE) PEPTIDE VARIANTS | ARDANA BIOSCIENCE LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007140953-A1 | PEPTIDE ASSOCIATED WITH RHEUMATIC FEVER (PARF) AND ITS USE AS A DIAGNOSTIC MARKER | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2007-12-13 | — | — | WO | disclosed |
| EP-1864996-A1 | Peptide associated with rheumatic fever (PARF) and its use as a diagnostic marker. | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007138066-A2 | METHOD OF SCREENING FOR COMPOUNDS THAT ALTER SKIN AND/OR HAIR PIGMENTATION | UNILEVER N.V. (NL) | 2007-12-06 | — | — | WO | disclosed |
| US-20070254005-A1 | Implantable Tissue Compositions and Method | PATHAK HOLDINGS, LLC | 2007-11-01 | — | — | US | disclosed |
| US-20070248616-A1 | Canine Respiratory Coronavirus (Crcv) Spike Protein, Polymerase and Hemagglutinin/Esterase | ROYAL VETERINARY COLLEGE, THE (GB) | 2007-10-25 | — | — | US | disclosed |
| EP-1834969-A2 | Curable materials containing siloxane | National Starch and Chemical Investment Holding Corporation (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070212556-A1 | Curable materials containing siloxane | HENKEL AG & CO. KGAA (DE) | 2007-09-13 | — | — | US | disclosed |
| CN-101033295-A | Curable materials containing siloxane | NAT STARCH CHEM INVEST (US) | 2007-09-12 | — | — | CN | disclosed |
| EP-1806359-A1 | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules | Immatics Biotechnologies GmbH (DE) | 2007-07-11 | — | — | EP | disclosed |
| EP-1806358-A2 | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules | Immatics Biotechnologies GmbH (DE) | 2007-07-11 | — | — | EP | disclosed |
| EP-1796693-A2 | IMPLANTABLE TISSUE COMPOSITIONS AND METHOD | Pathak, Chandrashekhar P. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20070134763-A1 | Anti-virus therapy for respiratory diseases | UNIVERSITY OF SOUTHAMPTON HIGHFIELD (GB) | 2007-06-14 | — | — | US | disclosed |
| EP-1794190-A2 | IMMUNOGENIC T-HELPER EPITOPES FROM HUMAN TUMOUR ANTIGENS AND IMMUNOTHERAPEUTIC METHODS USING SAID EPITOPES | Immatics Biotechnologies GmbH (DE) | 2007-06-13 | — | — | EP | disclosed |
| US-7227017-B2 | Process for the preparation of phosphorothioate oligonucleotides | AVECIA LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| EP-1790728-A2 | Imaging, diagnosis and treatment of disease | Cancer Research Technology Limited (GB) | 2007-05-30 | — | — | EP | disclosed |
| EP-1334194-B1 | IMAGING, DIAGNOSIS AND TREATMENT OF DISEASE | CANCER REC TECH LTD (GB) | 2007-04-18 | — | — | EP | disclosed |
| US-7205390-B2 | Antibody which activates protein kinase; drug screening | MEDICAL RESEARCH COUNCIL (GB) | 2007-04-17 | — | — | US | disclosed |
| WO-2007029041-A2 | INTERFERON LAMBDA THERAPY FOR TREATMENT OF RESPIRATORY DISEASES | IMPERIAL INNOVATIONS LIMITED (GB) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028573-A1 | TUMOR-ASSOCIATED PEPTIDES BINDING TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I OR II MOLECULES AND RELATED ANTI-CANCER VACCINE | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028574-A2 | TUMOR-ASSOCIATED PEPTIDES BINDING PROMISCUOUSLY TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS II MOLECULES | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2007-03-15 | — | — | WO | disclosed |
| EP-1759213-A2 | ANALYSIS METHOD | BIOINVENT INTERNATIONAL AB (SE) | 2007-03-07 | — | — | EP | disclosed |
| EP-1760089-A1 | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine | Immatics Biotechnologies GmbH (DE) | 2007-03-07 | — | — | EP | disclosed |
| EP-1760088-A1 | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules | Immatics Biotechnologies GmbH (DE) | 2007-03-07 | — | — | EP | disclosed |
| US-20070025913-A1 | Imaging, diagnosis and treatment of disease | CANCER RESEARCH TECHNOLOGY LIMITED, A UNITED KINGDOM CORPORATION | 2007-02-01 | — | — | US | disclosed |
| EP-1339745-B1 | IMMUNOTHERAPEUTIC METHODS AND MOLECULES | IMP INNOVATIONS LTD (GB) | 2007-01-10 | — | — | EP | disclosed |
| US-20070004911-A1 | Silylated oligonucleotide compounds | AVECIA LIMITED (GB) | 2007-01-04 | — | — | US | disclosed |
| EP-1448789-A4 | DEVICE AND METHODS FOR DIRECTED SYNTHESIS OF CHEMICAL LIBRARIES | NANOMICS BIOSYSTEMS PTY LTD (AU) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006114307-A1 | T-CELL EPITOPES FROM THE ONCOFETAL ANTIGEN-IMMATURE LAMININ RECEPTOR PROTEIN AND MEDICAL USES THEREOF | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2006-11-02 | — | — | WO | disclosed |
| EP-1717245-A1 | T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof | Immatics Biotechnologies GmbH (DE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060247177-A1 | Gonadotropin releasing hormone analogues conjugates with steroid hormones | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2006-11-02 | — | — | US | disclosed |
| WO-2006109055-A2 | METHOD FOR COATING A SUBSTRATE TO GIVE PROTEIN RESISTANCE AND COATED SUBSTRATE | UNIVERSITY OF DURHAM (GB) | 2006-10-19 | — | — | WO | disclosed |
| US-7122360-B1 | Polypeptides, polynucleotides and uses thereof | UNIVERSITY OF DUNDEE (GB) | 2006-10-17 | — | — | US | disclosed |
| EP-1504022-B1 | PROCESS FOR THE SYNTHESIS OF PEPTIDE AMIDES BY SIDE-CHAIN ATTACHMENT TO A SOLID PHASE | AVECIA LTD (GB) | 2006-10-11 | — | — | EP | disclosed |
| EP-1109918-B1 | MITOGEN- AND STRESS-ACTIVATED PROTEIN KINASES THAT CONTAIN TWO KINASE DOMAINS AND USES THEREOF | UNIV DUNDEE (GB) | 2006-10-04 | — | — | EP | disclosed |
| EP-1701784-A1 | IDENTIFICATION OF ENCODED BEADS | VersaMatrix A/S (DK) | 2006-09-20 | — | — | EP | disclosed |
| US-7109160-B1 | Peptides containing the motif IGD and their use as cell migration modulators | UNIVERSITY OF DUNDEE (GB) | 2006-09-19 | — | — | US | disclosed |
| EP-1699553-A2 | APPARATUS AND METHODS FOR ANALYSIS AND SORTING OF PARTICLES SUCH AS POLYMER BEADS | VersaMatrix A/S (DK) | 2006-09-13 | — | — | EP | disclosed |
| WO-2006089678-A2 | ANTIBODIES AND PEPTIDES BINDING TO HIV TAT, AND USES THEREOF | BIOINVENT INTERNATIONAL AB (SE) | 2006-08-31 | — | — | WO | disclosed |
| US-20060189799-A1 | Method of preventing modification of synthetic oligonucleotides | SINHA NANDA D | 2006-08-24 | — | — | US | disclosed |
| WO-2006075172-A2 | METHODS FOR IDENTIFYING COMPOUNDS CAPABLE OF MODULATING CFTR/CK2 INTERACTION AND/OR CFTR PHOSPHORYLATION BY CK2 | UNIVERSITY OF DUNDEE (GB) | 2006-07-20 | — | — | WO | disclosed |
| US-20060149052-A1 | Process for the preparation of oligonucleotides | AVECIA LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| US-20060127369-A1 | Spatially encoded polymer matrix | CARLSBERG A/S (DK) | 2006-06-15 | — | — | US | disclosed |
| WO-2006056009-A1 | PEPTIDES HAVING ADHESIVE PROPERTIES FOR USE IN SOLID PHASE ASSAY AND CHEMICAL POLYMER SYNTHESIS REGIMES. | HEPGENICS PTY LTD (AU) | 2006-06-01 | — | — | WO | disclosed |
| US-20060110733-A1 | Coded nucleic acid carriers | GENERA BIOSYSTEMS PTY LTD. (AU) | 2006-05-25 | — | — | US | disclosed |
| US-7038027-B2 | Method of preventing modification of synthetic oligonucleotides | AVECIA BIOTECHNOLOGY, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| WO-2006037421-A2 | IMMUNOGENIC T-HELPER EPITOPES FROM HUMAN TUMOUR ANTIGENS AND IMMUNOTHERAPEUTIC METHODS USING SAID EPITOPES | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2006-04-13 | — | — | WO | disclosed |
| US-20060073575-A1 | Methods and reagents for assaying protein kinase activity | DUNDEE, UNIVERSITY OF, THE (GB) | 2006-04-06 | — | — | US | disclosed |
| EP-1642905-A1 | Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes | Immatics Biotechnologies GmbH (DE) | 2006-04-05 | — | — | EP | disclosed |
| WO-2006026325-A2 | IMPLANTABLE TISSUE COMPOSITIONS AND METHOD | PATHAK CHANDRASHEKHAR P (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060024334-A1 | Immunotherapeutic methods and systems | CIRCASSIA LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| EP-1619202-A2 | immunotherapeutic methods using epitopes of wt-1 and gata-1 | Ganymed Pharmaceuticals AG (DE) | 2006-01-25 | — | — | EP | disclosed |
| EP-1127068-B1 | IMMUNOTHERAPEUTIC METHODS USING EPITOPES OF WT-1 AND GATA-1 | GANYMED PHARMACEUTICALS AG (DE) | 2006-01-18 | — | — | EP | disclosed |
| WO-2006002841-A2 | ANALYSIS METHOD | BIOINVENT INTERNATIONAL AB (SE) | 2006-01-12 | — | — | WO | disclosed |
| EP-1613357-A1 | GONADOTROPIN RELEASING HORMONE ANALOGUE CONJUGATES WITH STEROID HORMONES | Ardana Bioscience Limited (GB) | 2006-01-11 | — | — | EP | disclosed |
| EP-1608669-A1 | SILYLATED OLIGONUCLEOTIDE COMPOUNDS | Avecia Limited (GB) | 2005-12-28 | — | — | EP | disclosed |
| US-20050266520-A1 | Process for the synthesis of peptides | FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED (GB) | 2005-12-01 | — | — | US | disclosed |
| EP-0983363-B1 | PHOSPHATIDYL-3,4.5-TRIPHOSPHATE-DEPENDENT PROTEIN KINASE | MEDICAL RES COUNCIL (GB) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005100378-A1 | PROCESS FOR THE PREPARATION OF A PEPTIDE, AND COMPOUNDS COMPRISING A THIOESTER CARBOXYL-ACTIVATING GROUP FOR USE THEREIN | AVECIA LIMITED (GB) | 2005-10-27 | — | — | WO | disclosed |
| EP-1575975-A1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | Avecia Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005062018-A2 | APPARATUS AND METHODS FOR ANALYSIS AND SORTING OF PARTICLES SUCH AS POLYMER BEADS | VERSAMATRIX A/S (DK) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061094-A1 | IDENTIFICATION OF ENCODED BEADS | VERSAMATRIX A/S (DK) | 2005-07-07 | — | — | WO | disclosed |
| EP-1545762-A2 | SPATIALLY ENCODED POLYMER MATRIX | Carlsberg A/S (DK) | 2005-06-29 | — | — | EP | disclosed |
| EP-1534735-A1 | CODED NUCLEIC ACID CARRIERS | Genera Biosystems Pty Ltd (AU) | 2005-06-01 | — | — | EP | disclosed |
| EP-1525313-A1 | CANINE RESPIRATORY CORONAVIRUS (CRCV) SPIKE PROTEIN, POLYMERASE AND HEMAGGLLUTININ/ESTERASE | The Royal Veterinary College (GB) | 2005-04-27 | — | — | EP | disclosed |
| US-6884600-B1 | Protein phosphatase-1 catalytic subunit interactions | MEDICAL RESEARCH COUNCIL LONDON (GB) | 2005-04-26 | — | — | US | disclosed |
| EP-1135350-A4 | CARRIERS FOR COMBINATORIAL COMPOUND LIBRARIES | NANOMICS BIOSYSTEMS PTY LTD (AU) | 2005-03-30 | — | — | EP | disclosed |
| EP-1506231-A2 | HYBRID AND FUSION POLYPEPTIDE SUBUNITS OF K+ CHANNELS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2005-02-16 | — | — | EP | disclosed |
| US-20050032185-A1 | Enzyme | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2005-02-10 | — | — | US | disclosed |
| EP-1504022-A2 | PROCESS FOR THE SYNTHESIS OF PEPTIDE AMIDES BY SIDE-CHAIN ATTACHMENT TO A SOLID PHASE | Avecia Limited (GB) | 2005-02-09 | — | — | EP | disclosed |
| EP-1492882-A1 | METHODS AND REAGENTS FOR ASSAYING PROTEIN KINASE ACTIVITY | The University of Dundee (GB) | 2005-01-05 | — | — | EP | disclosed |
| EP-0932666-B1 | MAP KINASES: POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF | MEDICAL RES COUNCIL (GB) | 2004-12-15 | — | — | EP | disclosed |
| US-6805861-B2 | Immunotherapy using cytotoxic T lymphocytes (CTL) | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2004-10-19 | — | — | US | disclosed |
| WO-2004087215-A1 | GONADOTROPIN RELEASING HORMONE ANALOGUES CONJUGATES WITH STEROID HORMONES | ARDANA BIOSCIENCE LIMITED (GB) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004085454-A1 | SILYLATED OLIGONUCLEOTIDE COMPOUNDS | AVECIA LIMITED (GB) | 2004-10-07 | — | — | WO | disclosed |
| EP-1453539-A2 | IMMUNOTHERAPEUTIC METHODS AND SYSTEMS | Circassia Limited (GB) | 2004-09-08 | — | — | EP | disclosed |
| EP-1448789-A2 | DEVICE AND METHODS FOR DIRECTED SYNTHESIS OF CHEMICAL LIBRARIES | Nanomics Biosystems Pty, Ltd. (AU) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004064999-A2 | PROCESS, REACTOR AND SAMPLING DEVICE | AVECIA LIMITED (GB) | 2004-08-05 | — | — | WO | disclosed |
| US-6768005-B2 | GENERATION OF PREFERENTIAL OLIGONUCLEOTIDES; GENERATE SOLID SUPPORT, INCUBATE WITH OLIGONUCLEOTIDES, ATTACH OLIGONUCLELOTIDE TO SOLID SUPPORT, EXPOSE TO ACETONITRILE, RECOVER ADJUSTED OLIGONUCLEOTIDE | AVECIA LIMITED (GB) | 2004-07-27 | — | — | US | disclosed |
| WO-2004055036-A1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 2004-07-01 | — | — | WO | disclosed |
| EP-0633939-B1 | NISINS | INST OF FOOD RES (GB) | 2004-06-30 | — | — | EP | disclosed |
| WO-2004050686-A2 | PROCESS AND SUPPORTS FOR SYNTHESIS OF PEPTIDES COMPRISING A THIOESTER OR THIOACID | AVECIA LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
| US-6750312-B1 | PEPTIDE SYNTHESIS; REACTING AN AMINO FUNCTIONALISED POLYMER WITH A CARBOXYLIC ACID HAVING AT LEAST TWO SIMILARLY PROTECTED AMINO GROUPS TO FORM AMIDE BONDS BETWEEN THEM | AVECIA LIMITED (GB) | 2004-06-15 | — | — | US | disclosed |
| US-20040106148-A1 | Polypeptides | MEDICAL RESEARCH COUNCEL (GB) | 2004-06-03 | — | — | US | disclosed |
| US-6734001-B1 | USED IN DRUG SCREENING | MEDICAL RESEARCH COUNCIL (GB) | 2004-05-11 | — | — | US | disclosed |
| US-20040071711-A1 | Imaging, diagnosis and treatment of disease | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-04-15 | — | — | US | disclosed |
| WO-2004028682-A2 | SPATIALLY ENCODED POLYMER MATRIX | CARLSBERG A/S (DK) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004018500-A1 | CODED NUCLEIC ACID CARRIERS | GENERA BIOSYSTEMS PTY LTD (AU) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004011651-A1 | CANINE RESPIRATORY CORONAVIRUS (CRCV) SPIKE PROTEIN, POLYMERASE AND HEMAGGLUTININ/ESTERASE | THE ROYAL VETERINARY COLLEGE (GB) | 2004-02-05 | — | — | WO | disclosed |
| EP-1385877-A2 | POLYPEPTIDES | MEDICAL RESEARCH COUNCIL (GB) | 2004-02-04 | — | — | EP | disclosed |
| US-20030229221-A1 | Process for the preparation of phosphorothioate oligonucleotides | AVECIA LIMITED (GB) | 2003-12-11 | — | — | US | disclosed |
| WO-2003093302-A2 | PROCESS FOR THE SYNTHESIS OF PEPTIDES AMIDES BY SIDE-CHAIN ATTACHEMENT TO A SOLID PHASE | AVECIA LIMITED (GB) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003093301-A2 | PROCESS FOR THE SYNTHESIS OF PEPTIDES | AVECIA LIMITED (GB) | 2003-11-13 | — | — | WO | disclosed |
| US-20030211521-A1 | Breast cancer antigen | IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED | 2003-11-13 | — | — | US | disclosed |
| US-20030203390-A1 | Comprises coded particle immobilized on microarrays for use in synthesizing, screening and monitoring biological, pharmacological or chemical compounds | KAYE PAUL H (GB) | 2003-10-30 | — | — | US | disclosed |
| WO-2003087400-A1 | METHODS AND REAGENTS FOR ASSAYING PROTEIN KINASE ACTIVITY | UNIVERSITY OF DUNDEE (GB) | 2003-10-23 | — | — | WO | disclosed |
| US-20030182068-A1 | Device and methods for directed synthesis of chemical libraries | NANOMICS BIOSYSTEMS PTY LTD (AU) | 2003-09-25 | — | — | US | disclosed |
| EP-1343802-A2 | PROCESS FOR THE PREPARATION OF PHOSPHOROTHIONATE OLIGONUCLEOTIDES | Avecia Limited (GB) | 2003-09-17 | — | — | EP | disclosed |
| US-6617117-B1 | Identifying a compound which blocks the activation of a stress-activated protein kinase; useful in treating inflammatory disease | MEDICAL RESEARCH COUNCIL (GB) | 2003-09-09 | — | — | US | disclosed |
| EP-1339745-A1 | IMMUNOTHERAPEUTIC METHODS AND MOLECULES | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2003-09-03 | — | — | EP | disclosed |
| EP-0764047-B1 | POLYMERIC MICROBEADS AND METHOD OF PREPARATION | BIOPORE CORP (US) | 2003-08-27 | — | — | EP | disclosed |
| US-6608025-B1 | Isolated polypeptide, neuroendocrine secretory protein 55, comprising specified amino acid sequence; treating or preventing obesity | KNOLL, AG (DE) | 2003-08-19 | — | — | US | disclosed |
| EP-1334194-A2 | IMAGING, DIAGNOSIS AND TREATMENT OF DISEASE | Cancer Research Technology Limited (GB) | 2003-08-13 | — | — | EP | disclosed |
| EP-0879282-B1 | IMMUNOTHERAPY USING CYTOTOXIC T LYMPHOCYTES (CTL) | IMP COLLEGE INNOVATIONS LTD (GB) | 2003-07-02 | — | — | EP | disclosed |
| WO-2003047618-A2 | IMMUNOTHERAPEUTIC METHODS AND SYSTEMS | CIRCASSIA LIMITED (GB) | 2003-06-12 | — | — | WO | disclosed |
| US-20030108971-A1 | Enzyme | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2003-06-12 | — | — | US | disclosed |
| WO-2003045969-A1 | COUPLING REAGENT FOR H-PHOSPHONATE CHEMISTRY | AVECIA BIOTECHNOLOGY INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030103946-A1 | Immunotherapeutic methods and molecules | IMPERIAL COLLEGE INNOVATIONS LIMITED | 2003-06-05 | — | — | US | disclosed |
| WO-2003038558-A2 | DEVICE AND METHODS FOR DIRECTED SYNTHESIS OF CHEMICAL LIBRARIES | NANOMICS BIOSYSTEMS PTY, LTD. (AU) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003035690-A2 | HYBRID AND FUSION POLYPEPTIDE SUBUNITS OF K+ CHANNELS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2003-05-01 | — | — | WO | disclosed |
| EP-1294736-A1 | DEPROTECTION OF SYNTHETIC OLIGONUCLEOTIDES USING AN ACRYLONITRILE SCAVENGER | Avecia Biotechnology, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-1153050-A4 | AMINO-KETONE SOLID SUPPORT TEMPLATES | ADVANCED SYNTECH LLC (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002070702-A2 | POLYPEPTIDES CAPABLE OF INTERACTING WITH SMAD POLYPEPTIDE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-09-12 | — | — | WO | disclosed |
| US-20020111479-A1 | Generation of preferential oligonucleotides; generate solid support, incubate with oligonucleotides, attach oligonuclelotide to solid support, expose to acetonitrile, recover adjusted oligonucleotide | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2002-08-15 | — | — | US | disclosed |
| EP-1224193-A1 | PROCESS FOR THE PREPARATION OF PHOSPHOROTHIOATE TRIESTERS AND OLIGONUCLEOTIDES | Avecia Limited (GB) | 2002-07-24 | — | — | EP | disclosed |
| US-20020090362-A1 | IMMUNOTHERAPY USING CYTOTOXIC T LYMPHOCYTES (CTL) | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2002-07-11 | — | — | US | disclosed |
| WO-2002046205-A2 | PROCESS FOR THE PREPARATION OF PHOSPHOROTHIONATE OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 2002-06-13 | — | — | WO | disclosed |
| US-20020072593-A1 | Method of preventing modification of synthetic oligonucleotides | AVECIA BIOTECHNOLOGY INC. | 2002-06-13 | — | — | US | disclosed |
| EP-1212414-A2 | POLYPEPTIDES CAPABLE OF INTERACTING WITH THE SMAD PEPTIDE AND COMPRISING THE SEQUENCE PP(T/N)K | IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-06-12 | — | — | EP | disclosed |
| WO-2002044207-A1 | IMMUNOTHERAPEUTIC METHODS AND MOLECULES | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2002-06-06 | — | — | WO | disclosed |
| EP-1210444-A2 | ISOFORMS OF SNARE MOLECULES AND THE USES THEREOF IN MODULATION OF CELLULAR EXOCYTOSIS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2002-06-05 | — | — | EP | disclosed |
| US-20020065225-A1 | Methods of determining altered NDPK functions and the diagnosis of cystic fibrosis | DUNDEE, THE UNIVERSITY OF (GB) | 2002-05-30 | — | — | US | disclosed |
| WO-2002036771-A2 | IMAGING, DIAGNOSIS AND TREATMENT OF DISEASE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002034770-A1 | IDENTIFICATION OF HLA-DR RESTRICTED HCV EPITOPES | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2002-05-02 | — | — | WO | disclosed |
| EP-1200591-A1 | HUMAN HOMOLOGUE OF BOVINE NEUROENDOCRINE SECRETORY PROTEIN, NESP55, POLYNUCLEOTIDES AND USES THEREOF LINKED WITH OBESITY | Knoll GmbH (DE) | 2002-05-02 | — | — | EP | disclosed |
| EP-1189927-A1 | PROCESS FOR THE PREPARATION OF SUPPORTS FOR SOLID PHASE SYNTHESIS | Avecia Limited (GB) | 2002-03-27 | — | — | EP | disclosed |
| WO-2002020786-A2 | KINASE D INTERACTING PROTEIN | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-03-14 | — | — | WO | disclosed |
| US-20020019013-A1 | Combined resin method for high-speed synthesis of combinatorial libraries | ADVANCED SYNTECH, LLC | 2002-02-14 | — | — | US | disclosed |
| WO-2002012276-A2 | PLECKSTRIN HOMOLOGY POLYPEPTIDES AND DNA ENCODING SUCH | MEDICAL RESEARCH COUNCIL (GB) | 2002-02-14 | — | — | WO | disclosed |
| WO-2001096358-A1 | DEPROTECTION OF SYNTHETIC OLIGONUCLEOTIDES USING ACRYLONITRILE SCAVENGER | AVECIA BIOTECHNOLOGY, INC. (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-0863797-B1 | CODED PARTICLES FOR PROCESS SEQUENCE TRACKING IN COMBINATORIAL COMPOUND LIBRARY PREPARATION | UNIV HERTFORDSHIRE (GB) | 2001-12-12 | — | — | EP | disclosed |
| EP-1157274-A1 | METHODS OF DETERMINING ALTERED NDPK FUNCTIONS | The University of Dundee (GB) | 2001-11-28 | — | — | EP | disclosed |
| EP-1153050-A1 | AMINO-KETONE SOLID SUPPORT TEMPLATES | Advanced syntech, LLC (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1135350-A1 | CARRIERS FOR COMBINATORIAL COMPOUND LIBRARIES | THE UNIVERSITY OF QUEENSLAND (AU) | 2001-09-26 | — | — | EP | disclosed |
| EP-1127068-A1 | IMMUNOTHERAPEUTIC METHODS USING EPITOPES OF WT-1 AND GATA-1 | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2001-08-29 | — | — | EP | disclosed |
| EP-1109918-A2 | POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF | University of Dundee (GB) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001027126-A1 | PROCESS FOR THE PREPARATION OF PHOSPHOROTHIOATE TRIESTERS AND OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001018038-A2 | ISOFORMS OF SNARE MOLECULES AND THE USES THEREOF IN MODULATION OF CELLULAR EXOCYTOSIS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2001-03-15 | — | — | WO | disclosed |
| WO-2001014413-A2 | POLYPEPTIDES CAPABLE OF INTERACTING WITH THE SMAD PEPTIDE AND COMPRISING THE SEQUENCE PP (T/N)K | IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2001-03-01 | — | — | WO | disclosed |
| WO-2001011042-A1 | DAPP1, A DUAL ADAPTOR FOR PHOSPHOTYROSINE AND 3-PHOSPHOINOSITIDES | MEDICAL RESEARCH COUNCIL (GB) | 2001-02-15 | — | — | WO | disclosed |
| US-6187993-B1 | Transgenic animals as model of psoriasis | IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2001-02-13 | — | — | US | disclosed |
| EP-1073735-A1 | HOST-ENCODED PROTEIN EXPRESSED ON MAREK'S DISEASE VIRUS (MDV)-INFECTED CELLS AND ANTIBODY THERETO | INSTITUTE FOR ANIMAL HEALTH LIMITED (GB) | 2001-02-07 | — | — | EP | disclosed |
| WO-2001007617-A1 | HUMAN HOMOLOGUE OF BOVINE NEUROENDOCRINE SECRETORY PROTEIN, NESP55, POLYNUCLEOTIDES AND USES THEREOF LINKED WITH OBESITY | KNOLL GMBH (DE) | 2001-02-01 | — | — | WO | disclosed |
| EP-1066315-A1 | USE OF INHIBITORS OF MAMMALIAN ASPARAGINYL ENDOPEPTIDASE FOR THERAPY OF AUTOIMMUNE DISEASE | UNIVERSITY OF DUNDEE (GB) | 2001-01-10 | — | — | EP | disclosed |
| EP-1062335-A1 | BREAST CANCER ANTIGEN | IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2000-12-27 | — | — | EP | disclosed |
| WO-2000075171-A1 | PROCESS FOR THE PREPARATION OF SUPPORTS FOR SOLID PHASE SYNTHESIS | AVECIA LIMITED (GB) | 2000-12-14 | — | — | WO | disclosed |
| EP-1057025-A1 | PROTEIN KINASE C | Imperial Cancer Research Technology ( ICRT) (GB) | 2000-12-06 | — | — | EP | disclosed |
| EP-1042466-A1 | POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF | The University of Dundee (GB) | 2000-10-11 | — | — | EP | disclosed |
| US-6117940-A | SOLID PHASE SYNTHESIS OF COMPOUNDS SUCH AS THE IMIDAZOLES, BENZODIAZEPINES, PYRAZINES, AND STEROID MIMICS. | ADVANCED SYNTECH, LLC, A KENTUCKY LIMITED LIABILITY CORPORATION | 2000-09-12 | — | — | US | disclosed |
| WO-2000052467-A1 | METHODS OF DETERMINING ALTERED NDPK FUNCTIONS | THE UNIVERSITY OF DUNDEE (GB) | 2000-09-08 | — | — | WO | disclosed |
| US-6100056-A | LACTOCOCCUS WHICH DOES NOT SECRETE A NATURAL NISIN, BUT WHICH EXPRESSES GENES FOR NISIN MODIFICATION, IMMUNITY, AND TRANSLOCATION OUT OF CELL; FOR PRODUCTION OF MUTANT NISINS INCLUDING ACID STABLE VARIANT | BIOTECHNOLOGY AND BIOLOGICAL SCIENCES RESEARCH COUNCIL (GB) | 2000-08-08 | — | — | US | disclosed |
| US-6100306-A | A DRUG DELIVERY CARRIER HAVING THE POROUS CROSSLINKED PARTICLES LOADED WITH A DRUG | BIOPORE CORPORATION (US) | 2000-08-08 | — | — | US | disclosed |
| EP-1018365-A2 | Coded particles for process sequence tracking in combinatorial compound library preparation | UNIVERSITY OF HERTFORDSHIRE (GB) | 2000-07-12 | — | — | EP | disclosed |
| WO-2000032542-A1 | CARRIERS FOR COMBINATORIAL COMPOUND LIBRARIES | THE UNIVERSITY OF QUEENSLAND (AU) | 2000-06-08 | — | — | WO | disclosed |
| EP-1005555-A1 | HUMAN STRESS-ACTIVATED PROTEIN KINASE, SKK4 | MEDICAL RESEARCH COUNCIL (GB) | 2000-06-07 | — | — | EP | disclosed |
| EP-1002069-A1 | PEPTIDES CONTAINING THE MOTIF IGD AND THEIR USE AS CELL MIGRATION MODULATORS | UNIVERSITY OF DUNDEE (GB) | 2000-05-24 | — | — | EP | disclosed |
| WO-2000026249-A1 | IMMUNOTHERAPEUTIC METHODS USING EPITOPES OF WT-1 AND GATA-1 | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000023487-A1 | AMINO-KETONE SOLID SUPPORT TEMPLATES | ADVANCED SYNTECH, LLC (US) | 2000-04-27 | — | — | WO | disclosed |
| EP-0983363-A1 | PHOSPHATIDYL-3,4.5-TRIPHOSPHATE-DEPENDENT PROTEIN KINASE | MEDICAL RESEARCH COUNCIL (GB) | 2000-03-08 | — | — | EP | disclosed |
| WO-1999067283-A2 | TWO-KINASE DOMAIN MITOGEN- AND STRESS-ACTIVATED PROTEIN KINASES AND USES THEREOF | UNIVERSITY OF DUNDEE (GB) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999055860-A1 | HOST-ENCODED PROTEIN EXPRESSED ON MAREK'S DISEASE (MDV)-INFECTED CELLS AND ANTIBODY THERETO | INSTITUTE FOR ANIMAL HEALTH LIMITED (GB) | 1999-11-04 | — | — | WO | disclosed |
| WO-1999048910-A1 | USE OF INHIBITORS OF MAMMALIAN ASPARAGINYL ENDOPEPTIDASE FOR THERAPY OF AUTOIMMUNE DISEASE | UNIVERSITY OF DUNDEE (GB) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999049034-A1 | BREAST CANCER ANTIGEN | IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999042833-A1 | PROTEIN KINASE C | IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 1999-08-26 | — | — | WO | disclosed |
| WO-1999041006-A1 | AN IMPROVED METHOD OF FABRICATING CODED PARTICLES | UNIVERSITY OF HERTFORDSHIRE (GB) | 1999-08-19 | — | — | WO | disclosed |
| EP-0932666-A1 | MAP KINASES: POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF | MEDICAL RESEARCH COUNCIL (GB) | 1999-08-04 | — | — | EP | disclosed |
| WO-1999031233-A1 | POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF | UNIVERSITY OF DUNDEE (GB) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999027370-A1 | BIOASSAY TO DETECT COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 1999-06-03 | — | — | WO | disclosed |
| WO-1999014233-A1 | PEPTIDES DERIVED FROM COWDRIA RUMINANTIUM, ANTIBODIES THERETO AND THEIR DIAGNOSTICAL AND MEDICAL USES | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999009181-A1 | HUMAN STRESS-ACTIVATED PROTEIN KINASE, SKK4 | MEDICAL RESEARCH COUNCIL (GB) | 1999-02-25 | — | — | WO | disclosed |
| US-5863957-A | POROUS CROSSLINKED POLYMERIC MICROBEADS HAVING CAVITIES JOINED BY INTERCONNECTING PORES WHEREIN AT LEAST SOME OF THE CAVITIES AT THE INTERIOR OF EACH MICROBEAD COMMUNICATE WITH THE SURFACE OF THE BEAD | BIOPORE CORPORATION (US) | 1999-01-26 | — | — | US | disclosed |
| WO-1999002674-A1 | PEPTIDES CONTAINING THE MOTIF IGD AND THEIR USE AS CELL MIGRATION MODULATORS | UNIVERSITY OF DUNDEE (GB) | 1999-01-21 | — | — | WO | disclosed |
| EP-0891551-A1 | PROTEIN PHOSPHATASE-1 CATALYTIC SUBUNIT INTERACTIONS | MEDICAL RESEARCH COUNCIL (GB) | 1999-01-20 | — | — | EP | disclosed |
| EP-0879282-A1 | IMMUNOTHERAPY USING CYTOTOXIC T LYMPHOCYTES (CTL) | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 1998-11-25 | — | — | EP | disclosed |
| US-5840315-A | TREATING OR PREVENTING BOVINE MASTITIS | PFIZER INC. (US) | 1998-11-24 | — | — | US | disclosed |
| WO-1998041638-A1 | PHOSPHATIDYL-3,4.5-TRIPHOSPHATE-DEPENDENT PROTEIN KINASE | MEDICAL RESEARCH COUNCIL (GB) | 1998-09-24 | — | — | WO | disclosed |
| EP-0863797-A1 | CODED PARTICLES FOR PROCESS SEQUENCE TRACKING IN COMBINATORIAL COMPOUND LIBRARY PREPARATION | UNIVERSITY OF HERTFORDSHIRE (GB) | 1998-09-16 | — | — | EP | disclosed |
| US-5760097-A | COMBINING MONOMER, CROSSLINKING AGENT, EMULSIFIER, STABILIZER, FORMING EMULSION, ADDING EMULSION TO MONOMER-IMMISCILE SUSPENSION MEDIUM, POLYMERIZING | BIOPORE CORPORATION (US) | 1998-06-02 | — | — | US | disclosed |
| WO-1998015618-A1 | MAP KINASES: POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF | MEDICAL RESEARCH COUNCIL (GB) | 1998-04-16 | — | — | WO | disclosed |
| US-5733880-A | ANTITUMOR AGENTS | NAPIER UNIVERSITY VENTURES LIMITED (GB) | 1998-03-31 | — | — | US | disclosed |
| WO-1998011251-A1 | DETECTION OF SUBSTRATE RECOGNITION OF PROTEIN KINASES AND PHOSPHATASES | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 1998-03-19 | — | — | WO | disclosed |
| EP-0721447-B1 | ANTHRACENE DERIVATIVES FOR USE AS ANTICANCER AGENT OR DYE | UNIV NAPIER (GB) | 1998-02-25 | — | — | EP | disclosed |
| EP-0764047-A4 | POLYMERIC MICROBEADS AND METHOD OF PREPARATION | BIOPORE CORP (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0811072-A1 | TRANSGENIC ANIMALS AS MODEL OF PSORIASIS | IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 1997-12-10 | — | — | EP | disclosed |
| WO-1997037224-A1 | PROTEIN PHOSPHATASE-1 CATALYTIC SUBUNIT INTERACTIONS | MEDICAL RESEARCH COUNCIL (GB) | 1997-10-09 | — | — | WO | disclosed |
| US-5653922-A | POROUS CROSSLINKED ION EXCHANGE RESINS, CATIONIC POLYMER, CARBONIZED CARBON OR GEL-FILLED PARTICLES; PROTEIN SYNTHESIS, HIGH DENSITY CELL CULTURE | BIOPORE CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1997026328-A1 | IMMUNOTHERAPY USING CYTOTOXIC T LYMPHOCYTES (CTL) | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 1997-07-24 | — | — | WO | disclosed |
| WO-1997015390-A1 | CODED PARTICLES FOR PROCESS SEQUENCE TRACKING IN COMBINATORIAL COMPOUND LIBRARY PREPARATION | UNIVERSITY OF HERTFORDSHIRE (GB) | 1997-05-01 | — | — | WO | disclosed |
| EP-0764047-A1 | POLYMERIC MICROBEADS AND METHOD OF PREPARATION | BIOPORE CORPORATION (US) | 1997-03-26 | — | — | EP | disclosed |
| US-5583162-A | MIXING WATER INSOLUBLE MONOMER AND CROSSLINKER WITH EMULSIFIER, COMBINING WITH WATER SOLUBLE INITIATOR AND SUSPENDING AGENT, POLYMERIZING | BIOPORE CORPORATION (US) | 1996-12-10 | — | — | US | disclosed |
| WO-1996027019-A1 | TRANSGENIC ANIMALS AS MODEL OF PSORIASIS | IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 1996-09-06 | — | — | WO | disclosed |
| EP-0721447-A1 | ANTHRACENE DERIVATIVES FOR USE AS ANTICANCER AGENT OR DYE | NAPIER UNIVERSITY VENTURES LIMITED (GB) | 1996-07-17 | — | — | EP | disclosed |
| WO-1995033553-A1 | POLYMERIC MICROBEADS AND METHOD OF PREPARATION | BIOPORE CORPORATION (US) | 1995-12-14 | — | — | WO | disclosed |
| WO-1995009149-A1 | ANTHRACENE DERIVATIVES FOR USE AS ANTICANCER AGENT OR DYE | NAPIER UNIVERSITY VENTURES LIMITED (GB) | 1995-04-06 | — | — | WO | disclosed |
| EP-0405763-B1 | GRF peptides | MALLINCKRODT VETERINARY LTD (GB) | 1995-03-29 | — | — | EP | disclosed |
| US-5401829-A | A peptide containing a partial amino acid sequence of growth hormone, antibodies | COOPERS ANIMAL HEALTH LTD. (GB) | 1995-03-28 | — | — | US | disclosed |
| EP-0633939-A1 | NISINS | BIOTECHNOLOGY AND BIOLOGICAL SCIENCES RESEARCH COUNCIL (GB) | 1995-01-18 | — | — | EP | disclosed |
| EP-0303488-B1 | Biologically active molecules | MALLINCKRODT VETERINARY LTD (GB) | 1994-12-28 | — | — | EP | disclosed |
| WO-1994028127-A1 | CANCER TREATMENT | IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 1994-12-08 | — | — | WO | disclosed |
| EP-0623170-A1 | VACCINES BASED ON STREPTOKINASE | PFIZER INC. (US) | 1994-11-09 | — | — | EP | disclosed |
| EP-0284406-B1 | Biologically active molecules | PITMAN MOORE LTD (GB) | 1994-09-14 | — | — | EP | disclosed |
| WO-1993020213-A1 | NISINS | AGRICULTURE AND FOOD RESEARCH COUNCIL (GB) | 1993-10-14 | — | — | WO | disclosed |
| WO-1993014209-A1 | VACCINES BASED ON STREPTOKINASE | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
| US-5191015-A | Solid phase synthesis on crosslinked polymer, removal of crosslinks to solubilize | MEDICAL RESEARCH COUNCIL (GB) | 1993-03-02 | — | — | US | disclosed |
| EP-0288310-B1 | SUBSTRATE AND PROCESS FOR MAKING A SUBSTRATE | UNILEVER PLC (GB) | 1992-10-28 | — | — | EP | disclosed |
| US-5066784-A | Porous vinyl polymeric matrix filled with a physically- or chemically-bound reactive gel; high loadings; solid phase synthesis; chromatography; ion exchanging | UNILEVER PATENT HOLDINGS B.V. (NL) | 1991-11-19 | — | — | US | disclosed |
| EP-0405763-A1 | GRF peptides | MALLINCKRODT VETERINARY LIMITED (GB) | 1991-01-02 | — | — | EP | disclosed |
| EP-0394318-A1 | POLYMERS AND POLYMER-PEPTIDE CONJUGATES | MEDICAL RESEARCH COUNCIL (GB) | 1990-10-31 | — | — | EP | disclosed |
| US-4965289-A | Substrate and process for making a substrate | UNILEVER PATENT HOLDINGS B.V. (NL) | 1990-10-23 | — | — | US | disclosed |
| WO-1990002605-A1 | AN APPARATUS AND A METHOD FOR THE SYNTHESIS OF PEPTIDES | MELDAL MORTEN (DK) | 1990-03-22 | — | — | WO | disclosed |
| WO-1989005305-A1 | POLYMERS AND POLYMER-PEPTIDE CONJUGATES | 3I RESEARCH EXPLOITATION LIMITED (GB) | 1989-06-15 | — | — | WO | disclosed |
| EP-0303488-A2 | Biologically active molecules | MALLINCKRODT VETERINARY LIMITED (GB) | 1989-02-15 | — | — | EP | disclosed |
| EP-0288310-A2 | Substrate and process for making a substrate | UNILEVER PLC (GB) | 1988-10-26 | — | — | EP | disclosed |
| WO-1988007547-A1 | BIOLOCICALLY ACTIVE MOLECULES | COOPERS ANIMAL HEALTH LIMITED (GB) | 1988-10-06 | — | — | WO | disclosed |
| EP-0284406-A1 | Biologically active molecules | PITMAN-MOORE LIMITED (GB) | 1988-09-28 | — | — | EP | disclosed |
| US-4753985-A | Synthesis of organic compounds using deformable gel in porous rigid support | UNITED KINGDOM ATOMIC ENERGY AUTHORITY (GB) | 1988-06-28 | — | — | US | disclosed |
| EP-0097994-B1 | METHOD FOR THE SOLID-PHASE SYNTHESIS OF RETRO-INVERSO POLYPEPTIDES | ENICHEM S.p.A. (IT) | 1987-09-30 | — | — | EP | disclosed |
| EP-0097994-A2 | Method for the solid-phase synthesis of retro-inverso polypeptides | ENICHEM S.p.A. (IT) | 1984-01-11 | — | — | EP | disclosed |
| EP-0097994-A2 | Method for the solid-phase synthesis of retro-inverso polypeptides | ENICHEM S.p.A. (IT) | 1984-01-11 | — | — | EP | disclosed |